

A Randomized Trial of Bevacizumab for Newly Diagnos

New England Journal of Medicine

370, 699-708

DOI: [10.1056/nejmoa1308573](https://doi.org/10.1056/nejmoa1308573)

Citation Report

#	ARTICLE	IF	CITATIONS
1	TRIM28 and β -Actin Identified via Nanobody-Based Reverse Proteomics Approach as Possible Human Glioblastoma Biomarkers. PLoS ONE, 2014, 9, e113688.	1.1	26
2	Antineoplastic Effect of Decoy Oligonucleotide Derived from MGMT Enhancer. PLoS ONE, 2014, 9, e113854.	1.1	3
3	Effects of Anti-Angiogenesis on Glioblastoma Growth and Migration: Model to Clinical Predictions. PLoS ONE, 2014, 9, e115018.	1.1	28
4	Orphan drugs in glioblastoma multiforme: a review. Orphan Drugs: Research and Reviews, 0, , 83.	0.6	6
5	Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial. OncoTargets and Therapy, 2014, 7, 1551.	1.0	14
6	The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Management and Research, 2014, 6, 373.	0.9	32
7	Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. OncoTargets and Therapy, 2014, 7, 751.	1.0	12
8	High Grade Glioma – Standard Approach, Obstacles and Future Directions. , 0, , .		0
9	For the Next Trick: New Discoveries in Radiobiology Applied to Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e95-e99.	1.8	22
10	Antiangiogenic therapies for glioblastoma. CNS Oncology, 2014, 3, 349-358.	1.2	9
11	Antiangiogenesis in Cancer Therapy. , 2014, , .		0
12	Targeting glioblastoma cancer stem cells: the next great hope?. Neurosurgical Focus, 2014, 37, E7.	1.0	13
13	Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. CNS Oncology, 2014, 3, 389-400.	1.2	38
14	Bevacizumab for glioblastoma: current indications, surgical implications, and future directions. Neurosurgical Focus, 2014, 37, E9.	1.0	43
15	Trial Watch: Radioimmunotherapy for oncological indications. OncoImmunology, 2014, 3, e954929.	2.1	40
16	Antiangiogenic therapy for high-grade glioma. The Cochrane Library, 2014, , CD008218.	1.5	84
17	Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. Journal of Neuro-Oncology, 2014, 120, 431-440.	1.4	17
19	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. Journal of Translational Medicine, 2014, 12, 291.	1.8	32

#	ARTICLE	IF	CITATIONS
20	Therapeutic targeting of tumor angiogenesis: how far have we come?. <i>Clinical Investigation</i> , 2014, 4, 1113-1122.	0.0	0
21	Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme. <i>Targeted Oncology</i> , 2014, 9, 395-398.	1.7	10
25	Patient Reported Endpoints for Measuring Clinical Benefit in (High Grade Glioma) Primary Brain Tumor Patients. <i>Current Treatment Options in Oncology</i> , 2014, 15, 519-528.	1.3	21
26	Current Role of Anti-Angiogenic Strategies for Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 551-566.	1.3	24
27	Hippocampal EUD in primarily irradiated glioblastoma patients. <i>Radiation Oncology</i> , 2014, 9, 276.	1.2	9
28	Potential novel role of bevacizumab in glioblastoma and cervical cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 1296-1298.	1.5	4
29	Treating glioblastoma patients with poor performance status: where do we go from here?. <i>CNS Oncology</i> , 2014, 3, 231-241.	1.2	3
30	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. <i>Future Oncology</i> , 2014, 10, 1137-1145.	1.1	16
31	Recent Updates in the Treatment of Glioblastoma: Introduction. <i>Seminars in Oncology</i> , 2014, 41, S1-S3.	0.8	6
32	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. <i>Neuro-Oncology</i> , 2014, 16, viii7-viii13.	0.6	85
33	Bevacizumab for glioblastoma. <i>Neurology</i> , 2014, 82, 1670-1671.	1.5	7
34	Straying from the path in neuro-oncology. <i>Neuro-Oncology</i> , 2014, 16, 1155-1156.	0.6	0
35	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. <i>Neuro-Oncology</i> , 2014, 16, 1427-1428.	0.6	6
36	Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. <i>Frontiers in Microbiology</i> , 2014, 5, 303.	1.5	44
37	Emerging Insights into Barriers to Effective Brain Tumor Therapeutics. <i>Frontiers in Oncology</i> , 2014, 4, 126.	1.3	127
38	Galectins and neovascularization in central nervous system tumors. <i>Glycobiology</i> , 2014, 24, 892-898.	1.3	10
40	Cytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme. <i>Frontiers in Oncology</i> , 2014, 4, 275.	1.3	21
41	BMPs as Therapeutic Targets and Biomarkers in Astrocytic Glioma. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	24

#	ARTICLE	IF	CITATIONS
42	Avastin, Once Considered Promising for Glioblastoma, Disappoints in Large Trial. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2014, 14, 20-21.	0.0	0
43	Progression-free survival: too much risk, not enough reward?. <i>Neuro-Oncology</i> , 2014, 16, 615-616.	0.6	16
45	Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma. <i>Nature Reviews Neurology</i> , 2014, 10, 179-179.	4.9	6
46	Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 2048-2049.	13.9	98
47	Further delineating bevacizumab's response spectrum. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 243-244.	12.5	0
48	Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. <i>Annals of Oncology</i> , 2014, 25, 1442-1447.	0.6	90
49	Advances in Diagnostic and Treatment Modalities for Intracranial Tumors. <i>Journal of Veterinary Internal Medicine</i> , 2014, 28, 1165-1185.	0.6	75
50	High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii93-iii101.	0.6	532
51	Management of high-grade gliomas in the pediatric patient: Past, present, and future. <i>Neuro-Oncology Practice</i> , 2014, 1, 145-157.	1.0	31
52	Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects. <i>Clinical Cancer Research</i> , 2014, 20, 5612-5619.	3.2	129
53	"We will know it when we see it;" bevacizumab and glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 469-470.	0.6	4
54	Beating the odds: extreme long-term survival with glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1159-1160.	0.6	63
55	Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 192.	1.0	13
56	Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. <i>Radiation Oncology</i> , 2014, 9, 299.	1.2	30
57	Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. <i>Neuro-Oncology</i> , 2014, 16, 765-767.	0.6	13
58	A Randomized Clinical Trial of Vascular Endothelial Growth Factor Inhibition in the Treatment of Glioblastoma Multiforme. <i>Neurosurgery</i> , 2014, 74, N14-N17.	0.6	0
59	Glioblastoma survival. <i>Current Opinion in Neurology</i> , 2014, 27, 666-674.	1.8	82
60	Welcoming the Era of Quality Improvement in Neuro-Oncology. <i>Journal of Oncology Practice</i> , 2014, 10, 371-372.	2.5	4

#	ARTICLE	IF	CITATIONS
61	Phase I/II randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2014, 17, 430-9.	0.6	108
62	Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?. <i>Neuro-Oncology</i> , 2014, 16, 1427-1427.	0.6	4
63	Emerging Therapies for Glioblastoma. <i>JAMA Neurology</i> , 2014, 71, 1437.	4.5	148
64	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014, 32, 2273-2274.	0.8	0
65	The Regulatory Network of Proneural Glioma in Tumor Progression. <i>Neurosurgery</i> , 2014, 75, N15-N16.	0.6	0
66	Ephs and Ephrins in malignant gliomas. <i>Growth Factors</i> , 2014, 32, 190-201.	0.5	26
67	The future of antiangiogenic treatment in glioblastoma. <i>Current Opinion in Neurology</i> , 2014, 27, 675-682.	1.8	16
68	Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 642-648.	0.7	8
69	Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: The potential of combination strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 38-48.	2.0	10
70	Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenografts. <i>Radiotherapy and Oncology</i> , 2014, 111, 468-474.	0.3	43
72	Bevacizumab plus Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 709-722.	13.9	2,078
73	Bevacizumab in Glioblastoma – Still Much to Learn. <i>New England Journal of Medicine</i> , 2014, 370, 764-765.	13.9	46
74	Driving Glioblastoma to Drink. <i>Cell</i> , 2014, 157, 289-290.	13.5	9
75	Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 66-74.	3.3	39
76	Brain Metastases in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 249-257.	1.1	31
77	Current and Investigational Drug Strategies for Glioblastoma. <i>Clinical Oncology</i> , 2014, 26, 419-430.	0.6	31
78	REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2014, 25, 2351-2356.	0.6	51
79	Epigenetic Changes in Gliomas. , 2014, , 23-45.		0

#	ARTICLE	IF	CITATIONS
80	NF- κ B and STAT3 in glioblastoma: therapeutic targets coming of age. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 1293-1306.	1.4	89
81	<i>Glioma Cell Biology.</i> , 2014, , .		3
82	Signaling Cascades Driving the Malignant Phenotype of Glioma Cells. , 2014, , 47-75.		2
83	Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians. <i>CNS Drugs</i> , 2014, 28, 1127-1137.	2.7	10
86	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	3.2	89
87	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	5.1	800
88	Facing the Future of Brain Tumor Clinical Research. <i>Clinical Cancer Research</i> , 2014, 20, 5591-5600.	3.2	4
89	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1441-1458.	0.6	164
90	G protein-coupled receptors as oncogenic signals in glioma: Emerging therapeutic avenues. <i>Neuroscience</i> , 2014, 278, 222-236.	1.1	34
91	Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies. <i>Seminars in Oncology</i> , 2014, 41, 511-522.	0.8	21
92	Response to Lai et al., "Development of a Symptom Index for Patients with Primary Brain Tumors" Value in Health, 2014, 17, 752-753.	0.1	0
93	The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review. <i>European Journal of Cancer</i> , 2014, 50, 2432-2448.	1.3	47
95	How to Get From Here to There: Tracking Down Invasive Glioma Cells. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju120.	3.0	1
96	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology</i> , The, 2014, 15, e395-e403.	5.1	647
97	Renewing interest in targeting angiogenesis in glioblastoma. <i>Lancet Oncology</i> , The, 2014, 15, 907-908.	5.1	4
98	Vessel calibre "a potential MRI biomarker of tumour response in clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 566-584.	12.5	55
99	VEGF-targeted cancer therapeutics "paradoxical effects in endocrine organs. <i>Nature Reviews Endocrinology</i> , 2014, 10, 530-539.	4.3	89
100	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 943-953.	5.1	639

#	ARTICLE	IF	CITATIONS
101	Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy. <i>Neoplasia</i> , 2014, 16, 543-561.	2.3	131
102	Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. <i>Advanced Drug Delivery Reviews</i> , 2014, 76, 98-115.	6.6	48
103	Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. <i>Journal of Neuro-Oncology</i> , 2014, 120, 361-370.	1.4	18
104	A Multilayer Grow-or-Go Model for GBM: Effects of Invasive Cells and Anti-Angiogenesis on Growth. <i>Bulletin of Mathematical Biology</i> , 2014, 76, 2306-2333.	0.9	50
106	Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 883-893.	1.5	16
107	Molecular Neuro-oncology and the Challenge of the Blood-Brain Barrier. <i>Seminars in Oncology</i> , 2014, 41, 438-445.	0.8	12
109	HIV-1-induced AIDS in monkeys. <i>Science</i> , 2014, 344, 1401-1405.	6.0	76
110	Medical therapy of gliomas. <i>Journal of Neuro-Oncology</i> , 2014, 119, 503-512.	1.4	15
111	Clinical End Points and Relevant Clinical Benefits in Advanced Colorectal Cancer Trials. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 254-262.	1.0	0
112	Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy. <i>Journal of Translational Medicine</i> , 2014, 12, 148.	1.8	16
113	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. <i>Science</i> , 2014, 344, 1396-1401.	6.0	3,648
114	MGMT testing—the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014, 10, 372-385.	4.9	454
115	Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. <i>European Journal of Cancer, Supplement</i> , 2014, 12, 29-40.	2.2	82
116	Emerging treatment strategies for glioblastoma multiforme. <i>EMBO Molecular Medicine</i> , 2014, 6, 1359-1370.	3.3	280
117	Genetics and epigenetics of gliomas. <i>Swiss Medical Weekly</i> , 2014, 144, w14018.	0.8	7
118	Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma. <i>Journal of Visualized Experiments</i> , 2014, , e51638.	0.2	8
119	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology. <i>CNS Oncology</i> , 2014, 3, 191-193.	1.2	0
120	Pituitary Apoplexy After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitor: A Novel Complication. <i>Journal of Neurological Surgery Reports</i> , 2015, 76, e205-e210.	0.3	4

#	ARTICLE	IF	CITATIONS
121	Glioblastoma: Defining Tumor Niches. Trends in Cancer, 2015, 1, 252-265.	3.8	326
122	Selective depletion of tumor neovasculature by microbubble destruction with appropriate ultrasound pressure. International Journal of Cancer, 2015, 137, 2478-2491.	2.3	48
123	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. Journal of Internal Medicine, 2015, 278, 545-570.	2.7	46
124	Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Scientific Reports, 2015, 5, 8990.	1.6	58
125	Targeted cellular ablation based on the morphology of malignant cells. Scientific Reports, 2015, 5, 17157.	1.6	75
126	Glioma. Nature Reviews Disease Primers, 2015, 1, 15017.	18.1	718
127	Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis. Scientific Reports, 2015, 5, 14698.	1.6	20
129	Double-edged Sword in the Placement of Carmustine (BCNU) Wafers along the Eloquent Area: A Case Report. NMC Case Report Journal, 2015, 2, 40-45.	0.2	13
130	Dose-dense Temozolomide: Is It Still Promising?. Neurologia Medico-Chirurgica, 2015, 55, 38-49.	1.0	15
131	<i>In silico</i> analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma. Journal of the Royal Society Interface, 2015, 12, 20150388.	1.5	13
132	Anti-gliomas Effect of Chlorotoxin-Conjugated Onconase at High Dose. Cell Biochemistry and Biophysics, 2015, 73, 389-392.	0.9	4
134	Diffuse, non-traumatic, non-aneurysmal subarachnoid haemorrhage during bevacizumab treatment of high grade glioma: case report and review of the literature. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2015, 2, 65-68.	0.2	2
135	Extracranial metastasis of glioblastoma: Three illustrative cases and current review of the molecular pathology and management strategies. Molecular and Clinical Oncology, 2015, 3, 479-486.	0.4	55
136	Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. Neuro-Oncology, 2015, 17, 765-766.	0.6	3
138	Brain Tumor Clinical Trials. Neurosurgery, 2015, 62, 141-145.	0.6	0
139	Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Fluids and Barriers of the CNS, 2015, 12, 5.	2.4	27
140	Biopsy vs. extensive resection for first recurrence of glioblastoma: is a prospective clinical trial warranted?. BMC Research Notes, 2015, 8, 414.	0.6	5
141	Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma. Neurosurgery, 2015, 77, 777-785.	0.6	46

#	ARTICLE	IF	CITATIONS
142	Imaging of the Posttherapeutic Brain. Topics in Magnetic Resonance Imaging, 2015, 24, 147-154.	0.7	9
143	Management of diffusely infiltrating glioma in the elderly. Current Opinion in Oncology, 2015, 27, 502-509.	1.1	8
144	Imaging Genomics of Glioblastoma. Topics in Magnetic Resonance Imaging, 2015, 24, 155-163.	0.7	14
145	Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas. Topics in Magnetic Resonance Imaging, 2015, 24, 127-136.	0.7	20
146	Tumor treating fields. Current Opinion in Neurology, 2015, 28, 659-664.	1.8	8
148	The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors. Journal of Cancer, 2015, 6, 812-818.	1.2	19
149	Bevacizumab for glioblastoma. Therapeutics and Clinical Risk Management, 2015, 11, 1759.	0.9	36
150	Trends in Malignant Glioma Monoclonal Antibody Therapy. Current Cancer Therapy Reviews, 2015, 11, 102-118.	0.2	5
151	Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget, 2015, 6, 1190-1201.	0.8	87
152	Bevacizumab Trough Concentration in Recurrent Glioblastoma Patients. Journal of Integrative Oncology, 2015, 04, .	0.3	0
153	A fibrin antibody binding to fibronectin induces potent inhibition of angiogenesis. Thrombosis and Haemostasis, 2015, 113, 143-153.	1.8	4
154	Bevacizumab and Temozolomide plus Radiation Regimen for Glioblastoma Multiforme. Hospital Pharmacy, 2015, 50, 672-677.	0.4	1
155	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications. Frontiers in Immunology, 2015, 6, 505.	2.2	86
156	Targeting Aggressive Cancer Stem Cells in Glioblastoma. Frontiers in Oncology, 2015, 5, 159.	1.3	107
157	Commentary: “Neuropsychological Assessment of Individuals with Brain Tumor: Comparison of Approaches Used in the Classification of Impairment” Frontiers in Oncology, 2015, 5, 188.	1.3	3
158	International Differences in Treatment and Clinical Outcomes for High Grade Glioma. PLoS ONE, 2015, 10, e0129602.	1.1	11
159	Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PLoS ONE, 2015, 10, e0141334.	1.1	52
160	VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment. International Journal of Inflammation, 2015, 2015, 1-7.	0.9	6

#	ARTICLE	IF	CITATIONS
161	A Role of Boron Neutron Capture Therapy in the Multimodal Treatment for Malignant Glioma. <i>Radioisotopes</i> , 2015, 64, 79-91.	0.1	0
164	Clinical Trials in Glioblastoma " Designs and Challenges. , 2015, , .		4
167	Temozolomide Nanoparticles for Targeted Glioblastoma Therapy. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 6674-6682.	4.0	161
168	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. <i>Journal of Neuro-Oncology</i> , 2015, 123, 307-314.	1.4	16
169	Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. <i>British Journal of Cancer</i> , 2015, 113, 226-231.	2.9	16
170	Brain Tumor Imaging. <i>Medical Radiology</i> , 2015, , 1-9.	0.0	1
171	Malignant Glioma: Viewpoint"Chemotherapy. , 2015, , 279-293.		0
172	Limited advances in therapy of glioblastoma trigger re-consideration of research policy. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 257-261.	2.0	28
173	Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood-brain barrier. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 336-346.	2.3	104
175	Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1131-1137.	1.2	30
176	Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 124, 101-110.	1.4	11
178	AvancÃ©es dans les tumeurs cÃ©rÃ©brales primitives malignes de l'adulte : quels patients transfÃ©rer en rÃ©animation mÃ©dicale?. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2015, 24, 424-432.	0.1	1
179	Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor Å. <i>Neuro-Oncology</i> , 2015, 17, 832-842.	0.6	18
180	Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2166-2175.	0.8	112
181	Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy"Are We There Yet?. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 337-342.	1.0	8
182	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535.	3.8	982
183	Alternating Electric Fields for the Treatment of Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2511.	3.8	21
184	Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase II trial of radiotherapy/tipifarnib combination. <i>Journal of Neuro-Oncology</i> , 2015, 124, 465-473.	1.4	12

#	ARTICLE	IF	CITATIONS
185	Advances in the treatment of newly diagnosed glioblastoma. <i>BMC Medicine</i> , 2015, 13, 293.	2.3	36
186	Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. <i>Translational Oncology</i> , 2015, 8, 446-455.	1.7	3
187	A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 743-750.	1.2	12
188	Repair mechanisms help glioblastoma resist treatment. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 14-20.	0.8	48
189	Unravelling tumour heterogeneityâ€™ implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 69-70.	12.5	89
190	Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 122, 135-143.	1.4	29
191	Potential use of glioblastoma tumorsphere: clinical credentialing. <i>Archives of Pharmacal Research</i> , 2015, 38, 402-407.	2.7	23
192	Factorial clinical trials: a new approach to phase II neuro-oncology studies. <i>Neuro-Oncology</i> , 2015, 17, 174-176.	0.6	6
193	Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastoma. <i>CNS Oncology</i> , 2015, 4, 47-52.	1.2	24
194	New Strategies in Glioblastoma: Exploiting the New Biology. <i>Clinical Cancer Research</i> , 2015, 21, 1984-1988.	3.2	31
195	Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma. <i>Brain Tumor Pathology</i> , 2015, 32, 176-183.	1.1	28
197	Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis. <i>Journal of Neuro-Oncology</i> , 2015, 121, 591-598.	1.4	17
198	Differential regulation of TGF- β -induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 254-265.	0.6	65
199	Glioblastoma. , 2015, , 909-917.		6
200	Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. <i>Oncologist</i> , 2015, 20, 166-175.	1.9	66
201	Drug radiotherapy combinations: Review of previous failures and reasons for future optimism. <i>Cancer Treatment Reviews</i> , 2015, 41, 105-113.	3.4	78
202	Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. <i>Neuro-Oncology</i> , 2015, 17, 1106-1113.	0.6	21
203	Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. <i>Neuro-Oncology</i> , 2015, 17, 784-800.	0.6	49

#	ARTICLE	IF	CITATIONS
204	Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2015, 122, 317-323.	0.9	9
205	Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 121, 91-100.	1.4	30
206	Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2015, 122, 567-573.	1.4	39
207	Molecular Biology of Pediatric Brain Tumors and Impact on Novel Therapies. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 10.	2.0	6
208	Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 122, 585-593.	1.4	12
209	Liquid biopsies in patients with diffuse glioma. <i>Acta Neuropathologica</i> , 2015, 129, 849-865.	3.9	81
210	Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. <i>Journal of Neurology</i> , 2015, 262, 742-751.	1.8	10
211	Lessons From Anti-VEGF Vascular Endothelial Growth Factor and Anti-VEGFR Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1197-1213.	0.8	145
212	Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015, 122, 273-281.	1.4	12
213	Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. <i>Cancer</i> , 2015, 121, 1456-1462.	2.0	34
214	VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGF β 2R signaling-dependent manner. <i>Cancer Letters</i> , 2015, 360, 60-67.	3.2	39
215	Current evidence of temozolomide and bevacizumab in treatment of gliomas. <i>Neurological Research</i> , 2015, 37, 167-183.	0.6	45
216	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
217	Porphyryn Derivatives-Mediated Sonodynamic Therapy for Malignant Gliomas In Vitro. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2458-2465.	0.7	32
218	Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. <i>British Journal of Radiology</i> , 2015, 88, 20150354.	1.0	53
219	RNA-Binding Protein Musashi1 Is a Central Regulator of Adhesion Pathways in Glioblastoma. <i>Molecular and Cellular Biology</i> , 2015, 35, 2965-2978.	1.1	51
220	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. <i>European Journal of Cancer</i> , 2015, 51, 1321-1330.	1.3	45
221	Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. <i>Neuro-Oncology</i> , 2015, 17, 1609-1619.	0.6	60

#	ARTICLE	IF	CITATIONS
222	Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon- β , and/or bevacizumab for glioblastoma. <i>Nuclear Medicine and Biology</i> , 2015, 42, 598-607.	0.3	14
223	What is the optimal use of bevacizumab in glioblastoma?. <i>Nature Reviews Neurology</i> , 2015, 11, 429-430.	4.9	9
224	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2735-2744.	0.8	244
225	Recent advances in targeted therapy for glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 935-946.	1.4	42
226	Clinical Significance of Epigenetic Alterations in Glioblastoma. , 2015, , 339-350.		0
227	Heat shock protein vaccines against glioblastoma: from bench to bedside. <i>Journal of Neuro-Oncology</i> , 2015, 123, 441-448.	1.4	63
228	Treatment of Gliomas: How did we get here?. , 2015, 6, 85.		11
229	Cancer stem cells in glioblastoma. <i>Genes and Development</i> , 2015, 29, 1203-1217.	2.7	1,248
230	Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors. <i>Nanomedicine</i> , 2015, 10, 993-1018.	1.7	98
231	Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1000-1007.	0.4	80
232	Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain. <i>Neuroradiology Journal</i> , 2015, 28, 112-119.	0.6	19
233	Rindopimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?. <i>Immunotherapy</i> , 2015, 7, 603-606.	1.0	13
234	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	3.2	79
235	Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. <i>Journal of Neuro-Oncology</i> , 2015, 124, 215-221.	1.4	21
236	Molecular profiling of gliomas: potential therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 955-962.	1.1	22
237	Treatment of Elderly Patients With Glioblastoma. <i>JAMA Neurology</i> , 2015, 72, 589.	4.5	78
238	Toward precision medicine in glioblastoma: the promise and the challenges. <i>Neuro-Oncology</i> , 2015, 17, 1051-1063.	0.6	178
239	Polymeric drug delivery for the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, ii9-ii23.	0.6	65

#	ARTICLE	IF	CITATIONS
241	A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. <i>Gynecologic Oncology</i> , 2015, 137, 490-496.	0.6	52
242	VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. <i>Neurology</i> , 2015, 84, 1906-1908.	1.5	22
243	Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015, 19, 187-191.	0.6	4
245	Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 121, 331-339.	1.4	39
246	Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. <i>Journal of Neuro-Oncology</i> , 2015, 122, 595-605.	1.4	11
247	Bevacizumab in high-grade gliomas: past, present, and future. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 387-397.	1.1	18
248	Î³-Glutamyl transferase 7 is a novel regulator of glioblastoma growth. <i>BMC Cancer</i> , 2015, 15, 225.	1.1	16
250	Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. <i>Journal of Neuro-Oncology</i> , 2015, 123, 251-257.	1.4	22
252	Production of Antibodies in Hybridoma and Non-hybridoma Cell Lines. <i>Cell Engineering</i> , 2015, , 65-88.	0.4	1
253	Radiation Therapy for Glioma Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2015, 853, 85-110.	0.8	14
254	Overview of Epidemiology, Pathology, and Treatment of Primary Brain Tumors. , 2015, , 11-28.		2
256	Phase 1/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Cy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 961-967.	0.4	27
257	Molecular targets in glioblastoma. <i>Future Oncology</i> , 2015, 11, 1407-1420.	1.1	32
258	Bevacizumab in Recurrent Glioblastoma: Five Informative Patient Scenarios. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 149-156.	0.3	3
259	Chemotherapy in glioma. <i>CNS Oncology</i> , 2015, 4, 179-192.	1.2	58
260	Glioblastoma multiforme: Pathogenesis and treatment. , 2015, 152, 63-82.		588
261	Genetic Modulation of Neurocognitive Function in Glioma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3340-3346.	3.2	29
262	<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064.	3.2	264

#	ARTICLE	IF	CITATIONS
263	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , 2015, 17, 992-998.	0.6	116
264	The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas. <i>Neoplasia</i> , 2015, 17, 239-255.	2.3	114
265	Functional VEGFA knockdown with artificial 3'ΰ-tailed mirtrons defined by 5'ΰ splice site and branch point. <i>Nucleic Acids Research</i> , 2015, 43, 6568-6578.	6.5	8
266	Self-assembled 20-nm 64Cu-micelles enhance accumulation in rat glioblastoma. <i>Journal of Controlled Release</i> , 2015, 220, 51-60.	4.8	57
268	Radiation Therapy Intensification for Solid Tumors: A Systematic Review of RandomizedΰTrials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 737-745.	0.4	42
269	Case-Based Review: newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 106-121.	1.0	13
270	Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. <i>Clinical Cancer Research</i> , 2015, 21, 4630-4641.	3.2	56
271	Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations. <i>Expert Review of Medical Devices</i> , 2015, 12, 717-726.	1.4	18
272	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
273	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	0.6	346
274	A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 986-992.	0.4	166
275	Withholding temozolomide in glioblastoma patients with unmethylated<i>MGMT</i>promoterΰstill a dilemma?: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, 1425-1427.	0.6	78
276	MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 1174-1176.	0.6	48
277	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2015, 16, 54.	1.3	44
279	<i>CCR</i> 20th Anniversary Commentary: Bevacizumab in the Treatment of GlioblastomaΰThe Progress and the Limitations. <i>Clinical Cancer Research</i> , 2015, 21, 4248-4250.	3.2	5
280	Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 885-891.	1.1	12
281	The Globalization of Cooperative Groups. <i>Seminars in Oncology</i> , 2015, 42, 693-712.	0.8	6
282	Wound healing complications in brain tumor patients on Bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 124, 501-506.	1.4	18

#	ARTICLE	IF	CITATIONS
283	The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors. <i>Current Treatment Options in Oncology</i> , 2015, 16, 36.	1.3	10
284	Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma. <i>Cell Death and Disease</i> , 2015, 6, e1732-e1732.	2.7	22
285	Does Hippocampal-Avoidance Whole-Brain Radiotherapy for Brain Metastases Meaningfully Change Current Practice?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1985-1985.	0.8	5
286	Novel chemotherapeutics and other therapies for treating high-grade glioma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1361-1379.	1.9	23
287	The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner. <i>Journal of Clinical Pathology</i> , 2015, 68, 830-834.	1.0	14
288	Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging. <i>Acta Oncol</i> , 2015, 54, 1521-1528.	0.8	8
289	Can We Predict Bevacizumab Responders in Patients With Glioblastoma?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2721-2722.	0.8	13
290	Circulating biomarkers for gliomas. <i>Nature Reviews Neurology</i> , 2015, 11, 556-566.	4.9	154
291	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2015, 33, 2986-2998.	0.8	175
292	Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis. <i>Journal of Biological Chemistry</i> , 2015, 290, 23401-23415.	1.6	67
293	To what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?. <i>CNS Oncology</i> , 2015, 4, 265-272.	1.2	10
294	What next for newly diagnosed glioblastoma?. <i>Future Oncology</i> , 2015, 11, 3273-3283.	1.1	22
295	Microenvironmental regulation of therapeutic response in cancer. <i>Trends in Cell Biology</i> , 2015, 25, 198-213.	3.6	604
297	Inositol Polyphosphate-5-Phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity. <i>Scientific Reports</i> , 2015, 4, 7330.	1.6	28
298	Current Medical Treatment of Glioblastoma. <i>Cancer Treatment and Research</i> , 2015, 163, 103-115.	0.2	66
299	Contemporary murine models in preclinical astrocytoma drug development. <i>Neuro-Oncology</i> , 2015, 17, 12-28.	0.6	23
300	Medical management of brain tumors and the sequelae of treatment. <i>Neuro-Oncology</i> , 2015, 17, 488-504.	0.6	114
301	Current Understanding and Treatment of Gliomas. <i>Cancer Treatment and Research</i> , 2015, , .	0.2	11

#	ARTICLE	IF	CITATIONS
302	Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. <i>Acta Neuropathologica</i> , 2015, 129, 115-131.	3.9	122
303	Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. <i>Neuro-Oncology</i> , 2015, 17, 580-587.	0.6	115
304	Novel Points of Attack for Targeted Cancer Therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 9-18.	1.2	61
305	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	0.6	28
306	Anti-tumor effects of progesterone in human glioblastoma multiforme: Role of PI3K/Akt/mTOR signaling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 146, 62-73.	1.2	82
307	Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. <i>Cancer</i> , 2015, 121, 502-516.	2.0	120
308	Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies. <i>Cancer</i> , 2015, 121, 997-1007.	2.0	62
309	The Roles of MicroRNAs in Glioblastoma Biology and Biomarker. , 2016, , .		4
310	Current Trends in High-Grade Gliomas. , 2016, , .		0
311	Novel Endocrine Targets for GBM Therapy. , 2016, , .		0
312	Brain Tumors: Epidemiology and Current Trends in Treatment. <i>Journal of Brain Tumors & Neurooncology</i> , 2016, 01, .	0.1	6
313	Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. <i>OncoTargets and Therapy</i> , 2016, 9, 1115.	1.0	14
314	Vascular complications in glioma patients. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016, 134, 251-266.	1.0	8
315	Current Standards of Care in Glioblastoma Therapy. , 2016, , 73-80.		7
316	Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma. <i>OncoTargets and Therapy</i> , 2016, 9, 1205.	1.0	18
317	Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6669-6677.	1.0	8
318	Sirolimus and Hydroxychloroquine as an Add-On to Standard Therapy for Glioblastoma Multiforme: Case Report. <i>Journal of Biomolecular Research & Therapeutics</i> , 2016, 5, .	0.2	0
319	National and Global Economic Impact of Glioblastoma. , 2016, , 271-278.		1

#	ARTICLE	IF	CITATIONS
320	Multimodality Targeting of Glioma Cells. , 2016, , 55-72.		0
321	Hallmarks of glioblastoma: a systematic review. ESMO Open, 2016, 1, e000144.	2.0	122
322	Therapeutic Potential of Curcumin for the Treatment of Brain Tumors. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-14.	1.9	61
323	High-Grade Glioma Management and Response Assessment—Recent Advances and Current Challenges. Current Oncology, 2016, 23, 383-391.	0.9	33
324	Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. Frontiers in Oncology, 2016, 6, 165.	1.3	9
325	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. Frontiers in Oncology, 2016, 6, 256.	1.3	39
326	Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme. PLoS ONE, 2016, 11, e0146617.	1.1	20
327	A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015. PLoS ONE, 2016, 11, e0148312.	1.1	20
328	c-Met—mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. Journal of Clinical Investigation, 2016, 126, 1801-1814.	3.9	92
329	Evolving Molecular Genetics of Glioblastoma. Chinese Medical Journal, 2016, 129, 464-471.	0.9	41
330	Immune Evasion Strategies of Glioblastoma. Frontiers in Surgery, 2016, 3, 11.	0.6	189
331	Health-related Quality of Life and Neurocognitive Functioning After Glioblastoma Treatment. , 2016, , 253-263.		0
332	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Oncotarget, 2016, 7, 65643-65659.	0.8	35
333	Health-related quality of life in glioma patients. , 0, , 190-204.		0
334	Chemotherapy for gliomas. , 0, , 76-90.		0
335	Comprehensive Genomic Analysis of Infiltrative Gliomas Based on Molecular Profile. Neurosurgery, 2016, 78, N15-N16.	0.6	0
336	Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. Journal of Pediatric Hematology/Oncology, 2016, 38, 249-260.	0.3	26
337	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer, 2016, 122, 582-587.	2.0	33

#	ARTICLE	IF	CITATIONS
338	Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas. <i>International Journal of Cancer</i> , 2016, 138, 1269-1280.	2.3	12
339	A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. <i>International Journal of Cancer</i> , 2016, 138, 1538-1544.	2.3	5
340	Role of microRNA's Located on Chromosome Arm 10q in Malignant Gliomas. <i>Brain Pathology</i> , 2016, 26, 344-358.	2.1	26
341	MicroRNA-20b Downregulates HIF-1 α and Inhibits the Proliferation and Invasion of Osteosarcoma Cells. <i>Oncology Research</i> , 2016, 23, 257-266.	0.6	37
342	Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with ^{131}T cells in human glioblastoma in vitro and in vivo. <i>Journal of Neuro-Oncology</i> , 2016, 129, 231-241.	1.4	15
343	The effects of sequential treatments on hippocampal volumes in malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2016, 129, 433-441.	1.4	14
344	Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2016, 20, 282-291.	0.6	11
345	Depletion of thymopoietin inhibits proliferation and induces cell cycle arrest/apoptosis in glioblastoma cells. <i>World Journal of Surgical Oncology</i> , 2016, 14, 267.	0.8	21
346	Brain Tumours. <i>Medical Radiology</i> , 2016, , 127-142.	0.0	0
347	EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance. <i>Nature Communications</i> , 2016, 7, 12329.	5.8	57
348	Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. <i>Neuro-Oncology</i> , 2017, 19, now270.	0.6	32
349	Reply to T.J. Kruser et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1282-1283.	0.8	1
350	Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. <i>American Journal of Neuroradiology</i> , 2016, 37, 2201-2208.	1.2	59
351	Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF- β 2 Small Molecule Inhibitor. <i>Neoplasia</i> , 2016, 18, 795-805.	2.3	35
352	Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy. <i>Journal of Neurosurgery</i> , 2016, 125, 40-49.	0.9	24
353	Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. <i>EMBO Molecular Medicine</i> , 2016, 8, 39-57.	3.3	140
354	Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. <i>World Journal of Surgical Oncology</i> , 2016, 14, 225.	0.8	134
355	Neurocognitive functioning in patients with glioma of the left and right temporal lobes. <i>Journal of Neuro-Oncology</i> , 2016, 128, 323-331.	1.4	54

#	ARTICLE	IF	CITATIONS
357	Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2016, 6, 217-225.	1.1	162
358	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4470-4475.	3.3	251
359	Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4476-4481.	3.3	287
360	Ipilimumab and Bevacizumab in Glioblastoma. <i>Clinical Oncology</i> , 2016, 28, 622-626.	0.6	64
361	Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial. <i>Medical Decision Making</i> , 2016, 36, 615-628.	1.2	7
362	Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 1953-1956.	0.8	59
363	Clinical research and methodology: What usage and what hierarchical order for secondary endpoints?. <i>Therapie</i> , 2016, 71, 35-41.	0.6	5
364	Investigational new drugs for brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 937-956.	1.9	16
365	Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2016, 129, 93-100.	1.4	22
366	Rehabilitation of patients with glioma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 287-304.	1.0	19
367	The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1129-1136.	0.6	85
368	Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4526-4538.	2.9	28
369	Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. <i>Neuro-Oncology</i> , 2016, 18, ii13-ii20.	0.6	27
370	Predictors of Venous Thromboembolism in Patients with Glioblastoma. <i>Pathology and Oncology Research</i> , 2016, 22, 311-316.	0.9	10
371	Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2016, 18, 1313-1318.	0.6	39
372	Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results. <i>Journal of Clinical Oncology</i> , 2016, 34, 1567-1569.	0.8	21
373	Pharmacotherapies for the treatment of glioblastoma â€“ current evidence and perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1259-1270.	0.9	24
374	HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. <i>Angiogenesis</i> , 2016, 19, 257-273.	3.7	22

#	ARTICLE	IF	CITATIONS
375	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796.	3.2	95
376	Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials. <i>Molecular and Clinical Oncology</i> , 2016, 4, 833-838.	0.4	35
377	A critical balance: managing coagulation in patients with glioma. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 803-814.	1.4	3
378	Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1581-1589.	1.2	28
379	Complications from radiotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 219-234.	1.0	16
380	Complications from pharmacotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 235-250.	1.0	4
381	Translation of Targeted Radiation Sensitizers into Clinical Trials. <i>Seminars in Radiation Oncology</i> , 2016, 26, 261-270.	1.0	16
382	Subventricular zone-associated glioblastoma: A call for translational research to guide clinical decision making. <i>Neurogenesis (Austin, Tex)</i> , 2016, 3, e1225548.	1.5	6
383	Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 591-599.	1.4	28
384	Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis. <i>Oncology Letters</i> , 2016, 12, 2139-2144.	0.8	17
385	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. <i>Molecular Oncology</i> , 2016, 10, 1296-1304.	2.1	19
386	Imaging Genomics in Glioblastoma Multiforme. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 731-740.	0.6	7
387	Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. <i>Cell Death and Disease</i> , 2016, 7, e2325-e2325.	2.7	34
388	High-Grade Gliomas. , 2016, , 469-482.e4.		1
389	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Neuro-Oncology</i> , 2017, 19, now208.	0.6	109
390	The Long and Winding Road. <i>Advances in Pharmacology</i> , 2016, 76, 147-173.	1.2	2
391	Detecting tumor progression in glioma: current standards and new techniques. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1177-1188.	1.1	18
392	Precision medicine in glioblastoma therapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 451-468.	0.4	0

#	ARTICLE	IF	CITATIONS
393	Psycho-oncology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 305-313.	1.0	0
394	CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway. Cancer Letters, 2016, 381, 391-403.	3.2	25
395	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. Current Treatment Options in Oncology, 2016, 17, 51.	1.3	32
396	Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncology, 2016, 18, 1434-1441.	0.6	68
397	Morphological Changes of Cortical and Hippocampal Neurons after Treatment with <sc>VEGF</sc> and Bevacizumab. CNS Neuroscience and Therapeutics, 2016, 22, 440-450.	1.9	13
398	Inhibition of cell proliferation, migration and invasion by a glioma-targeted fusion protein combining the p53 C terminus and MDM2-binding domain. Cell Proliferation, 2016, 49, 79-89.	2.4	9
399	Human cytomegalovirus infection contributes to glioma disease progression via upregulating endocan expression. Translational Research, 2016, 177, 113-126.	2.2	22
400	Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. Journal of Neuro-Oncology, 2016, 130, 171-179.	1.4	24
401	Coffee and green tea consumption in relation to brain tumor risk in a Japanese population. International Journal of Cancer, 2016, 139, 2714-2721.	2.3	22
402	Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide. Journal of Neuro-Oncology, 2016, 130, 165-170.	1.4	39
403	Targeted Therapies for Glioma Stem Cells. , 2016, , 459-471.		0
404	Efficacy and safety of bevacizumab for the treatment of glioblastoma. Experimental and Therapeutic Medicine, 2016, 11, 371-380.	0.8	12
405	Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 705-718.	0.6	25
406	Dynamic Susceptibility Contrast MR Imaging in Glioma. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 649-670.	0.6	43
407	Caring for Patients with Newly Diagnosed High-Grade Gliomas. Seminars in Neurology, 2016, 36, 324-329.	0.5	0
408	The nuts and bolts of hypothesis testing. Neuro-Oncology Practice, 2016, 3, 139-144.	1.0	3
409	A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Neuro-Oncology, 2016, 129, 487-494.	1.4	52
410	Overview of Pathology and Treatment of Primary Brain Tumors. , 2016, , 9-22.		2

#	ARTICLE	IF	CITATIONS
411	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 533-539.	1.4	5
412	OTX015 (MK-8628), a novel BET inhibitor, displays <i>in vitro</i> and <i>in vivo</i> antitumor effects alone and in combination with conventional therapies in glioblastoma models. <i>International Journal of Cancer</i> , 2016, 139, 2047-2055.	2.3	112
413	Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response. <i>Clinical Cancer Research</i> , 2016, 22, 5765-5771.	3.2	230
414	Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme. <i>Scientific Reports</i> , 2016, 6, 29052.	1.6	19
415	Emerging targeted therapies for glioma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 441-452.	1.0	45
417	Future Directions for Tumor Treating Fields. , 2016, , 117-126.		0
418	Tumor Treating Fields in Clinical Practice with Emphasis on PRiDe Registry. , 2016, , 79-92.		1
419	Tumor Treating Fields Therapy for Newly Diagnosed Glioblastoma. , 2016, , 93-102.		0
420	Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. <i>Nature Communications</i> , 2016, 7, 12680.	5.8	89
421	Laser Ablation of Recurrent Malignant Gliomas. <i>Neurosurgery</i> , 2016, 79, S35-S39.	0.6	20
422	MediBoost: a Patient Stratification Tool for Interpretable Decision Making in the Era of Precision Medicine. <i>Scientific Reports</i> , 2016, 6, 37854.	1.6	85
424	Brève de l'IAERIO. <i>Oncologie</i> , 2016, 18, 355-357.	0.2	2
428	Health-related quality of life in brain tumor patients: as an endpoint in clinical trials and its value in clinical care. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 37-44.	0.6	14
429	Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma—An Easy Question Turned Difficult: Treat the Scan or the Patient?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1281-1282.	0.8	6
430	Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology Group. <i>Radiation Oncology</i> , 2016, 10, 137.	1.2	20
431	Radiotherapy of spinal cord gliomas. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 139-145.	1.0	14
432	Assessment of Brain Tumor Response: RANO and Its Offspring. <i>Current Treatment Options in Oncology</i> , 2016, 17, 35.	1.3	65
433	Radiobiology of Glioblastoma. <i>Current Clinical Pathology</i> , 2016, , .	0.0	2

#	ARTICLE	IF	CITATIONS
434	Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report. <i>Neuro-Oncology</i> , 2016, 18, ii1-ii12.	0.6	26
435	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2016, 18, ii26-ii36.	0.6	22
437	Glioblastoma in the elderly: making sense of the evidence. <i>Neuro-Oncology Practice</i> , 2016, 3, 77-86.	1.0	17
438	Molecular Radio-Oncology. <i>Recent Results in Cancer Research</i> , 2016, , .	1.8	1
439	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. <i>Recent Results in Cancer Research</i> , 2016, 198, 107-122.	1.8	12
440	From Molecular to Clinical Radiation Biology of Glioblastoma. <i>Current Clinical Pathology</i> , 2016, , 275-292.	0.0	0
441	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2166-2174.	1.9	51
442	ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2018-2029.	1.9	22
443	Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. <i>Current Treatment Options in Oncology</i> , 2016, 17, 42.	1.3	95
444	Developing immunotherapeutic strategies to target brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 775-788.	1.1	5
447	Neuroimaging Issues in Assessing Response to Brain Tumor Therapy. , 2016, , 667-680.		0
448	Neuroimaging. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 27-50.	1.0	6
449	Limited role for transforming growth factor α pathway activation-mediated escape from VEGF inhibition in murine glioma models. <i>Neuro-Oncology</i> , 2016, 18, 1610-1621.	0.6	27
450	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
451	Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. <i>Seminars in Radiation Oncology</i> , 2016, 26, 281-298.	1.0	23
452	Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients. <i>Molecular Neurobiology</i> , 2016, 53, 1501-1508.	1.9	10
453	Tumor vasculature and glioma stem cells: Contributions to glioma progression. <i>Cancer Letters</i> , 2016, 380, 545-551.	3.2	106
454	High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma. <i>Molecular Neurobiology</i> , 2016, 53, 2354-2360.	1.9	23

#	ARTICLE	IF	CITATIONS
455	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	0.8	159
456	Controlled delivery of antibodies from injectable hydrogels. <i>Materials Science and Engineering C</i> , 2016, 59, 801-806.	3.8	30
457	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. <i>Cancer Research</i> , 2016, 76, 525-534.	0.4	93
458	Ten years of anti-vascular endothelial growth factor therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 385-403.	21.5	724
459	Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM). <i>Molecular and Cellular Proteomics</i> , 2016, 15, 481-492.	2.5	41
461	Similar Trials With Differing Outcomes: Reconciliation in Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 291-292.	0.8	1
462	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2016, 34, 292-293.	0.8	0
463	Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts. <i>Investigational New Drugs</i> , 2016, 34, 24-40.	1.2	49
464	A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 127, 53-61.	1.4	37
465	Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. <i>Neuro-Oncology</i> , 2016, 18, 173-183.	0.6	35
466	Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean) Tj ETQq0 0 0 rgB10 Overlook 10 Tf 50	0.0	0
467	Glioblastoma: Radiation treatment margins, how small is large enough?. <i>Practical Radiation Oncology</i> , 2016, 6, 298-305.	1.1	36
468	Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. <i>Neurotherapeutics</i> , 2016, 13, 226-236.	2.1	24
469	Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 241-250.	1.4	26
470	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O ⁶ -Methylguanine "DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1611-1619.	0.8	151
471	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 381-397.	1.0	289
472	Tumor cell "specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. <i>Journal of Neurosurgery</i> , 2016, 125, 995-1001.	0.9	1
473	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 497-521.	9.6	37

#	ARTICLE	IF	CITATIONS
474	Creating clinical trial designs that incorporate clinical outcome assessments. <i>Neuro-Oncology</i> , 2016, 18, ii21-ii25.	0.6	6
475	Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. <i>Neuro-Oncology</i> , 2016, 18, 486-496.	0.6	44
476	Targeting metastasis. <i>Nature Reviews Cancer</i> , 2016, 16, 201-218.	12.8	1,111
477	Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 47-53.	0.7	15
478	Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept. <i>CNS Oncology</i> , 2016, 5, 101-108.	1.2	59
479	Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. <i>Neuro-Oncology</i> , 2016, 18, 1242-1252.	0.6	61
480	Personalized medicine in neuro-oncology. <i>CNS Oncology</i> , 2016, 5, 55-58.	1.2	8
481	Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. <i>British Journal of Cancer</i> , 2016, 114, 485-496.	2.9	61
482	Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. <i>Neuro-Oncology</i> , 2016, 18, 991-1001.	0.6	38
483	Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet, The</i> , 2016, 388, 518-529.	6.3	663
484	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. <i>Journal of Neuro-Oncology</i> , 2016, 127, 569-579.	1.4	40
485	How I treat glioblastoma in older patients. <i>Journal of Geriatric Oncology</i> , 2016, 7, 1-6.	0.5	6
486	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556.	0.6	187
487	A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. <i>Journal of Neuro-Oncology</i> , 2016, 128, 259-266.	1.4	53
488	A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature. <i>Pathology Research and Practice</i> , 2016, 212, 491-499.	1.0	25
489	Experimental therapies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 183-197.	1.0	22
490	TFields: where does all the skepticism come from?. <i>Neuro-Oncology</i> , 2016, 18, 303-305.	0.6	55
491	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2016, 22, 2885-2896.	3.2	45

#	ARTICLE	IF	CITATIONS
492	Epithelial-mesenchymal transition in glioblastoma progression. <i>Oncology Letters</i> , 2016, 11, 1615-1620.	0.8	207
493	Neurocognitive functioning and genetic variation in patients with primary brain tumours. <i>Lancet Oncology</i> , 2016, 17, e97-e108.	5.1	51
494	A case of complete clearance of chronic subdural hematoma accompanied by recurrent glioblastoma multiforme after administration of bevacizumab. <i>Neurosurgical Review</i> , 2016, 39, 525-529.	1.2	2
495	Standard chemoradiation for glioblastoma results in progressive brain volume loss. <i>Neurology</i> , 2016, 86, 979-979.	1.5	3
496	<i>ADCY5</i> mutations are another cause of benign hereditary chorea. <i>Neurology</i> , 2016, 86, 978-979.	1.5	4
497	Prospective of curcumin, a pleiotropic signalling molecule from <i>Curcuma longa</i> in the treatment of Glioblastoma. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 23-35.	2.6	59
498	The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. <i>Journal of Neuro-Oncology</i> , 2016, 127, 165-171.	1.4	14
499	Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 82-88.	0.6	15
500	Angiotensin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma. <i>Cancer Investigation</i> , 2016, 34, 39-44.	0.6	34
501	Low density lipoprotein receptor-related protein 1 mediated endocytosis of β 1-integrin influences cell adhesion and cell migration. <i>Experimental Cell Research</i> , 2016, 340, 102-115.	1.2	31
502	Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. <i>Journal of Neuro-Oncology</i> , 2016, 126, 567-575.	1.4	31
503	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. <i>Cancer Immunology Research</i> , 2016, 4, 124-135.	1.6	339
504	USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance. <i>Neuro-Oncology</i> , 2016, 18, 37-47.	0.6	77
505	Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey. <i>Journal of Cancer Survivorship</i> , 2016, 10, 302-311.	1.5	52
506	New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it. <i>Journal of NeuroInterventional Surgery</i> , 2016, 8, 1078-1082.	2.0	13
507	Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 467-478.	0.6	67
508	Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. <i>Oncogene</i> , 2016, 35, 2615-2623.	2.6	100
509	Application of Ultrahigh Field Magnetic Resonance Imaging in the Treatment of Brain Tumors: A Meta-Analysis. <i>World Neurosurgery</i> , 2016, 86, 450-465.	0.7	7

#	ARTICLE	IF	CITATIONS
510	Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. <i>Journal of Neuro-Oncology</i> , 2016, 126, 175-183.	1.4	18
511	A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. <i>Journal of Neuro-Oncology</i> , 2016, 126, 185-192.	1.4	63
512	Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. <i>Journal of Neurosurgery</i> , 2016, 124, 998-1007.	0.9	109
513	Current status and future directions of anti-angiogenic therapy for gliomas. <i>Neuro-Oncology</i> , 2016, 18, 315-328.	0.6	61
514	The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. <i>Neuro-Oncology</i> , 2016, 18, 252-260.	0.6	105
515	Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma. <i>Tumor Biology</i> , 2016, 37, 1173-1182.	0.8	39
516	Integrating chemoradiation and molecularly targeted therapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 74-83.	6.6	22
517	Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. <i>Neuro-Oncology Practice</i> , 2017, 4, 15-23.	1.0	6
518	Trans sodium crocetin with temozolomide and radiation therapy for glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2017, 126, 460-466.	0.9	31
519	Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab. <i>Clinical and Translational Oncology</i> , 2017, 19, 51-57.	1.2	13
520	Current and future strategies for treatment of glioma. <i>Neurosurgical Review</i> , 2017, 40, 1-14.	1.2	416
521	The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 53-65.	1.6	80
522	SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI. <i>Neoplasia</i> , 2017, 19, 1-7.	2.3	43
523	Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 60-65.	2.0	75
524	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. <i>Seminars in Immunopathology</i> , 2017, 39, 225-239.	2.8	42
525	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 181-188.	1.4	16
526	Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 105-110.	0.4	15
527	Glioma: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 263-282.	3.9	223

#	ARTICLE	IF	CITATIONS
528	Combating Established Mouse Glioblastoma through Nicotinylatedâ€Liposomesâ€Mediated Targeted Chemotherapy in Combination with Dendriticâ€Cellâ€Based Genetic Immunization. <i>Advanced Biology</i> , 2017, 1, e1600009.	3.0	15
529	Antiangiogenic Therapy for Malignant Gliomas. , 2017, , 163-175.		0
530	Glioblastoma. , 2017, , 265-288.		11
531	Current Standard Treatment Options for Malignant Glioma. , 2017, , 123-131.		1
532	New Directions in Anti-Angiogenic Therapy for Glioblastoma. <i>Neurotherapeutics</i> , 2017, 14, 321-332.	2.1	91
533	Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 239-247.	1.4	32
534	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. <i>Neurotherapeutics</i> , 2017, 14, 307-320.	2.1	294
535	Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma. <i>Cell Reports</i> , 2017, 18, 961-976.	2.9	76
536	1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 561-570.	2.8	12
537	Role of ketogenic metabolic therapy in malignant glioma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 41-58.	2.0	67
538	Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. <i>Cytotherapy</i> , 2017, 19, 445-457.	0.3	59
539	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3575-3584.	3.2	78
540	On glioblastoma and the search for a cure: where do we stand?. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2451-2466.	2.4	56
541	Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model. <i>BMC Cancer</i> , 2017, 17, 126.	1.1	21
542	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017, 75, 245-258.	1.3	82
543	Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 94-102.	2.0	73
544	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 3794-3801.	3.2	103
545	Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism. <i>Radiation Research</i> , 2017, 187, 79-88.	0.7	15

#	ARTICLE	IF	CITATIONS
546	Coâ€inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. <i>Immunological Reviews</i> , 2017, 276, 9-25.	2.8	13
547	The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas. <i>International Journal of Oncology</i> , 2017, 50, 515-524.	1.4	12
548	Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 81.	6.9	114
552	Inhibitors of Vascular Endothelial Growth Factor Receptor. <i>Topics in Medicinal Chemistry</i> , 2017, , 105-139.	0.4	1
553	How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. <i>Annals of Oncology</i> , 2017, 28, 2077-2085.	0.6	30
554	PET/MRI and brain tumors: focus on radiation oncology treatment planning. <i>Clinical and Translational Imaging</i> , 2017, 5, 159-167.	1.1	3
555	Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a <i>post hoc</i> analysis of the EF-14 trial. <i>CNS Oncology</i> , 2017, 6, 185-193.	1.2	43
556	Neuro-Oncology: Current Concepts and Emerging Therapeutics. <i>Neurotherapeutics</i> , 2017, 14, 253-255.	2.1	1
557	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	4.9	125
558	Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2017, 19, 1688-1697.	0.6	84
559	Primary spinal glioblastoma multiforme. <i>Medicine (United States)</i> , 2017, 96, e6634.	0.4	42
560	A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. <i>Journal of Translational Medicine</i> , 2017, 15, 104.	1.8	100
562	The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis. <i>Clinical Neurology and Neurosurgery</i> , 2017, 159, 6-12.	0.6	8
563	Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma. <i>British Journal of Cancer</i> , 2017, 116, 1572-1584.	2.9	35
564	Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature. <i>World Neurosurgery</i> , 2017, 105, 53-62.	0.7	16
565	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	5.1	816
567	A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery. <i>Brain Tumor Pathology</i> , 2017, 34, 98-102.	1.1	4
568	Angiogenesis inhibitors in tackling recurrent glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 507-515.	1.1	28

#	ARTICLE	IF	CITATIONS
569	Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. <i>Cancer Medicine</i> , 2017, 6, 1192-1200.	1.3	24
570	Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 17-27.	1.0	8
571	Brain Tumors and Metastases. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2017, 28, 115-141.	0.7	35
572	Metabolomic signature of brain cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 2355-2371.	1.3	86
574	An Update on the Approach to the Imaging of Brain Tumors. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 53.	2.0	11
575	The role of bevacizumab in the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 133, 455-467.	1.4	157
576	Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 469-474.	0.6	34
577	Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. <i>Journal of Neuro-Oncology</i> , 2017, 133, 297-307.	1.4	20
578	Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era. <i>Mayo Clinic Proceedings</i> , 2017, 92, 995-1004.	1.4	15
579	Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma. <i>Cancer Letters</i> , 2017, 402, 131-141.	3.2	33
581	Glioblastoma targeted therapy: updated approaches from recent biological insights. <i>Annals of Oncology</i> , 2017, 28, 1457-1472.	0.6	314
582	Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. <i>Oncologist</i> , 2017, 22, 570-575.	1.9	23
583	The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. <i>Angiogenesis</i> , 2017, 20, 217-232.	3.7	26
584	Primary Spinal Cord Glioblastoma Multiforme: A Retrospective Study of Patients at a Single Institution. <i>World Neurosurgery</i> , 2017, 106, 113-119.	0.7	15
585	Asim K. Bag. , 0, , 443-444.		0
586	Milestones of the last 10 years. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 18-21.	0.3	8
587	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126.	0.6	107
588	Allergy is associated with reduced risk of glioma: A meta-analysis. <i>Allergologia Et Immunopathologia</i> , 2017, 45, 553-559.	1.0	5

#	ARTICLE	IF	CITATIONS
589	Management of Elderly Patients with Glioblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 35.	2.0	12
590	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 908-917.	0.6	23
591	Central nervous system gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 213-234.	2.0	109
592	Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. <i>Brain Tumor Pathology</i> , 2017, 34, 62-77.	1.1	82
593	Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. <i>American Journal of Pathology</i> , 2017, 187, 940-953.	1.9	80
594	The Microenvironmental Landscape of Brain Tumors. <i>Cancer Cell</i> , 2017, 31, 326-341.	7.7	1,163
595	Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. <i>Radiotherapy and Oncology</i> , 2017, 123, 106-111.	0.3	32
596	Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. <i>Journal of Neuro-Oncology</i> , 2017, 132, 433-437.	1.4	12
597	Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. <i>Scientific Reports</i> , 2017, 7, 44075.	1.6	27
598	Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme. <i>Scientific Reports</i> , 2017, 7, 43523.	1.6	20
599	Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. <i>Journal of Neurology</i> , 2017, 264, 350-358.	1.8	27
600	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-369.	0.8	109
601	The network of immunosuppressive pathways in glioblastoma. <i>Biochemical Pharmacology</i> , 2017, 130, 1-9.	2.0	76
602	Advances in the molecular genetics of gliomas – implications for classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 434-452.	12.5	497
603	Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity. <i>Cancer Drug Discovery and Development</i> , 2017, , 35-55.	0.2	1
604	Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice. <i>Neuro-Oncology Practice</i> , 2017, 4, 209-219.	1.0	17
605	Targeting Aberrant Signaling Pathways. , 2017, , 133-150.		1
606	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanine-DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-351.	0.8	110

#	ARTICLE	IF	CITATIONS
607	The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion on Drug Safety, 2017, 16, 277-287.	1.0	19
608	Toward Personalized Targeted Therapeutics: An Overview. Neurotherapeutics, 2017, 14, 256-264.	2.1	22
609	Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma. Cancer Immunology, Immunotherapy, 2017, 66, 379-389.	2.0	20
610	ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. Oncology Letters, 2017, 14, 5443-5451.	0.8	6
611	Angiogenesis and Lymphangiogenesis in Gastric MALT Lymphoma: Relation of VEGF and VASH2. , 2017, , 177-188.		0
612	Treatment of Glioblastoma in Older Adults. Current Oncology Reports, 2017, 19, 81.	1.8	45
613	Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. Cancer Investigation, 2017, 35, 519-534.	0.6	54
614	Recent Advances for Targeted Therapies in Glioblastoma. Current Cancer Research, 2017, , 91-115.	0.2	0
615	Targeting cellular pathways in glioblastoma multiforme. Signal Transduction and Targeted Therapy, 2017, 2, 17040.	7.1	233
616	Actein inhibits glioma growth via a mitochondria-mediated pathway. Cancer Biomarkers, 2017, 18, 329-338.	0.8	5
617	Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy related intracranial effects. British Journal of Radiology, 2018, 91, 20170553.	1.0	3
618	Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation. OMICS A Journal of Integrative Biology, 2017, 21, 429-439.	1.0	15
619	Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. Journal of Extracellular Vesicles, 2017, 6, 1359479.	5.5	206
620	TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2230-2238.	3.3	91
621	RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Life Sciences, 2017, 188, 26-36.	2.0	47
622	Hypoxia and positron emission tomography in patients with gliomas. Clinical and Translational Imaging, 2017, 5, 447-453.	1.1	1
623	The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma. Journal of Neuro-Oncology, 2017, 135, 553-560.	1.4	24
624	Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology, 2017, 119, 75-93.	2.0	13

#	ARTICLE	IF	CITATIONS
625	Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216.		0
627	Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity. <i>Clinical Cancer Research</i> , 2017, 23, 6292-6304.	3.2	69
628	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. <i>Oncology Letters</i> , 2017, 14, 1141-1146.	0.8	58
629	Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature. <i>Journal of Clinical Neuroscience</i> , 2017, 44, 101-106.	0.8	28
630	The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET). <i>Cancer</i> , 2017, 123, 3576-3582.	2.0	9
631	A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK. <i>Stem Cell Reports</i> , 2017, 9, 451-463.	2.3	63
632	MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells. <i>Cancer Research</i> , 2017, 77, 4947-4960.	0.4	91
633	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. <i>Journal of Neuro-Oncology</i> , 2017, 135, 183-192.	1.4	138
634	Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. <i>International Journal of Cancer</i> , 2017, 141, 1891-1900.	2.3	23
635	Genetically Engineered Multilineage-Differentiating Stress-Enduring Cells as Cellular Vehicles against Malignant Gliomas. <i>Molecular Therapy - Oncolytics</i> , 2017, 6, 45-56.	2.0	8
636	Current Therapies and Future Directions in Treatment of Glioblastoma. <i>Current Cancer Research</i> , 2017, , 57-89.	0.2	1
637	GBM radiosensitizers: dead in the water or just the beginning?. <i>Journal of Neuro-Oncology</i> , 2017, 134, 513-521.	1.4	19
638	Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature. <i>Nanoscale</i> , 2017, 9, 12096-12109.	2.8	23
639	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	2.0	4
640	The Prognostic Impact of Ventricular Opening in Glioblastoma Surgery: A Retrospective Single Center Analysis. <i>World Neurosurgery</i> , 2017, 106, 615-624.	0.7	19
641	Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients. <i>Medicine (United States)</i> , 2017, 96, e7422.	0.4	39
642	Cell Signaling Pathways in Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 15-26.	0.7	5
643	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 75.	2.0	15

#	ARTICLE	IF	CITATIONS
644	Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2017, 133, 571-579.	1.4	18
645	Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. <i>Neoplasia</i> , 2017, 19, 684-694.	2.3	13
646	PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma. <i>Scientific Reports</i> , 2017, 7, 7391.	1.6	8
647	Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2017, 531, 389-410.	2.6	41
648	Tumor-Host Interactions in Malignant Gliomas. , 2017, , 465-479.		0
649	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 377, 1954-1963.	13.9	670
650	Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1205-1215.	1.5	1
651	Implications of Antiangiogenic Therapy on Radiographic Assessment of Brain Tumors. <i>World Neurosurgery</i> , 2017, 108, 380-382.	0.7	0
652	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2017, 134, 331-338.	1.4	21
653	Pericytes promote abnormal tumor angiogenesis in a rat RG2 glioma model. <i>Brain Tumor Pathology</i> , 2017, 34, 120-129.	1.1	20
654	Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 135, 173-181.	1.4	43
655	What are the prospects for combination therapy for glioblastoma?. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 947-949.	1.4	3
656	Next-Generation Sequencing in Glioblastoma Personalized Therapy. <i>Current Cancer Research</i> , 2017, , 161-190.	0.2	1
657	Targeting EGFRvIII for glioblastoma multiforme. <i>Cancer Letters</i> , 2017, 403, 224-230.	3.2	48
659	Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 133, 623-631.	1.4	15
660	Optimizing bevacizumab dosing in glioblastoma: less is more. <i>Journal of Neuro-Oncology</i> , 2017, 135, 99-105.	1.4	20
661	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 797-804.	0.4	40
662	Adipocytokines, Energy Balance, and Cancer. <i>Energy Balance and Cancer</i> , 2017, , .	0.2	4

#	ARTICLE	IF	CITATIONS
663	Carboxyethylpyrroles: From Hypothesis to the Discovery of Biologically Active Natural Products. <i>Chemical Research in Toxicology</i> , 2017, 30, 105-113.	1.7	8
665	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 193-199.	1.4	55
666	Apelin and Cancer. <i>Energy Balance and Cancer</i> , 2017, , 137-160.	0.2	3
667	The Added Prognostic Value of Metabolic Tumor Size on FDGâ€PET at First Suspected Recurrence of Glioblastoma Multiforme. <i>Journal of Neuroimaging</i> , 2017, 27, 243-247.	1.0	15
668	Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. <i>Molecular Neurobiology</i> , 2017, 54, 5780-5797.	1.9	52
669	Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses. <i>Journal of Neuro-Oncology</i> , 2017, 131, 11-20.	1.4	14
670	Targeting cancer stemâ€like cells in glioblastoma and colorectal cancer through metabolic pathways. <i>International Journal of Cancer</i> , 2017, 140, 10-22.	2.3	51
671	Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis. <i>Journal of Neuro-Oncology</i> , 2017, 131, 125-133.	1.4	84
672	A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters. <i>Oncology Letters</i> , 2018, 15, 3362-3368.	0.8	10
673	Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. <i>Neurochirurgie</i> , 2017, 63, 433-443.	0.6	16
674	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	3.8	1,619
675	Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. <i>F1000Research</i> , 2017, 6, 1892.	0.8	72
676	Practice-Changing Abstracts From the 2016 Society for Neuro-Oncology Annual Scientific Meeting. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 187-191.	1.8	3
677	Essence of survival analysisâ€. <i>Neuro-Oncology Practice</i> , 2017, 4, 77-81.	1.0	1
678	Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment. <i>Journal of Cancer</i> , 2017, 8, 1417-1424.	1.2	8
679	Treatment of Edema Formation in Oncology. , 2017, , 477-495.		0
680	Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. <i>Frontiers in Pharmacology</i> , 2016, 07, 519.	1.6	59
681	Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database. <i>Cancer Management and Research</i> , 2017, Volume 9, 159-166.	0.9	16

#	ARTICLE	IF	CITATIONS
682	The Molecular and Phenotypic Basis of the Glioma Invasive Perivascular Niche. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2342.	1.8	39
683	Bevacizumab for Patients with Recurrent Multifocal Glioblastomas. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2469.	1.8	12
684	Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2576.	1.8	31
685	Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes – An ESDO Report. <i>Cancers</i> , 2017, 9, 59.	1.7	5
686	Neutrophils in Gliomas. <i>Frontiers in Immunology</i> , 2017, 8, 1349.	2.2	101
687	CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression. <i>Frontiers in Immunology</i> , 2017, 8, 1451.	2.2	47
688	Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion. <i>Frontiers in Oncology</i> , 2017, 7, 120.	1.3	83
689	Gliomatosis Cerebri: Current Understanding and Controversies. <i>Frontiers in Oncology</i> , 2017, 7, 165.	1.3	26
690	Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients. <i>Neuroscience Journal</i> , 2017, 2017, 1-8.	2.3	8
691	Recognition of Transmembrane Protein 39A as a Tumor-Specific Marker in Brain Tumor. <i>Toxicological Research</i> , 2017, 33, 63-69.	1.1	13
692	Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 351.	1.8	15
693	Mitochondrial transcription factor A (TFAM) is upregulated in glioma. <i>Molecular Medicine Reports</i> , 2017, 15, 3781-3786.	1.1	21
694	Ketogenic diets as an adjuvant therapy in glioblastoma (the KEATING trial): study protocol for a randomised pilot study. <i>Pilot and Feasibility Studies</i> , 2017, 3, 67.	0.5	12
695	Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. <i>Oncotarget</i> , 2017, 8, 49702-49712.	0.8	84
696	Advances in the Treatment of Primary Brain Tumors: The Realm of Immunotherapy. , 0, , .		0
697	Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 429-437.	1.0	15
698	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. <i>Oncotarget</i> , 2017, 8, 91779-91794.	0.8	298
699	The integrative metabolomic-transcriptomic landscape of glioblastome multiforme. <i>Oncotarget</i> , 2017, 8, 49178-49190.	0.8	22

#	ARTICLE	IF	CITATIONS
700	Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov. <i>Journal of Clinical Oncology</i> , 2017, 35, 1686-1694.	0.8	52
701	Treatment of Glioblastoma. <i>Journal of Oncology Practice</i> , 2017, 13, 629-638.	2.5	94
702	Clinical trial endpoints for patients with gliomas. <i>Neuro-Oncology Practice</i> , 2017, 4, 201-208.	1.0	7
703	Adult Glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2402-2409.	0.8	561
704	Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome. <i>ELife</i> , 2017, 6, .	2.8	50
705	Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. <i>Oncotarget</i> , 2017, 8, 44015-44031.	0.8	69
706	Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma. <i>Oncotarget</i> , 2017, 8, 31329-31346.	0.8	26
707	Targeting the microenvironment in solid tumors. <i>Cancer Treatment Reviews</i> , 2018, 65, 22-32.	3.4	342
708	Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 325-340.	12.5	1,192
709	Evaluation of the quality of RNA extracted from archival FFPE glioblastoma and epilepsy surgical samples for gene expression assays. <i>Journal of Clinical Pathology</i> , 2018, 71, 695-701.	1.0	11
710	Combining Clinical and Molecular Data to Predict the Benefits of Carmustine Wafers in Newly Diagnosed High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2018, 20, 3.	0.7	14
711	Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). <i>Oncologist</i> , 2018, 23, 524.	1.9	30
712	Imaging in neuro-oncology. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875986.	1.5	41
713	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491875907.	0.6	4
714	Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775359.	1.5	5
715	Sustained delivery of anti-VEGF from injectable hydrogel systems provides a prolonged decrease of endothelial cell proliferation and angiogenesis <i>in vitro</i> . <i>RSC Advances</i> , 2018, 8, 8999-9005.	1.7	9
716	The Modified Ketogenic Diet in Adults with Glioblastoma: An Evaluation of Feasibility and Deliverability within the National Health Service. <i>Nutrition and Cancer</i> , 2018, 70, 643-649.	0.9	89
717	Current Challenges and Opportunities in Treating Glioblastoma. <i>Pharmacological Reviews</i> , 2018, 70, 412-445.	7.1	571

#	ARTICLE	IF	CITATIONS
719	A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. <i>World Neurosurgery</i> , 2018, 115, e375-e385.	0.7	17
720	ARTE and craft of bevacizumab in elderly patients with glioblastoma. <i>Annals of Oncology</i> , 2018, 29, 1346-1347.	0.6	0
721	Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. <i>Journal of Pathology</i> , 2018, 245, 209-221.	2.1	70
722	Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. <i>Neuro-Oncology</i> , 2018, 20, 1356-1367.	0.6	8
723	A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. <i>Cancer Cell</i> , 2018, 33, 874-889.e7.	7.7	180
724	Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. <i>Cancer Medicine</i> , 2018, 7, 1774-1783.	1.3	5
725	Palliative Care Issues in Glioblastoma #350. <i>Journal of Palliative Medicine</i> , 2018, 21, 567-568.	0.6	0
726	Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. <i>Annals of Oncology</i> , 2018, 29, 1431-1436.	0.6	73
727	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. <i>Annals of Oncology</i> , 2018, 29, 1423-1430.	0.6	65
728	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	12.5	873
729	Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. <i>Journal of Experimental Medicine</i> , 2018, 215, 963-983.	4.2	36
730	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	0.6	93
731	Renin angiotensin system and its role in biomarkers and treatment in gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 138, 1-15.	1.4	22
732	Orthotopic Patient-Derived Glioblastoma Xenografts in Mice. <i>Methods in Molecular Biology</i> , 2018, 1741, 183-190.	0.4	18
733	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. <i>Neuro-Oncology</i> , 2018, 20, 966-974.	0.6	33
734	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 975-985.	0.6	11
735	Chemotherapy of High-Grade Astrocytomas in Adults. <i>Progress in Neurological Surgery</i> , 2018, 31, 116-144.	1.3	5
736	Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. <i>CNS Oncology</i> , 2018, 7, 7-13.	1.2	3

#	ARTICLE	IF	CITATIONS
737	Role of Radiosensitizers in Radiation Treatment of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 31, 102-115.	1.3	3
738	Actin-capping protein CapG is associated with prognosis, proliferation and metastasis in human glioma. <i>Oncology Reports</i> , 2018, 39, 1011-1022.	1.2	23
739	Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. <i>Practical Radiation Oncology</i> , 2018, 8, 230-238.	1.1	22
740	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	1.0	60
741	The roles of TRIO and F-actin-binding protein in glioblastoma cells. <i>Molecular Medicine Reports</i> , 2018, 17, 4540-4546.	1.1	2
742	Anti-glioma Efficacy and Mechanism of Action of Tripolinolate A from <i>Tripolium pannonicum</i> . <i>Planta Medica</i> , 2018, 84, 786-794.	0.7	2
743	Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 105-111.	1.4	35
744	Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. <i>Scientific Reports</i> , 2018, 8, 7.	1.6	113
746	Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. <i>Journal of Neuro-Oncology</i> , 2018, 138, 141-145.	1.4	6
747	Lentiviral Transduction of Primary Human Glioblastoma Cultures. <i>Methods in Molecular Biology</i> , 2018, 1741, 81-89.	0.4	7
748	From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence. <i>Clinical and Translational Oncology</i> , 2018, 20, 989-1003.	1.2	9
749	Tumor treating fields: a new approach to glioblastoma therapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 447-453.	1.4	38
750	Targeted and theranostic applications for nanotechnologies in medicine. , 2018, , 399-511.		7
751	Head-to-Head Comparison of ¹¹ C-PBR28 and ¹⁸ F-GE180 for Quantification of the Translocator Protein in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1260-1266.	2.8	48
752	A novel prognostic six CpG signature in glioblastomas. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 167-177.	1.9	30
753	The siren song of bevacizumab: swan song or clarion call?. <i>Neuro-Oncology</i> , 2018, 20, 147-148.	0.6	7
754	Phase 2 and biomarker study of trebananib, an angiopoietin-1 blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer</i> , 2018, 124, 1438-1448.	2.0	38
755	Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. <i>Journal of Neuro-Oncology</i> , 2018, 137, 171-177.	1.4	9

#	ARTICLE	IF	CITATIONS
756	PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. <i>Clinical and Translational Radiation Oncology</i> , 2018, 8, 12-16.	0.9	51
757	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1195-1203.	0.4	45
758	Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. <i>World Neurosurgery</i> , 2018, 110, e727-e737.	0.7	14
759	Therapeutic efficacy of specific immunotherapy for glioma: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2018, 29, 443-461.	1.4	17
760	Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma. <i>Journal of Neurosurgery</i> , 2018, 129, 1446-1455.	0.9	22
761	Microenvironment-Derived Regulation of HIF Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme. <i>Molecular Cancer Research</i> , 2018, 16, 655-668.	1.5	21
762	Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. <i>Journal of Neuro-Oncology</i> , 2018, 137, 533-542.	1.4	19
763	Rationale and design of the 500-patient, 3-year, and prospective Vigilant Observation of Glioblastoma Wafer Implants registry. <i>CNS Oncology</i> , 2018, 7, CNS08.	1.2	12
764	Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. <i>Cancer</i> , 2018, 124, 1455-1463.	2.0	41
765	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 1162-1172.	0.6	92
766	Establishing a Preclinical Multidisciplinary Board for Brain Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1654-1666.	3.2	12
767	Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2018, 5, 246-250.	1.0	12
768	Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies. <i>Oncologist</i> , 2018, 23, 1063-1075.	1.9	10
769	The impact of surgery on survival after progression of glioblastoma: A retrospective cohort analysis of a contemporary patient population. <i>Journal of Clinical Neuroscience</i> , 2018, 53, 41-47.	0.8	24
770	Temozolomide for immunomodulation in the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1566-1572.	0.6	166
771	Brain tumors – other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.0	2
772	Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2018, 10, 47-52.	0.9	36
773	Neuropsychological Practice in the Oncology Setting. <i>Archives of Clinical Neuropsychology</i> , 2018, 33, 344-353.	0.3	21

#	ARTICLE	IF	CITATIONS
774	Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis. <i>Acta Neurochirurgica</i> , 2018, 160, 1167-1174.	0.9	10
775	Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. <i>Neuro-Oncology</i> , 2018, 20, 1400-1410.	0.6	27
776	A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 527-535.	1.4	16
777	Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. <i>World Neurosurgery</i> , 2018, 113, e508-e514.	0.7	26
778	Motor Cortex Reorganization in Patients with Glioma Assessed by Repeated Navigated Transcranial Magnetic Stimulation—A Longitudinal Study. <i>World Neurosurgery</i> , 2018, 112, e442-e453.	0.7	18
779	Anthropometrics and Body Composition in Adults with High-Grade Gliomas: Effects of Disease-Related Variables. <i>Nutrition and Cancer</i> , 2018, 70, 431-440.	0.9	5
780	JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon- β plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 627-636.	1.4	49
781	Anti-Angiogenics: Their Role in the Treatment of Glioblastoma. <i>Oncology Research and Treatment</i> , 2018, 41, 181-186.	0.8	28
782	Current Clinical State of Advanced Magnetic Resonance Imaging for Brain Tumor Diagnosis and Follow Up. <i>Seminars in Roentgenology</i> , 2018, 53, 45-61.	0.2	10
783	Radiomics, Metabolic, and Molecular MRI for Brain Tumors. <i>Seminars in Neurology</i> , 2018, 38, 032-040.	0.5	19
784	New Directions in the Treatment of Glioblastoma. <i>Seminars in Neurology</i> , 2018, 38, 050-061.	0.5	33
785	Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States. <i>Neuro-Oncology Practice</i> , 2018, 5, 251-261.	1.0	10
786	The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. <i>Oncolmmunology</i> , 2018, 7, e1448329.	2.1	79
787	PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 159-162.	0.6	15
788	Clinical effectiveness of bevacizumab in patients with recurrent brain tumours: A population-based evaluation. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 33-36.	0.5	8
789	Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1741-1753.	2.4	15
790	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. <i>Neuro-Oncology</i> , 2018, 20, 174-183.	0.6	33
791	Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. <i>Clinical Immunology</i> , 2018, 189, 43-51.	1.4	27

#	ARTICLE	IF	CITATIONS
792	Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. <i>Oncogene</i> , 2018, 37, 777-786.	2.6	37
793	Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. <i>Neuro-Oncology</i> , 2018, 20, 184-191.	0.6	443
794	Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2018, 20, 557-566.	0.6	24
795	Vaccination in the immunotherapy of glioblastoma. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 255-268.	1.4	50
796	Identification of Driver Genes and Key Pathways of Glioblastoma Shows JNJ-7706621 as a Novel Antiglioblastoma Drug. <i>World Neurosurgery</i> , 2018, 109, e329-e342.	0.7	14
797	Anti-VEGF treatment improves neurological function in tumors of the nervous system. <i>Experimental Neurology</i> , 2018, 299, 326-333.	2.0	14
798	Clinical implications of in silico mathematical modeling for glioblastoma: a critical review. <i>Journal of Neuro-Oncology</i> , 2018, 136, 1-11.	1.4	14
799	Histopathologic Features in Relation to Pretreatment Tumor Growth in Patients with Glioblastoma. <i>World Neurosurgery</i> , 2018, 109, e50-e58.	0.7	6
800	Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatin-based polychemotherapy regimen. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 215-224.	1.0	11
801	Utilizing 18F-fluoroethyl-L-tyrosine positron emission tomography in high grade glioma for radiation treatment planning in patients with contraindications to MRI. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 122-127.	0.9	8
802	The Evolving Role of Tumor Treating Fields in Managing Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 191-196.	0.6	48
803	Developmentally regulated signaling pathways in glioma invasion. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 385-402.	2.4	63
804	Survival improvements with adjuvant therapy in patients with glioblastoma. <i>ANZ Journal of Surgery</i> , 2018, 88, 196-201.	0.3	18
805	Neurological Complications of Primary Brain Tumors. , 2018, , 399-416.		0
806	Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma. <i>Journal of Neurochemistry</i> , 2018, 144, 421-430.	2.1	8
807	Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis. <i>Clinical and Translational Oncology</i> , 2018, 20, 939-953.	1.2	63
808	Contemporary management of high-grade gliomas. <i>CNS Oncology</i> , 2018, 7, 51-65.	1.2	32
809	SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 22-28.	1.2	56

#	ARTICLE	IF	CITATIONS
810	Advances in immunotherapeutic research for glioma therapy. Journal of Neurology, 2018, 265, 741-756.	1.8	77
811	Surgical oncology for gliomas: the state of the art. Nature Reviews Clinical Oncology, 2018, 15, 112-125.	12.5	221
812	Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 9-16.	0.6	13
813	State of the Art Treatment and Surveillance Imaging of Glioblastomas. Seminars in Roentgenology, 2018, 53, 23-36.	0.2	7
814	Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. , 2018, 184, 13-41.		230
815	Targeting the perivascular niche in brain tumors. Current Opinion in Oncology, 2018, 30, 54-60.	1.1	36
816	Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro-Oncology, 2018, 20, 113-122.	0.6	56
817	Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment. Anti-Cancer Drugs, 2018, 29, 924-928.	0.7	2
818	Role of amino-tracer PET for decision-making in neuro-oncology. Current Opinion in Neurology, 2018, 31, 720-726.	1.8	8
819	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of Clinical Oncology, 2018, 36, 1702-1709.	0.8	39
820	Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 239-253.	0.4	63
821	BRAF Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	0.8	247
822	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. Journal of Clinical Oncology, 2018, 36, 951-958.	0.8	95
823	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 148-157.	1.8	2
824	REXplore: A Sketch Based Interactive Explorer for Real Estates Using Building Floor Plan Images. , 2018, , .		2
825	Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?. Radiology and Oncology, 2018, 52, 121-128.	0.6	42
826	Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma. JCO Precision Oncology, 2018, 2, 1-6.	1.5	3
827	Impact of Immunotherapy in the Treatment of Glioblastoma. , 0, , .		0

#	ARTICLE	IF	CITATIONS
828	Comment to "Recurrent Glioblastoma Treated with Recombinant Poliovirus". Chinese Medical Journal, 2018, 131, 2645-2646.	0.9	3
829	Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D. Neuro-Oncology Practice, 2018, 5, 56-63.	1.0	8
830	Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma. Frontiers in Oncology, 2018, 8, 462.	1.3	108
831	Endophytic Fungus Isolated From <i>Achyrocline satureioides</i> Exhibits Selective Antiglioma Activity: The Role of Sch-642305. Frontiers in Oncology, 2018, 8, 476.	1.3	14
832	Impact of Cognitive Impairment in Patients with Gliomas. Seminars in Oncology Nursing, 2018, 34, 528-546.	0.7	16
833	Lower-grade gliomas: the wrong target for bevacizumab. Neuro-Oncology, 2018, 20, 1559-1560.	0.6	2
834	Approved Treatments for Patients with Recurrent High-grade Gliomas. Seminars in Oncology Nursing, 2018, 34, 486-493.	0.7	17
835	Current Options and Future Directions in Immune Therapy for Glioblastoma. Frontiers in Oncology, 2018, 8, 578.	1.3	21
836	Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?. Cancers, 2018, 10, 492.	1.7	45
837	Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab. Quantitative Imaging in Medicine and Surgery, 2018, 8, 268-279.	1.1	9
838	Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas " A Pilot Study. Neurologia Medico-Chirurgica, 2018, 58, 487-494.	1.0	18
839	Acid-Induced Activated Cell-Penetrating Peptide-Modified Cholesterol-Conjugated Polyoxyethylene Sorbitol Oleate Mixed Micelles for pH-Triggered Drug Release and Efficient Brain Tumor Targeting Based on a Charge Reversal Mechanism. ACS Applied Materials & Interfaces, 2018, 10, 43411-43428.	4.0	39
840	IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma. Oncotarget, 2018, 9, 15721-15731.	0.8	28
841	MGMT promoter methylation in Peruvian patients with glioblastoma. Ecancermedicalscience, 2018, 12, 812.	0.6	1
842	Principles of Radiation Oncology. , 2018, , 33-64.		2
843	Evidence-based Therapy and Problem of Glioblastoma. Japanese Journal of Neurosurgery, 2018, 27, 91-98.	0.0	0
844	Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurologia Medico-Chirurgica, 2018, 58, 405-421.	1.0	222
845	Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk. Frontiers in Oncology, 2018, 8, 373.	1.3	2

#	ARTICLE	IF	CITATIONS
846	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. <i>Bioconjugate Chemistry</i> , 2018, 29, 3937-3966.	1.8	23
847	Turn Back the TIME: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1977.	2.2	123
848	Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 84.	1.3	2
849	High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma. , 2018, , 193-221.		0
850	Non-methylated MGMT as Predictive Factor in Newly Diagnosed Glioblastoma Multiforme Treated with Bevacizumab Concurrent with Radiotherapy Followed by Adjuvant Bevacizumab plus Irinotecan versus Temozolomide Concurrent with Radiotherapy Followed by Adjuvant Temozolomide. <i>Archives in Cancer Research</i> , 2018, 06, .	0.3	1
851	Combination Therapy of Intravenously Injected Microglia and Radiation Therapy Prolongs Survival in a Rat Model of Spontaneous Malignant Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 601-608.	0.4	9
852	LPA4-Mediated Vascular Network Formation Increases the Efficacy of Anti-PD-1 Therapy against Brain Tumors. <i>Cancer Research</i> , 2018, 78, 6607-6620.	0.4	28
853	Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report. <i>Acta Neurochirurgica</i> , 2018, 160, 2387-2391.	0.9	2
854	Neuroimaging in patients with high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 221-224.	0.4	0
855	Management of diffuse glioma. <i>Presse Medicale</i> , 2018, 47, e199-e212.	0.8	11
856	Harnessing the immune system in glioblastoma. <i>British Journal of Cancer</i> , 2018, 119, 1171-1181.	2.9	138
857	The Evolving Role of the Oncologic Neurosurgeon: Looking Beyond Extent of Resection in the Modern Era. <i>Frontiers in Oncology</i> , 2018, 8, 406.	1.3	1
858	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	1.7	67
859	Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis. <i>Neurological Sciences</i> , 2018, 39, 2021-2031.	0.9	15
860	Baicalin suppresses proliferation, migration, and invasion in human glioblastoma cells via Ca ²⁺ -dependent pathway. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3247-3261.	2.0	40
861	WINDOW consortium: A path towards increased therapy efficacy against glioblastoma. <i>Drug Resistance Updates</i> , 2018, 40, 17-24.	6.5	15
862	Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG). <i>Bioengineering</i> , 2018, 5, 88.	1.6	15
863	Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. <i>Radiotherapy and Oncology</i> , 2018, 129, 347-351.	0.3	18

#	ARTICLE	IF	CITATIONS
864	Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?. Journal of Neuro-Oncology, 2018, 140, 623-628.	1.4	22
865	Angiogenesis and radiological tumor growth in patients with glioblastoma. BMC Cancer, 2018, 18, 862.	1.1	10
866	Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells. Anticancer Research, 2018, 38, 5049-5056.	0.5	82
867	The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor. Genes, 2018, 9, 105.	1.0	93
868	Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. British Journal of Radiology, 2019, 92, 20180405.	1.0	12
869	Bevacizumab and Glioblastoma. Cancer Journal (Sudbury, Mass), 2018, 24, 180-186.	1.0	78
870	Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. OncoTargets and Therapy, 2018, Volume 11, 5059-5074.	1.0	23
871	Perspectives on potential research benefits from big data efforts in Radiation Oncology. Medical Physics, 2018, 45, e848-e849.	1.6	2
872	Predicting patterns of failure in temporal lobe GBMs: possible implications on radiotherapy treatment portals. Radiation Oncology, 2018, 13, 133.	1.2	7
873	Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. Clinical Neurology and Neurosurgery, 2018, 170, 127-131.	0.6	8
874	Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged >75 years. International Journal of Clinical Oncology, 2018, 23, 820-825.	1.0	7
875	Neurologic and Medical Management of Brain Tumors. Neurologic Clinics, 2018, 36, 449-466.	0.8	12
876	Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motility. Oncogene, 2018, 37, 4838-4853.	2.6	40
877	Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma. World Neurosurgery, 2018, 116, 464-471.e1.	0.7	1
878	Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1263-1271.	0.6	15
879	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 2018, 20, 897-906.	0.6	41
880	Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study. Clinical Neurology and Neurosurgery, 2018, 171, 34-41.	0.6	6
881	Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1581-1589.	1.2	11

#	ARTICLE	IF	CITATIONS
882	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018, 379, 150-161.	13.9	570
883	VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. <i>Neuro-Oncology</i> , 2018, 20, 1462-1474.	0.6	56
884	Clinical Pharmacology of Brain Tumor Chemotherapy. , 2018, , 21-44.		1
885	Growth Factor Signaling Pathways and Targeted Therapy. , 2018, , 305-322.		0
886	Bevacizumab and Brain Tumors. , 2018, , 373-381.		0
887	Chemotherapy of Pediatric High-Grade Gliomas. , 2018, , 557-568.		0
888	Issues in Response Assessment of Brain Tumor Chemotherapy. , 2018, , 715-727.		2
889	Neuropsychology of Chemotherapy in Brain Tumor Patients. , 2018, , 783-809.		1
890	Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial). <i>Journal of Neuro-Oncology</i> , 2018, 140, 75-82.	1.4	31
891	Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". <i>Cancer Treatment Reviews</i> , 2018, 69, 121-131.	3.4	46
892	Molecular Pathogenesis and Emerging Treatment for Glioblastoma. <i>World Neurosurgery</i> , 2018, 116, 495-504.	0.7	13
893	Neurocognitive Changes. , 2018, , 591-603.		0
894	Neurologic Complications of Systemic Anticancer Therapy. <i>Neurologic Clinics</i> , 2018, 36, 627-651.	0.8	5
895	Neurocognitive Function in Adult Cancer Patients. <i>Neurologic Clinics</i> , 2018, 36, 653-674.	0.8	15
896	The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2396-2403.	3.3	25
897	Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme. <i>Medical Oncology</i> , 2018, 35, 122.	1.2	22
898	EGFL7 enhances surface expression of integrin $\alpha 5 \beta 1$ to promote angiogenesis in malignant brain tumors. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	33
899	The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3513-3520.	1.0	13

#	ARTICLE	IF	CITATIONS
900	The Role of Metabotropic Glutamate Receptor 1 Dependent Signaling in Glioma Viability. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 59-70.	1.3	9
901	Customizable biomaterials as tools for advanced anti-angiogenic drug discovery. <i>Biomaterials</i> , 2018, 181, 53-66.	5.7	4
902	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. <i>Frontiers in Immunology</i> , 2018, 9, 727.	2.2	55
903	Advances in Radiotherapy for Glioblastoma. <i>Frontiers in Neurology</i> , 2017, 8, 748.	1.1	103
904	Highlighting the need for reliable clinical trials in glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1031-1040.	1.1	12
905	Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1765.	1.8	44
906	Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges. <i>Pharmaceutics</i> , 2018, 10, 45.	2.0	19
907	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	1.8	376
908	Do Selected Blood Inflammatory Markers Combined with Radiological Features Predict Proliferation Index in Glioma Patients?. <i>World Neurosurgery</i> , 2018, 118, e137-e146.	0.7	13
909	Usefulness of ^{11}C -Methionine Positron Emission Tomography for Monitoring of Treatment Response and Recurrence in a Glioblastoma Patient on Bevacizumab Therapy: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 442-449.	0.3	1
910	Reader response: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. <i>Neurology</i> , 2018, 90, 1037-1037.	1.5	0
911	Prognostic value of NUSAP1 in progression and expansion of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2018, 140, 199-208.	1.4	30
912	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 41, 137-143.	0.9	41
913	Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas. <i>NeuroImage: Clinical</i> , 2018, 20, 51-60.	1.4	34
914	Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. <i>BMC Cancer</i> , 2018, 18, 105.	1.1	32
916	Vinblastine and antihelminthic mebendazole potentiate temozolomide in resistant gliomas. <i>Investigational New Drugs</i> , 2018, 36, 323-331.	1.2	34
917	VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. <i>BMC Cancer</i> , 2018, 18, 553.	1.1	11
918	A novel and practical synthesis of CAT3: a phenanthroindolizidine alkaloid with potential in treating glioblastoma. <i>RSC Advances</i> , 2018, 8, 29301-29308.	1.7	9

#	ARTICLE	IF	CITATIONS
919	CNS cancer immunity cycle and strategies to target this for glioblastoma. <i>Oncotarget</i> , 2018, 9, 22802-22816.	0.8	11
920	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology</i> , The, 2018, 19, 1170-1179.	5.1	80
921	Bevacizumab therapy for recurrent gliomas: another disappointment?. <i>Lancet Oncology</i> , The, 2018, 19, 1137-1138.	5.1	2
922	PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. <i>Nature Communications</i> , 2018, 9, 3439.	5.8	95
923	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. <i>Nature Medicine</i> , 2018, 24, 1611-1624.	15.2	229
924	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 477-483.	1.4	82
925	Effects of combined radiosurgery and temozolomide therapy on epidermal growth factor receptor and variant III in glioblastoma multiforme. <i>Oncology Letters</i> , 2018, 15, 5751-5759.	0.8	2
926	Neurosurgeons still wanted. <i>Neuro-Oncology</i> , 2018, 20, 1150-1151.	0.6	0
927	Raddeanin a Suppresses Glioblastoma Growth by Inducing ROS Generation and Subsequent JNK Activation to Promote Cell Apoptosis. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 1108-1121.	1.1	21
928	Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma. <i>CNS Oncology</i> , 2018, 7, CNS26.	1.2	11
929	MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results. <i>Medical Oncology</i> , 2018, 35, 103.	1.2	2
930	Influence of aflibercept on platelet activation profile. <i>Experimental Eye Research</i> , 2018, 175, 166-172.	1.2	6
931	Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study. <i>Journal of Neuroradiology</i> , 2019, 46, 186-192.	0.6	18
932	Commentary: BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction with Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. <i>Neurosurgery</i> , 2019, 84, 881-882.	0.6	1
933	Patterns and disparities of care in glioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 37-46.	1.0	25
934	Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. <i>Neuro-Oncology Practice</i> , 2019, 6, 194-202.	1.0	4
935	Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. <i>Supportive Care in Cancer</i> , 2019, 27, 477-484.	1.0	3
937	Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). <i>Journal of Neuro-Oncology</i> , 2019, 144, 303-311.	1.4	30

#	ARTICLE	IF	CITATIONS
938	Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. <i>Cells</i> , 2019, 8, 863.	1.8	156
939	The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 345-354.	0.7	15
940	Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management. , 2019, , .		0
941	The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 787-797.	1.9	22
942	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 663-677.	1.4	3
943	Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells. <i>BMC Cancer</i> , 2019, 19, 756.	1.1	18
944	A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?. <i>Future Oncology</i> , 2019, 15, 1717-1727.	1.1	1
945	Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study. <i>Journal of Neuro-Oncology</i> , 2019, 144, 419-426.	1.4	10
946	Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. <i>Journal of Neuro-Oncology</i> , 2019, 144, 501-509.	1.4	1
947	PET biomarkers and probes for treatment response assessment in glioblastoma: a work in progress. <i>Clinical and Translational Imaging</i> , 2019, 7, 285-294.	1.1	1
948	Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma. <i>Oncogene</i> , 2019, 38, 6142-6157.	2.6	29
949	Autocrine Production of PDGF Stimulated by the Tenascin-C-Derived Peptide TNIIIA2 Induces Hyper-Proliferation in Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3183.	1.8	15
950	Assumptions, damn assumptions and statistics. <i>Annals of Oncology</i> , 2019, 30, 1415-1416.	0.6	0
951	Brexipiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. <i>Cancers</i> , 2019, 11, 947.	1.7	26
952	The Role of Checkpoint Inhibitors in Glioblastoma. <i>Targeted Oncology</i> , 2019, 14, 375-394.	1.7	30
953	Detection of the KIAA1549-BRAF fusion gene in cells forming microvascular proliferations in pilocytic astrocytoma. <i>PLoS ONE</i> , 2019, 14, e0220146.	1.1	6
954	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. <i>Journal of Cancer</i> , 2019, 10, 3717-3727.	1.2	46
955	Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. <i>Brain</i> , 2019, 142, 2352-2366.	3.7	98

#	ARTICLE	IF	CITATIONS
956	The Roles of Hypoxia Imaging Using 18F-Fluoromisonidazole Positron Emission Tomography in Glioma Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1088.	1.0	34
957	Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e452-e463.	5.1	150
958	Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors. <i>Current Treatment Options in Neurology</i> , 2019, 21, 33.	0.7	14
959	The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 447.	1.3	10
960	Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes. <i>Journal of Neuro-Oncology</i> , 2019, 144, 239-248.	1.4	56
961	Standard external beam radiation therapy for oligodendroglioma. , 2019, , 263-270.		0
962	Bevacizumab for recurrent anaplastic oligodendroglial tumors. , 2019, , 367-377.		0
963	Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. <i>Radiotherapy and Oncology</i> , 2019, 138, 99-105.	0.3	34
964	Correlation between prognosis of glioblastoma and choline/N-acetyl aspartate ratio in MR spectroscopy. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2019, 18, 100498.	0.2	0
965	Hydroxychloroquine enhances the antitumor effects of BC001 in gastric cancer. <i>International Journal of Oncology</i> , 2019, 55, 405-414.	1.4	21
966	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	0.6	49
967	Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment. <i>Nano Letters</i> , 2019, 19, 8318-8332.	4.5	142
968	Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1608.	1.0	2
969	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	3.4	386
970	Current clinical management of patients with glioblastoma. <i>Cancer Reports</i> , 2019, 2, e1216.	0.6	11
971	Effects of VEGF blockade on the dynamics of the inflammatory landscape in glioblastoma-bearing mice. <i>Journal of Neuroinflammation</i> , 2019, 16, 191.	3.1	22
972	Glioblastoma Treatment Modalities besides Surgery. <i>Journal of Cancer</i> , 2019, 10, 4793-4806.	1.2	85
973	Surprising Anticancer Activities of Psychiatric Medications: Old Drugs Offer New Hope for Patients With Brain Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 1262.	1.6	27

#	ARTICLE	IF	CITATIONS
974	Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1723.	1.7	41
975	Effect of bevacizumab against cystic components of brain tumors. <i>Cancer Medicine</i> , 2019, 8, 6519-6527.	1.3	5
976	Management of Glioblastoma, Present and Future. <i>World Neurosurgery</i> , 2019, 131, 328-338.	0.7	39
977	Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. <i>Neuro-Oncology Practice</i> , 2019, 7, 164-175.	1.0	3
978	Microenvironmental Heterogeneity in Brain Malignancies. <i>Frontiers in Immunology</i> , 2019, 10, 2294.	2.2	78
980	Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma. <i>Molecules</i> , 2019, 24, 3046.	1.7	5
981	Cerebral blood volume and apparent diffusion coefficient “ Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116433.	0.3	14
982	Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance. <i>Cancers</i> , 2019, 11, 1231.	1.7	90
983	Impacts on Histological Features and 11C-Methyl-L-methionine Uptake After “One-Shot” Administration with Bevacizumab Before Surgery in Newly Diagnosed Glioblastoma. <i>Translational Oncology</i> , 2019, 12, 1480-1487.	1.7	2
984	Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence. <i>EJNMMI Research</i> , 2019, 9, 78.	1.1	21
985	First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 6590-6597.	3.2	52
986	Health-related quality of life and neurocognitive functioning with lomustine “temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1444-1453.	5.1	29
987	Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma. <i>Cancers</i> , 2019, 11, 1310.	1.7	18
988	PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. <i>Cancers</i> , 2019, 11, 1318.	1.7	61
989	Genetically Engineered Mouse Models of Gliomas: Technological Developments for Translational Discoveries. <i>Cancers</i> , 2019, 11, 1335.	1.7	31
990	Hydroxychloroquine potentiates the anti-cancer effect of bevacizumab on glioblastoma via the inhibition of autophagy. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109339.	2.5	37
991	The Potential Role of Radiomics and Radiogenomics in Patient Stratification by Tumor Hypoxia Status. <i>Journal of the American College of Radiology</i> , 2019, 16, 1329-1337.	0.9	16
992	From the Champion to the Team: New Treatment Paradigms in Contemporary Neurosurgery. <i>World Neurosurgery</i> , 2019, 131, 141-148.	0.7	8

#	ARTICLE	IF	CITATIONS
993	Biomarkers and smart intracranial devices for the diagnosis, treatment, and monitoring of high-grade gliomas: a review of the literature and future prospects. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz013.	0.4	2
994	Immunotherapy for inoperable gliomas. , 2019, , 181-192.		0
995	EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 337-345.	1.4	30
996	The process of life adjustment in patients at onset of glioma who are receiving continuous oral anticancer drug: A qualitative descriptive study. <i>International Journal of Nursing Sciences</i> , 2019, 6, 134-140.	0.5	4
997	Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2298-2313.	0.4	56
998	Central Nervous System Tumors. , 2019, , 1-41.		0
999	Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune [®] System. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491882544.	0.6	31
1000	Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma. <i>BMC Cancer</i> , 2019, 19, 445.	1.1	5
1001	Molecular biomarker-guided antiangiogenic targeted therapy for malignant glioma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 4876-4882.	1.6	11
1002	Genetic and molecular epidemiology of adult diffuse glioma. <i>Nature Reviews Neurology</i> , 2019, 15, 405-417.	4.9	437
1003	Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. <i>British Journal of Pharmacology</i> , 2019, 176, 3681-3694.	2.7	25
1004	MET in glioma: signaling pathways and targeted therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 270.	3.5	99
1005	Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. <i>World Neurosurgery</i> , 2019, 129, 90-100.	0.7	52
1006	Controversial roles for dexamethasone in glioblastoma – Opportunities for novel vascular targeting therapies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1460-1468.	2.4	33
1008	Radioterapia dei tumori cerebrali primitivi dell'adulto. <i>EMC - Neurologia</i> , 2019, 19, 1-11.	0.0	0
1009	Quality of Life and Cognition. , 2019, , 769-786.		1
1010	Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. <i>Journal of Neuro-Oncology</i> , 2019, 143, 605-611.	1.4	18
1012	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. , 2019, 7, 142.		31

#	ARTICLE	IF	CITATIONS
1013	Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. <i>Frontiers in Neurology</i> , 2019, 10, 460.	1.1	47
1014	Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1147, 65-91.	0.8	22
1015	Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme. <i>Tomography</i> , 2019, 5, 135-144.	0.8	28
1016	Glioblastoma. , 2019, , 237-247.		0
1017	Tumor Biology. , 2019, , 143-152.		0
1018	Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. <i>Nature Communications</i> , 2019, 10, 2541.	5.8	218
1019	Extracellular Vesicles in Glioma: From Diagnosis to Therapy. <i>BioEssays</i> , 2019, 41, e1800245.	1.2	54
1020	Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. <i>Clinical Cancer Research</i> , 2019, 25, 5094-5106.	3.2	32
1021	Leptomeningeal metastases in glioma. <i>Neurology</i> , 2019, 92, e2483-e2491.	1.5	51
1022	Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme. <i>Neuroradiology Journal</i> , 2019, 32, 241-249.	0.6	11
1023	The impact of timing of adjuvant therapy on survival for patients with glioblastoma: An analysis of the National Cancer Database. <i>Journal of Clinical Neuroscience</i> , 2019, 66, 92-99.	0.8	6
1024	Multifaceted Functional Role of Semaphorins in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2144.	1.8	18
1025	Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. <i>Chemical Society Reviews</i> , 2019, 48, 2967-3014.	18.7	389
1026	Glioblastoma vs temozolomide: can the red queen race be won?. <i>Cancer Biology and Therapy</i> , 2019, 20, 1083-1090.	1.5	63
1027	Neuro-oncology. , 2019, , 391-457.		0
1028	Interventions for cognitive problems in adults with brain cancer: A narrative review. <i>European Journal of Cancer Care</i> , 2019, 28, e13088.	0.7	31
1029	Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. <i>Clinical Epigenetics</i> , 2019, 11, 76.	1.8	14
1030	Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifer among Patient Populations. <i>Scientific Reports</i> , 2019, 9, 7442.	1.6	43

#	ARTICLE	IF	CITATIONS
1031	Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1418-1429.	1.9	22
1032	The efficacy and toxicity of ATM inhibition in glioblastoma initiating cells-driven tumor models. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 214-222.	2.0	13
1033	Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 845-854.	1.4	17
1034	Thrombotic Complications in Gliomas. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 326-333.	1.5	10
1035	Blocking VEGF by Bevacizumab Compromises Electrophysiological and Morphological Properties of Hippocampal Neurons. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 113.	1.8	16
1036	The role of caveolin-1 in tumors of the brain - functional and clinical implications. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 423-447.	2.1	10
1037	Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. <i>Journal of Translational Medicine</i> , 2019, 17, 96.	1.8	54
1038	HMGB1-Induced p62 Overexpression Promotes Snail-Mediated Epithelial-Mesenchymal Transition in Glioblastoma Cells via the Degradation of GSK-3 β . <i>Theranostics</i> , 2019, 9, 1909-1922.	4.6	58
1039	Preliminary exploration of a computerized cognitive battery and comparison with traditional testing in patients with high-grade glioma. <i>Neuro-Oncology Practice</i> , 2019, 6, 71-77.	1.0	10
1040	Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. <i>CNS Oncology</i> , 2019, 8, CNS28.	1.2	169
1041	Evaluating the decisions of glioma patients regarding clinical trial participation: a retrospective single provider review. <i>Medical Oncology</i> , 2019, 36, 34.	1.2	6
1042	Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma. <i>Oncolimmunology</i> , 2019, 8, e1577108.	2.1	35
1043	Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. <i>Clinical Cancer Research</i> , 2019, 25, 3643-3657.	3.2	128
1044	Regorafenib in patients with recurrent high-grade astrocytoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1037-1042.	1.2	22
1045	Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells. <i>Phytotherapy Research</i> , 2019, 33, 1670-1682.	2.8	14
1046	Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma. <i>Cancers</i> , 2019, 11, 314.	1.7	7
1047	Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2019, 143, 129-136.	1.4	32
1048	Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 287-301.	2.1	13

#	ARTICLE	IF	CITATIONS
1049	Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab. <i>Clinical and Translational Oncology</i> , 2019, 21, 1413-1423.	1.2	7
1050	Defective vascular signaling & prospective therapeutic targets in brain arteriovenous malformations. <i>Neurochemistry International</i> , 2019, 126, 126-138.	1.9	22
1051	Neuro-oncologists have spoken – the role of bevacizumab in the inpatient setting. A clinical and economic conundrum. <i>Neuro-Oncology Practice</i> , 2019, 6, 30-36.	1.0	9
1052	β-Catenin Promotes Bevacizumab-Induced Glioma Invasion. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 812-822.	1.9	14
1053	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	46
1054	Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 313-319.	1.4	11
1055	The long-lasting relationship of distress on radiation oncology-specific clinical outcomes. <i>Advances in Radiation Oncology</i> , 2019, 4, 354-361.	0.6	12
1056	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019, 21, 837-853.	0.6	66
1057	Fibulin-7 is overexpressed in glioblastomas and modulates glioblastoma neovascularization through interaction with angiopoietin-1. <i>International Journal of Cancer</i> , 2019, 145, 2157-2169.	2.3	12
1058	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2019, 20, 728-740.	5.1	271
1059	Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1071-1090.	4.2	89
1060	Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. <i>European Journal of Cancer</i> , 2019, 112, 83-93.	1.3	15
1061	A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma. <i>Journal of Clinical Medicine</i> , 2019, 8, 263.	1.0	16
1062	Clinical Concepts of Brain Tumors. , 2019, , 37-51.		1
1063	Radiosensitization of Glioblastoma Cells by a Novel DNA Methyltransferase-inhibiting Phthalimido-Alkanamide Derivative. <i>Anticancer Research</i> , 2019, 39, 759-769.	0.5	3
1064	Artificial intelligence in cancer imaging: Clinical challenges and applications. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 127-157.	157.7	965
1065	Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. <i>Cancers</i> , 2019, 11, 174.	1.7	155
1066	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	12.5	540

#	ARTICLE	IF	CITATIONS
1067	Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. <i>Frontiers in Neurology</i> , 2019, 10, 42.	1.1	46
1068	A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 537-544.	1.4	70
1069	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	15.2	569
1070	Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma. <i>Human Gene Therapy Clinical Development</i> , 2019, 30, 74-87.	3.2	7
1071	CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1. <i>Cancers</i> , 2019, 11, 194.	1.7	146
1072	Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	51
1073	The Role of ACKR3 in Breast, Lung, and Brain Cancer. <i>Molecular Pharmacology</i> , 2019, 96, 819-825.	1.0	25
1074	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 469-493.	12.5	285
1076	Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 147-161.	2.0	38
1077	Tumors of the Central Nervous System: Therapeutic Approaches. , 2019, , 69-83.		0
1078	Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 878-886.	0.4	10
1079	Improving survival in molecularly selected glioblastoma. <i>Lancet, The</i> , 2019, 393, 615-617.	6.3	32
1080	Pneumatosis Intestinalis After Molecular-Targeted Therapy. <i>World Neurosurgery</i> , 2019, 125, 312-315.	0.7	9
1081	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. <i>The Cochrane Library</i> , 2019, , ,	1.5	4
1082	Concurrent Thermochemoradiotherapy in Glioblastoma Treatment: Preliminary Results. , 0, , .		0
1083	Multiclass Classification of Brain Cancer with Multiple Multiclass Artificial Bee Colony Feature Selection and Support Vector Machine. <i>Journal of Physics: Conference Series</i> , 2019, 1417, 012015.	0.3	3
1085	Classification of glioma based on prognostic alternative splicing. <i>BMC Medical Genomics</i> , 2019, 12, 165.	0.7	21
1086	Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 1134.	1.3	28

#	ARTICLE	IF	CITATIONS
1087	DNX-2401: an investigational drug for the treatment of recurrent glioblastoma. Expert Opinion on Investigational Drugs, 2019, 28, 1041-1049.	1.9	28
1088	Adjuvant therapy and molecular profiling for inoperable gliomas. , 2019, , 193-208.		0
1089	ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 655-661.	0.6	3
1090	Neuroimaging for Radiation Therapy of Brain Tumors. Topics in Magnetic Resonance Imaging, 2019, 28, 63-71.	0.7	9
1091	Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases. Scientific Reports, 2019, 9, 17792.	1.6	13
1092	Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials. Molecules, 2019, 24, 4312.	1.7	77
1094	Tenascin-c mediated vasculogenic mimicry formation via regulation of MMP2/MMP9 in glioma. Cell Death and Disease, 2019, 10, 879.	2.7	44
1095	Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. Scientific Reports, 2019, 9, 17794.	1.6	9
1096	Computational modeling demonstrates that glioblastoma cells can survive spatial environmental challenges through exploratory adaptation. Nature Communications, 2019, 10, 5704.	5.8	21
1097	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy, 2019, 17, 917-927.	0.6	3
1098	Treatment of cognitive deficits in brain tumour patients: current status and future directions. Current Opinion in Oncology, 2019, 31, 540-547.	1.1	69
1099	Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy. Medicine (United States), 2019, 98, e17759.	0.4	5
1100	Tumor treating fields for glioblastoma: should it or will it ever be adopted?. Current Opinion in Neurology, 2019, 32, 857-863.	1.8	6
1101	Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma. Neurologist, 2019, 24, 87-89.	0.4	5
1102	<p>Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases</p>. Cancer Management and Research, 2019, Volume 11, 10083-10092.	0.9	9
1103	<p>Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study</p>. OncoTargets and Therapy, 2019, Volume 12, 10579-10585.	1.0	13
1104	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-Oncology, 2019, 21, 167-178.	0.6	173
1105	Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials. Neuro-Oncology Practice, 2019, 6, 81-92.	1.0	7

#	ARTICLE	IF	CITATIONS
1106	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Reviews in Oncology/Hematology, 2019, 134, 104-119.	2.0	10
1107	Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Science, 2019, 110, 499-508.	1.7	58
1108	shRNA-mediated PPAR α knockdown in human glioma stem cells reduces <i>in vitro</i> proliferation and inhibits orthotopic xenograft tumour growth. Journal of Pathology, 2019, 247, 422-434.	2.1	13
1109	Supratentorial high-grade astrocytoma with leptomeningeal spread to the fourth ventricle: a lethal dissemination with dismal prognosis. Journal of Neuro-Oncology, 2019, 142, 253-261.	1.4	13
1110	Strategy of Allogeneic and Autologous Cancer Vaccines. , 2019, , 75-80.		0
1111	Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells. Carcinogenesis, 2019, 40, 2-14.	1.3	12
1112	Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy. Journal of Neuro-Oncology, 2019, 141, 71-81.	1.4	18
1113	Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome. Neurosurgery, 2019, 85, 793-800.	0.6	10
1114	The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. Neuro-Oncology Practice, 2019, 6, 274-282.	1.0	9
1115	5-ALA and FDA approval for glioma surgery. Journal of Neuro-Oncology, 2019, 141, 479-486.	1.4	204
1116	Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma. Cancers, 2019, 11, 84.	1.7	4
1117	DNA damage response of clinical carbon ion versus photon radiation in human glioblastoma cells. Radiotherapy and Oncology, 2019, 133, 77-86.	0.3	31
1118	Maximizing the Extent of Resection in High-Grade Glioma. World Neurosurgery, 2019, 123, 256-258.	0.7	10
1119	Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. PLoS ONE, 2019, 14, e0210608.	1.1	14
1120	LGALS3 Promotes Treatment Resistance in Glioblastoma and Is Associated with Tumor Risk and Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 760-769.	1.1	36
1121	Neuropalliative Care. , 2019, , .		16
1122	The Increased Expression of Estrogen-Related Receptor α Correlates with Wnt5a and Poor Prognosis in Patients with Glioma. Molecular Cancer Therapeutics, 2019, 18, 173-184.	1.9	11
1123	Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. Journal of Neuro-Oncology, 2019, 142, 91-101.	1.4	52

#	ARTICLE	IF	CITATIONS
1124	Glioblastoma Therapy in the Age of Molecular Medicine. <i>Trends in Cancer</i> , 2019, 5, 46-65.	3.8	68
1125	<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1809-1816.	3.2	94
1126	Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology. <i>Neuro-Oncology Practice</i> , 2019, 6, 283-288.	1.0	1
1127	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 110-119.	5.1	238
1128	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Reviews in <i>Oncology/Hematology</i> , 2019, 134, 87-103.	2.0	7
1129	Sonodynamic Therapy for Malignant Glioma Using 220-kHz Transcranial Magnetic Resonance Imaging-Guided Focused Ultrasound and 5-Aminolevulinic acid. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 526-538.	0.7	30
1130	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528.	1.9	47
1131	Astrocytes, the rising stars of the glioblastoma microenvironment. <i>Glia</i> , 2019, 67, 779-790.	2.5	115
1132	Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2019, 58, 130-141.	4.3	49
1133	Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial. <i>Neurosurgery</i> , 2019, 84, 41-49.	0.6	39
1134	Ten-minute administration of bevacizumab. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 218-219.	0.5	3
1135	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. <i>Neurosurgery</i> , 2019, 84, 66-76.	0.6	7
1136	Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature. <i>European Journal of Cancer Care</i> , 2019, 28, e12410.	0.7	44
1137	Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies. <i>Cancer Gene Therapy</i> , 2020, 27, 301-310.	2.2	26
1138	Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab. <i>Clinical and Translational Oncology</i> , 2020, 22, 411-419.	1.2	0
1139	Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma. <i>Oncology</i> , 2020, 98, 16-22.	0.9	23
1140	Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2020, 81, 064-070.	0.4	38
1141	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 206-212.	3.2	48

#	ARTICLE	IF	CITATIONS
1142	Intraoperative radiotherapy for glioblastoma: an international pooled analysis. <i>Radiotherapy and Oncology</i> , 2020, 142, 162-167.	0.3	22
1143	Synergistic Therapies for Recurrent Malignant Gliomas. <i>World Neurosurgery</i> , 2020, 133, 237-239.	0.7	3
1144	CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. <i>Cancer Gene Therapy</i> , 2020, 27, 669-679.	2.2	15
1145	WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. <i>Neuro-Oncology</i> , 2020, 22, 116-127.	0.6	26
1146	Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy. <i>Clinical and Translational Oncology</i> , 2020, 22, 447-456.	1.2	4
1147	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.	1.0	9
1148	Autophagy as a mechanism for anti-angiogenic therapy resistance. <i>Seminars in Cancer Biology</i> , 2020, 66, 75-88.	4.3	26
1149	4-Hydroxy-7-oxo-5-heptenoic acid lactone is a potent inducer of brain cancer cell invasiveness that may contribute to the failure of anti-angiogenic therapies. <i>Free Radical Biology and Medicine</i> , 2020, 146, 234-256.	1.3	2
1150	Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 575-589.	1.9	24
1151	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. <i>Annals of Palliative Medicine</i> , 2020, 9, 4430-4445.	0.5	0
1152	Vessel co-option in glioblastoma: emerging insights and opportunities. <i>Angiogenesis</i> , 2020, 23, 9-16.	3.7	100
1153	Bevacizumab Moonshots: An Important Outcome From the Latest Ovarian Cancer Mission. <i>Journal of Clinical Oncology</i> , 2020, 38, 171-172.	0.8	5
1154	The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. <i>Medical Oncology</i> , 2020, 37, 2.	1.2	145
1155	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. <i>Neuro-Oncology</i> , 2020, 22, 470-479.	0.6	49
1156	Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2020, 7, 52-58.	1.0	1
1157	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. <i>Neuro-Oncology</i> , 2020, 22, 515-523.	0.6	140
1158	ACT001 modulates the NF- κ B/MnSOD/ROS axis by targeting IKK β to inhibit glioblastoma cell growth. <i>Journal of Molecular Medicine</i> , 2020, 98, 263-277.	1.7	26
1159	Identification of genes related to low-grade glioma progression and prognosis based on integrated transcriptome analysis. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3099-3111.	1.2	23

#	ARTICLE	IF	CITATIONS
1160	Supramaximal resection: A systematic review of its safety, efficacy and feasibility in glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 328-334.	0.8	24
1161	Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. <i>Neuro-Oncology</i> , 2020, 22, 450-456.	0.6	30
1162	Connexin43 peptide, TAT-Cx43266â€“283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo. <i>Neuro-Oncology</i> , 2020, 22, 493-504.	0.6	30
1163	Magnetic Resonance Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutation in Glioma. <i>World Neurosurgery</i> , 2020, 134, 187-189.	0.7	3
1164	TNIP1â€“mediated TNFâ€“ α /NFâ€“ κ B signalling cascade sustains glioma cell proliferation. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 530-538.	1.6	20
1165	Nanocarrier-based drug combination therapy for glioblastoma. <i>Theranostics</i> , 2020, 10, 1355-1372.	4.6	203
1166	Neuron-specific deletion of VEGF or its receptor Flk-1 impairs recognition memory. <i>European Neuropsychopharmacology</i> , 2020, 31, 145-151.	0.3	9
1167	Cancer of the Central Nervous System. , 2020, , 906-967.e12.		9
1168	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. <i>Neuro-Oncology</i> , 2020, 22, 694-704.	0.6	23
1169	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	12.8	389
1171	Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa112.	0.4	2
1172	Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas. <i>Biomolecules</i> , 2020, 10, 1370.	1.8	12
1174	Novel Treatment Strategies for Glioblastoma. <i>Cancers</i> , 2020, 12, 2883.	1.7	42
1175	Potential Therapeutic Effects of the Neural Stem Cell-Targeting Antibody Nilo1 in Patient-Derived Glioblastoma Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1665.	1.3	3
1176	Advances in drug delivery technology for the treatment of glioblastoma multiforme. <i>Journal of Controlled Release</i> , 2020, 328, 350-367.	4.8	58
1177	Differences in Gating Dynamics of BK Channels in Cellular and Mitochondrial Membranes from Human Glioblastoma Cells Unraveled by Short- and Long-Range Correlations Analysis. <i>Cells</i> , 2020, 9, 2305.	1.8	8
1178	Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. <i>Molecules</i> , 2020, 25, 4641.	1.7	7
1179	Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients. <i>BMC Cancer</i> , 2020, 20, 931.	1.1	4

#	ARTICLE	IF	CITATIONS
1180	Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis. <i>Neurosurgical Review</i> , 2021, 44, 1943-1955.	1.2	10
1181	Evaluating Outcome in HIV positive and HIV negative patients post elective brain tumor surgery at a single South African neurosurgical center – A prospective cohort study. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2020, 22, 100792.	0.2	0
1182	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1037-1048.	1.1	8
1183	Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy. , 2020, , .		2
1184	Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide. <i>Medicine (United States)</i> , 2020, 99, e21147.	0.4	10
1185	Pediatric Chemotherapy. , 2020, , 173-183.		0
1186	In vitro evidence for glioblastoma cell death in temperatures found in the penumbra of laser-ablated tumors. <i>International Journal of Hyperthermia</i> , 2020, 37, 20-26.	1.1	6
1187	Boron neutron capture therapy for malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2020, 149, 1-11.	1.4	45
1188	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. <i>Pharmaceuticals</i> , 2020, 13, 389.	1.7	36
1189	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults. <i>Journal of Neuro-Oncology</i> , 2020, 150, 165-213.	1.4	6
1190	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 150, 269-359.	1.4	8
1191	A Novel InÂVtro Device to Deliver Induced Electromagnetic Fields to Cell and Tissue Cultures. <i>Biophysical Journal</i> , 2020, 119, 2378-2390.	0.2	5
1192	Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283. <i>EBioMedicine</i> , 2020, 62, 103134.	2.7	18
1193	<p>Berberine Inhibits Cell Proliferation by Interfering with Wild-Type and Mutant P53 in Human Glioma Cells</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12151-12162.	1.0	11
1194	New Avenues in Radiotherapy of Glioblastoma: from Bench to Bedside. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	0.7	0
1195	Angiopoietin-2 Combined with Radiochemotherapy Impedes Glioblastoma Recurrence by Acting in an Autocrine and Paracrine Manner: A Preclinical Study. <i>Cancers</i> , 2020, 12, 3585.	1.7	3
1196	Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol. <i>Journal of Immunology Research</i> , 2020, 2020, 1-10.	0.9	22
1197	Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). , 2020, 8, e001146.		35

#	ARTICLE	IF	CITATIONS
1198	Targeting the RhoGEF \hat{I}^2 PIX/COOL-1 in Glioblastoma: Proof of Concept Studies. <i>Cancers</i> , 2020, 12, 3531.	1.7	4
1199	Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma. <i>Scientific Reports</i> , 2020, 10, 19542.	1.6	70
1200	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1133-1141.	1.9	28
1201	Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. <i>Journal of Cancer</i> , 2020, 11, 5056-5068.	1.2	6
1202	Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 1045.	1.3	29
1203	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5297-5303.	3.2	67
1204	TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. <i>Cancers</i> , 2020, 12, 1935.	1.7	8
1205	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020, 297, 164-175.	3.6	19
1206	Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade. <i>Frontiers in Oncology</i> , 2020, 10, 840.	1.3	41
1207	Ca ²⁺ as a therapeutic target in cancer. <i>Advances in Cancer Research</i> , 2020, 148, 233-317.	1.9	16
1208	Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide. <i>Frontiers in Oncology</i> , 2020, 10, 581814.	1.3	10
1209	MYC in Brain Development and Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7742.	1.8	20
1210	Feasibility of removable balloon implant for simultaneous magnetic nanoparticle heating and HDR brachytherapy of brain tumor resection cavities. <i>International Journal of Hyperthermia</i> , 2020, 37, 1189-1201.	1.1	3
1211	Glioblastoma Therapy Using Codelivery of Cisplatin and Glutathione Peroxidase Targeting siRNA from Iron Oxide Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 43408-43421.	4.0	92
1212	Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?" <i>Neuro-Oncology</i> , 2020, 22, 1889-1890.	0.6	2
1213	Metabolism-based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa087.	0.4	20
1214	MR-Spectroscopy and Survival in Mice with High Grade Glioma Undergoing Unrestricted Ketogenic Diet. <i>Nutrition and Cancer</i> , 2021, 73, 2315-2322.	0.9	9
1215	Ipilimumab: an investigational immunotherapy for glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1187-1193.	1.9	16

#	ARTICLE	IF	CITATIONS
1216	MicroRNA-93 acts as an anti-inflammatory tumor suppressor in glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa047.	0.4	9
1217	The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology. <i>International Journal of Hyperthermia</i> , 2020, 37, 27-34.	1.1	16
1218	Radioresistance in Glioblastoma and the Development of Radiosensitizers. <i>Cancers</i> , 2020, 12, 2511.	1.7	77
1219	Results from a 1-day workshop on the assessment of quality of life in cancer patients: a joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1333-1341.	0.6	1
1220	A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma. <i>Vaccines</i> , 2020, 8, 498.	2.1	2
1221	E2F7/EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression. <i>British Journal of Cancer</i> , 2020, 123, 1445-1455.	2.9	47
1222	Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma. <i>Pharmaceuticals</i> , 2020, 13, 470.	1.7	9
1223	Current Trends in Cancer Immunotherapy. <i>Biomedicines</i> , 2020, 8, 621.	1.4	34
1224	Glioblastoma Distance From the Subventricular Neural Stem Cell Niche Does Not Correlate With Survival. <i>Frontiers in Oncology</i> , 2020, 10, 564889.	1.3	9
1225	Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa082.	0.4	29
1226	Local Delivery of Minocycline and Vorinostat Targets the Tumor Microenvironment to Inhibit the Recurrence of Glioma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11397-11409.	1.0	5
1227	Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging. <i>Frontiers in Immunology</i> , 2020, 11, 592389.	2.2	23
1228	Glioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section. <i>Neurocirug�a (English Edition)</i> , 2020, 31, 289-297.	0.1	2
1229	Consenso sobre gu�as de tratamiento de los glioblastomas elaborado por el Grupo de Trabajo de Neurooncolog�a (GTNO) de la SENECA. <i>Neurocirug�a</i> , 2020, 31, 289-298.	0.2	4
1230	Effects of BMPER, CXCL10, and HOXA9 on Neovascularization During Early-Growth Stage of Primary High-Grade Glioma and Their Corresponding MRI Biomarkers. <i>Frontiers in Oncology</i> , 2020, 10, 711.	1.3	6
1231	Machine learning for radiation outcome modeling and prediction. <i>Medical Physics</i> , 2020, 47, e178-e184.	1.6	25
1232	Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (pseudo-randomized) treatment allocation by the health insurance provider. <i>Journal of Neuro-Oncology</i> , 2020, 148, 373-379.	1.4	7
1233	Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients. <i>BMC Cancer</i> , 2020, 20, 447.	1.1	20

#	ARTICLE	IF	CITATIONS
1234	Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. <i>Advanced Science</i> , 2020, 7, 1902971.	5.6	95
1235	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	0.6	19
1236	Comparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma. <i>Medicine (United Tj ETQq0 0.0 rgBT /Oerlock 10</i>	0.4	0
1237	Fully automated brain resection cavity delineation for radiation target volume definition in glioblastoma patients using deep learning. <i>Radiation Oncology</i> , 2020, 15, 100.	1.2	37
1238	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. <i>The Cochrane Library</i> , 2020, 2020, CD013238.	1.5	19
1239	Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography. <i>Journal of Controlled Release</i> , 2020, 324, 303-316.	4.8	41
1240	Biomarkers for immunotherapy for treatment of glioblastoma. , 2020, 8, e000348.		33
1241	Management of glioblastoma: State of the art and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 299-312.	157.7	969
1242	Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes. <i>Neuro-Oncology</i> , 2020, 22, 1062-1064.	0.6	0
1243	Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 659-684.	1.9	15
1244	Glioblastoma multiforme: novel therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 605-614.	1.5	36
1245	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020, 22, 1667-1676.	0.6	9
1246	ACYP2 contributes to malignant progression of glioma through promoting Ca ²⁺ efflux and subsequently activating c-Myc and STAT3 signals. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 106.	3.5	6
1247	Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2020, 7, 268-276.	1.0	12
1248	New strategies for managing adult gliomas. <i>Journal of Neurology</i> , 2021, 268, 3666-3674.	1.8	14
1249	Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. <i>BMC Medicine</i> , 2020, 18, 142.	2.3	21
1250	A systematic review of tumor treating fields therapy for high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 148, 433-443.	1.4	14
1251	Knockdown of the long noncoding RNA XIST suppresses glioma progression by upregulating miR-204-5p. <i>Journal of Cancer</i> , 2020, 11, 4550-4559.	1.2	24

#	ARTICLE	IF	CITATIONS
1252	Genomic analyses of early responses to radiation in glioblastoma reveal new alterations at transcription, splicing, and translation levels. <i>Scientific Reports</i> , 2020, 10, 8979.	1.6	11
1253	Apelin Controls Angiogenesis-Dependent Glioblastoma Growth. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4179.	1.8	19
1254	KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells. <i>Anticancer Research</i> , 2020, 40, 3231-3237.	0.5	15
1255	Î²2-Adrenergic Receptor Stimulation Upregulates Cx43 Expression on Glioblastoma Multiforme and Olfactory Ensheathing Cells. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1451-1460.	1.1	13
1256	Target treatment with stereotactic radiation for recurrent gliomas. <i>Chinese Clinical Oncology</i> , 2020, 9, 74-74.	0.4	0
1257	Neuronal signatures in cancer. <i>International Journal of Cancer</i> , 2020, 147, 3281-3291.	2.3	35
1258	Role of the default mode resting-state network for cognitive functioning in malignant glioma patients following multimodal treatment. <i>NeuroImage: Clinical</i> , 2020, 27, 102287.	1.4	18
1259	Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. <i>Journal of Child Neurology</i> , 2020, 35, 791-798.	0.7	11
1260	Self-Assembly of Integrin Ligands on the Apical Membrane Inhibits the Migration of Glioma Cells. <i>Langmuir</i> , 2020, 36, 3750-3757.	1.6	8
1261	NRG/RTOG 1122: A phase 2, double-blind, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. <i>Cancer</i> , 2020, 126, 2821-2828.	2.0	25
1262	Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. <i>Molecular Neurobiology</i> , 2020, 57, 2461-2478.	1.9	219
1263	Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. <i>Journal of Neuro-Oncology</i> , 2020, 147, 297-307.	1.4	116
1264	Identification and Analysis of Glioblastoma Biomarkers Based on Single Cell Sequencing. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 167.	2.0	28
1265	Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 653-661.	1.4	16
1266	Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models. <i>Cancer Letters</i> , 2020, 478, 71-81.	3.2	18
1267	Personalized neoantigen vaccines: a glimmer of hope for glioblastoma. <i>Expert Review of Vaccines</i> , 2020, 19, 407-417.	2.0	8
1268	Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series. <i>BMC Cancer</i> , 2020, 20, 196.	1.1	15
1269	A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. <i>BMC Cancer</i> , 2020, 20, 198.	1.1	25

#	ARTICLE	IF	CITATIONS
1270	Multifractal Properties of BK Channel Currents in Human Glioblastoma Cells. <i>Journal of Physical Chemistry B</i> , 2020, 124, 2382-2391.	1.2	12
1271	Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. <i>Cancer</i> , 2020, 126, 2625-2636.	2.0	60
1272	Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 32.	2.0	0
1273	Neurological and Medical Complications in Brain Tumor Patients. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 33.	2.0	7
1274	Current status of development of methylation biomarkers for in vitro diagnostic IVD applications. <i>Clinical Epigenetics</i> , 2020, 12, 100.	1.8	44
1275	Interferon- β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa043.	0.4	3
1276	Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 342-359.	1.3	19
1277	Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. <i>Targeted Oncology</i> , 2020, 15, 531-540.	1.7	12
1278	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa011.	0.4	22
1279	Pathogenesis of non-hereditary brain arteriovenous malformation and therapeutic implications. <i>Interventional Neuroradiology</i> , 2020, 26, 244-253.	0.7	8
1280	Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas. <i>Pathology Research and Practice</i> , 2020, 216, 152828.	1.0	8
1281	Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	86
1282	Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons. <i>Mitochondrion</i> , 2020, 52, 56-66.	1.6	18
1283	Angiogenesis in Malignant Gliomas and Bevacizumab Resistance. , 2020, , .		0
1284	Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates. <i>Neuro-Oncology Practice</i> , 2020, 7, 359-368.	1.0	5
1285	Glioblastoma Stem Cells: Driving Resilience through Chaos. <i>Trends in Cancer</i> , 2020, 6, 223-235.	3.8	217
1286	DNA inhibitors for the treatment of brain tumors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 195-207.	1.5	3
1287	Anticancer Potential of Raddeanin A, a Natural Triterpenoid Isolated from <i>Anemone raddeana</i> Regel. <i>Molecules</i> , 2020, 25, 1035.	1.7	33

#	ARTICLE	IF	CITATIONS
1288	Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa013.	0.4	26
1289	Small-sized gadolinium oxide based nanoparticles for high-efficiency theranostics of orthotopic glioblastoma. <i>Biomaterials</i> , 2020, 235, 119783.	5.7	61
1290	Glioblastome Multiforme: A Bibliometric Analysis. <i>World Neurosurgery</i> , 2020, 136, 270-282.	0.7	65
1291	Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study. <i>BMC Cancer</i> , 2020, 20, 24.	1.1	9
1292	VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. <i>Nature</i> , 2020, 577, 689-694.	13.7	321
1293	Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2020, 147, 109-116.	1.4	19
1294	Roles of circRNAs in the tumour microenvironment. <i>Molecular Cancer</i> , 2020, 19, 14.	7.9	146
1295	Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. <i>Lancet Oncology</i> , The, 2020, 21, e97-e103.	5.1	42
1296	Deleterious impact of a generic temozolomide formulation compared with brand name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 484-494.	1.0	1
1297	Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1004-1009.	1.0	16
1298	First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. <i>Journal of Neuro-Oncology</i> , 2020, 146, 451-458.	1.4	16
1299	Combating Glioblastoma by Codelivering the Small-Molecule Inhibitor of STAT3 and STAT3siRNA with $\hat{1}\pm 5\hat{1}^2$ 1 Integrin Receptor-Selective Liposomes. <i>Molecular Pharmaceutics</i> , 2020, 17, 1859-1874.	2.3	26
1300	Use of a head-tilting baseplate during volumetric-modulated arc therapy (VMAT) to better protect organs at risk in hippocampal sparing whole brain radiotherapy (HS-WBRT). <i>PLoS ONE</i> , 2020, 15, e0232430.	1.1	7
1301	Association between glioblastoma cell-derived vessels and poor prognosis of the patients. <i>Cancer Communications</i> , 2020, 40, 211-221.	3.7	11
1302	Adult Craniopharyngiomas. , 2020, , .		3
1304	Predictive models in precision medicine. , 2020, , 177-188.		1
1305	Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy. <i>International Journal of Pharmaceutics</i> , 2020, 581, 119283.	2.6	29
1306	Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. <i>Cancers</i> , 2020, 12, 937.	1.7	86

#	ARTICLE	IF	CITATIONS
1307	Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. <i>Cancer Research</i> , 2020, 80, 499-509.	0.4	68
1308	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
1309	Betulinic Acid-Mediated Tuning of PERK/CHOP Signaling by Sp1 Inhibition as a Novel Therapeutic Strategy for Glioblastoma. <i>Cancers</i> , 2020, 12, 981.	1.7	16
1310	Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. <i>Cancer Treatment Reviews</i> , 2020, 86, 102017.	3.4	573
1311	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020, 9, 7.	2.0	11
1312	Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 52.	2.4	9
1313	Albumin-Based Nanotheranostic Probe with Hypoxia Alleviating Potentiates Synchronous Multimodal Imaging and Phototherapy for Glioma. <i>ACS Nano</i> , 2020, 14, 6191-6212.	7.3	91
1314	Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2759.	1.8	40
1315	A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28283.	0.8	40
1316	Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial. <i>Radiation Oncology</i> , 2020, 15, 83.	1.2	11
1317	Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 42.	2.4	14
1318	Gross Total vs. Subtotal Resection on Survival Outcomes in Elderly Patients With High-Grade Glioma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 151.	1.3	36
1319	Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 329-339.	0.5	1
1320	Sonic hedgehog is expressed in human brain arteriovenous malformations and induces arteriovenous malformations in vivo. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 324-335.	2.4	7
1321	Management of glioblastoma: a perspective from Mexico. <i>Chinese Clinical Oncology</i> , 2021, 10, 1-1.	0.4	2
1322	Anti-angiogenic therapies in the management of glioblastoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 37-37.	0.4	11
1323	Attention, memory, and executive functions profile in a prospective cohort of patients with malignant glioma. <i>Applied Neuropsychology Adult</i> , 2021, 28, 197-209.	0.7	2
1324	Pulsed radiation therapy for the treatment of newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 447-456.	0.6	8

#	ARTICLE	IF	CITATIONS
1325	MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 179-188.	3.2	16
1326	Quantitating Interfraction Target Dynamics During Concurrent Chemoradiation for Glioblastoma: A Prospective Serial Imaging Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 736-746.	0.4	36
1327	Hypoxia-degradable zwitterionic phosphorylcholine drug nanogel for enhanced drug delivery to glioblastoma. <i>Chemical Engineering Journal</i> , 2021, 408, 127359.	6.6	28
1328	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	3.2	194
1329	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
1330	Radiosurgery for Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 117-128.	0.8	20
1331	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	0.6	42
1332	Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. <i>Supportive Care in Cancer</i> , 2021, 29, 2821-2840.	1.0	65
1333	Prognostic value of modified systemic inflammatory score in patients with newly diagnosed high-grade gliomas. <i>Clinical Neurology and Neurosurgery</i> , 2021, 201, 106428.	0.6	2
1334	Analysis of Patient-Reported Outcome Utilization Within National Clinical Trials Network Cooperative Group Radiation Oncology Trials Over the Past 2 Decades. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1151-1160.	0.4	7
1335	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	12.5	826
1336	Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. <i>Nature Cancer</i> , 2021, 2, 83-97.	5.7	56
1337	Transcription Factor ELF1 Activates MEIS1 Transcription and Then Regulates the GF11/FBW7 Axis to Promote the Development of Glioma. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 418-430.	2.3	13
1338	A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme. <i>European Journal of Health Economics</i> , 2021, 22, 89-100.	1.4	0
1339	Hypoxia and its therapeutic possibilities in paediatric cancers. <i>British Journal of Cancer</i> , 2021, 124, 539-551.	2.9	28
1340	Glioma stem cells and their roles within the hypoxic tumor microenvironment. <i>Theranostics</i> , 2021, 11, 665-683.	4.6	89
1341	Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial. <i>Neuro-Oncology</i> , 2021, 23, 314-323.	0.6	18
1343	Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. <i>Journal of Neuro-Oncology</i> , 2021, 151, 55-62.	1.4	42

#	ARTICLE	IF	CITATIONS
1344	Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results. <i>Quality of Life Research</i> , 2021, 30, 91-103.	1.5	7
1345	Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures?. <i>Quality of Life Research</i> , 2021, 30, 81-89.	1.5	3
1346	Current state and future perspective of drug repurposing in malignant glioma. <i>Seminars in Cancer Biology</i> , 2021, 68, 92-104.	4.3	35
1347	Recent progress in the research of suicide gene therapy for malignant glioma. <i>Neurosurgical Review</i> , 2021, 44, 29-49.	1.2	27
1348	Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases. <i>NMC Case Report Journal</i> , 2021, 8, 505-511.	0.2	6
1349	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRC/RTOG 0825). <i>Neuro-Oncology</i> , 2021, 23, 1125-1138.	0.6	10
1352	Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1912-1922.	3.2	26
1353	Avelumab in newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab118.	0.4	8
1354	Evidence-based approaches to chemotherapy for gliomas. , 2021, , 38-52.		0
1355	Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model. <i>Cancer Gene Therapy</i> , 2021, 28, 1339-1352.	2.2	13
1356	Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis. <i>Frontiers in Neurology</i> , 2020, 11, 603947.	1.1	10
1357	Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. <i>Scientific Reports</i> , 2021, 11, 2306.	1.6	25
1358	MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression. <i>Journal of Molecular Medicine</i> , 2021, 99, 289-301.	1.7	15
1359	Reuse of Molecules for Glioblastoma Therapy. <i>Pharmaceuticals</i> , 2021, 14, 99.	1.7	3
1360	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
1361	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 1 newly diagnosed disease. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab028.	0.4	4
1362	Window of Opportunity Clinical Trials to Evaluate Novel Therapies for Brain Tumors. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 93-104.	0.8	10
1364	Cell and gene therapies—Emerging technologies and drug delivery systems for treating brain cancer. , 2021, , 431-446.		0

#	ARTICLE	IF	CITATIONS
1365	Glioblastoma. , 2021, , 215-230.		0
1366	Therapeutic approaches to overcome temozolomide resistance in glioblastoma. , 2021, , 507-545.		1
1367	GLIMPSE: a glioblastoma prognostication model using ensemble learning—a surveillance, epidemiology, and end results study. Health Information Science and Systems, 2021, 9, 5.	3.4	10
1368	Treatment evaluation and prognosis prediction using radiomics in clinical practice. , 2021, , 175-264.		0
1369	Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres. Molecules, 2021, 26, 282.	1.7	6
1370	Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?. Neuro-Oncology Advances, 2021, 3, vdab008.	0.4	20
1371	A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma. Journal of Neuro-Oncology, 2021, 151, 193-200.	1.4	5
1372	Collagen type VIII alpha 2 chain (COL8A2), an important component of the basement membrane of the corneal endothelium, facilitates the malignant development of glioblastoma cells via inducing EMT. Journal of Bioenergetics and Biomembranes, 2021, 53, 49-59.	1.0	10
1373	Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers. Cancers, 2021, 13, 342.	1.7	15
1374	Past and present drug treatments for glioblastoma. , 2021, , 17-29.		0
1375	Mesenchymal glioblastoma-induced mature de-novo vessel formation of vascular endothelial cells in a microfluidic device. Molecular Biology Reports, 2021, 48, 395-403.	1.0	14
1376	Central Nervous System Molecular Imaging. , 2021, , 1261-1285.		0
1377	A Review of Newly Diagnosed Glioblastoma. Frontiers in Oncology, 2020, 10, 574012.	1.3	74
1378	A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution. Frontiers in Oncology, 2021, 11, 597587.	1.3	10
1379	Monoclonal Antibodies: A Prospective and Retrospective View. Current Medicinal Chemistry, 2021, 28, 435-471.	1.2	8
1380	A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opinion on Therapeutic Targets, 2021, 25, 87-100.	1.5	9
1381	Pathogenetic Features and Current Management of Glioblastoma. Cancers, 2021, 13, 856.	1.7	29
1382	Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection. Nature Nanotechnology, 2021, 16, 538-548.	15.6	165

#	ARTICLE	IF	CITATIONS
1383	Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control. <i>Journal of Neurosurgery</i> , 2021, 134, 426-436.	0.9	53
1384	The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment. <i>Oncolytic Virotherapy</i> , 2021, Volume 10, 1-27.	6.0	22
1385	Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas. <i>Annals of Nuclear Medicine</i> , 2021, 35, 493-503.	1.2	12
1386	Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. <i>Seminars in Cancer Biology</i> , 2022, 82, 162-175.	4.3	58
1387	Single-shot bevacizumab for cerebral radiation injury. <i>BMC Neurology</i> , 2021, 21, 77.	0.8	8
1388	CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma. <i>Cancer Medicine</i> , 2021, 10, 2013-2025.	1.3	15
1389	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631618.	1.3	0
1390	Mifepristone Repurposing in Treatment of High-Grade Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 606907.	1.3	7
1391	Putting Proteomics Into Immunotherapy for Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 593255.	2.2	11
1392	Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies. <i>Carcinogenesis</i> , 2021, 42, 804-813.	1.3	21
1393	Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I). <i>Brain Sciences</i> , 2021, 11, 386.	1.1	14
1394	The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. <i>Scientific Reports</i> , 2021, 11, 6067.	1.6	17
1395	Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin $\alpha 5 \beta 1$ in Glioblastoma Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 616580.	1.8	17
1396	Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters. <i>Cell Cycle</i> , 2021, 20, 702-715.	1.3	6
1397	Perspective of mesenchymal transformation in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2021, 9, 50.	2.4	63
1398	Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3381-3390.	1.2	16
1399	Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging. <i>Neuroradiology</i> , 2021, 63, 1811-1822.	1.1	7
1401	The Normal and Brain Tumor Vasculature: Morphological and Functional Characteristics and Therapeutic Targeting. <i>Frontiers in Physiology</i> , 2021, 12, 622615.	1.3	27

#	ARTICLE	IF	CITATIONS
1402	Prognostic value of test(s) for O6-methylguanineâ€“DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. The Cochrane Library, 2021, 2021, CD013316.	1.5	19
1403	Glioma C6 perivascular changes of invasion structural parameters variation (research study).. Voprosy Onkologii, 2021, 67, 144-149.	0.1	2
1404	The adaptive transition of glioblastoma stem cells and its implications on treatments. Signal Transduction and Targeted Therapy, 2021, 6, 124.	7.1	51
1405	Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma. Journal of Neurosurgery, 2020, 134, 1-10.	0.9	15
1406	Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines, 2021, 9, 324.	1.4	125
1407	Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles. Advanced Science, 2021, 8, e2002085.	5.6	25
1408	Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. Journal of Clinical Neuroscience, 2021, 85, 115-121.	0.8	9
1409	Anticancer Mechanism of Curcumin on Human Glioblastoma. Nutrients, 2021, 13, 950.	1.7	47
1410	Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 1367.	1.0	18
1411	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. Frontiers in Oncology, 2021, 11, 636672.	1.3	15
1412	The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 182-190.	0.6	6
1413	Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Current Neuropharmacology, 2021, 19, 513-537.	1.4	40
1414	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. Neuro-Oncology, 2021, 23, 1885-1897.	0.6	23
1415	Frontiers in the treatment of glioblastoma: Past, present and emerging. Advanced Drug Delivery Reviews, 2021, 171, 108-138.	6.6	125
1416	Highly Efficient Imaging-Guided Photothermal Therapy for Gliomas with MnFe ₂ O ₄ Nanoparticle Clusters as a One-For-All Theranostic Agent. ACS Applied Nano Materials, 2021, 4, 4238-4244.	2.4	5
1417	A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers, 2021, 13, 1795.	1.7	67
1418	Clinical significance of <i>CDKN2A</i> homozygous deletion in combination with methylated <i>MGMT</i> status for <i>IDH</i> wildtype glioblastoma. Cancer Medicine, 2021, 10, 3177-3187.	1.3	21
1419	A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma. Journal of Clinical Neuroscience, 2021, 86, 110-115.	0.8	1

#	ARTICLE	IF	CITATIONS
1421	An Alternative Pipeline for Glioblastoma Therapeutics: A Systematic Review of Drug Repurposing in Glioblastoma. <i>Cancers</i> , 2021, 13, 1953.	1.7	26
1422	Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas. <i>Brain Sciences</i> , 2021, 11, 466.	1.1	23
1423	Molecularly Targeted Clinical Trials. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 191-210.	0.8	7
1424	Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	74
1425	TNF α secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 67.	2.4	28
1426	Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features. <i>Frontiers in Oncology</i> , 2021, 11, 627325.	1.3	10
1427	Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma. <i>NMR in Biomedicine</i> , 2021, 34, e4516.	1.6	7
1428	High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas. <i>Translational Oncology</i> , 2021, 14, 101038.	1.7	4
1429	High Level of METTL7B Indicates Poor Prognosis of Patients and Is Related to Immunity in Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 650534.	1.3	15
1430	Integrated Analysis of Whole Genome and Epigenome Data Using Machine Learning Technology: Toward the Establishment of Precision Oncology. <i>Frontiers in Oncology</i> , 2021, 11, 666937.	1.3	25
1431	The Evolving Role of Targeted Therapies in Primary Central Nervous System Tumors. <i>Advances in Oncology</i> , 2021, 1, 203-212.	0.1	1
1432	Neuroimaging in the Era of the Evolving WHO Classification of Brain Tumors, From the AJR Special Series on Cancer Staging. <i>American Journal of Roentgenology</i> , 2021, 217, 1-13.	1.0	7
1433	Construction of nanomaterials as contrast agents or probes for glioma imaging. <i>Journal of Nanobiotechnology</i> , 2021, 19, 125.	4.2	22
1434	Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma). <i>International Journal of Clinical Oncology</i> , 2021, 26, 1441-1449.	1.0	3
1435	Improving acceptor efficacy rather than energy transfer efficiency: Dominant contribution of monomers of acceptors modified on upconversion nanoparticles. <i>Journal of Rare Earths</i> , 2022, 40, 702-708.	2.5	5
1436	Integrated analysis of the genomic and transcriptional profile of high-grade gliomas in different age groups. <i>Clinical Immunology</i> , 2021, 226, 108719.	1.4	1
1437	Targeting Energy Metabolism to Overcome Therapeutic Resistance of Glioblastoma and Tumor-associated Edema. , 0, , 121-138.		0
1438	Machine Learning-Based Prediction of 6-Month Postoperative Karnofsky Performance Status in Patients with Glioblastoma: Capturing the Real-Life Interaction of Multiple Clinical and Oncologic Factors. <i>World Neurosurgery</i> , 2021, 149, e866-e876.	0.7	3

#	ARTICLE	IF	CITATIONS
1439	Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 973-986.	1.9	55
1440	Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4899.	1.8	69
1441	Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. <i>Cancers</i> , 2021, 13, 2400.	1.7	28
1442	Brainstem Infiltration Predicts Survival in Patients With High-grade Gliomas Treated With Chemoradiotherapy. <i>Anticancer Research</i> , 2021, 41, 2583-2589.	0.5	4
1443	Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab050.	1.4	14
1444	Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 672508.	1.3	51
1445	Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. <i>Cells</i> , 2021, 10, 1226.	1.8	40
1446	Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme. <i>World Neurosurgery</i> , 2021, 149, e1026-e1037.	0.7	6
1447	Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker. <i>Genome Medicine</i> , 2021, 13, 88.	3.6	57
1448	The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 670145.	1.8	4
1449	Lost in application: Measuring hypoxia for radiotherapy optimisation. <i>European Journal of Cancer</i> , 2021, 148, 260-276.	1.3	21
1450	Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5544.	1.8	17
1451	A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 692403.	1.3	3
1452	An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma. <i>Cancers</i> , 2021, 13, 3241.	1.7	3
1453	Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients. <i>Radiologia Medica</i> , 2021, 126, 1249-1254.	4.7	20
1454	The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ). <i>Cancer Biology and Therapy</i> , 2021, 22, 392-403.	1.5	4
1455	Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. <i>Cancer Cell</i> , 2021, 39, 779-792.e11.	7.7	245
1456	Upregulated functional gene expression programmes in tumour pericytes mark progression in patients with low-grade glioma. <i>Molecular Oncology</i> , 2022, 16, 405-421.	2.1	5

#	ARTICLE	IF	CITATIONS
1457	A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas. <i>Frontiers in Oncology</i> , 2021, 11, 652133.	1.3	4
1458	Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. <i>Pharmaceuticals</i> , 2021, 14, 626.	1.7	14
1459	Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases. <i>Life Sciences</i> , 2021, 274, 119326.	2.0	39
1460	CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS. <i>Siberian Journal of Oncology</i> , 2021, 20, 5-17.	0.1	2
1461	Assessment and Management of Cognitive Symptoms in Patients With Brain Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e90-e99.	1.8	11
1462	Advances in the management of glioblastoma. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1103-1111.	0.9	58
1463	Targeting glioma cells by antineoplastic activity of reversine. <i>Oncology Letters</i> , 2021, 22, 610.	0.8	2
1464	Tumor Vessels Fuel the Fire in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6514.	1.8	35
1465	Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?. <i>Cureus</i> , 2021, 13, e15852.	0.2	0
1466	A narrative review of research progress on drug therapies for glioblastoma multiforme. <i>Annals of Translational Medicine</i> , 2021, 9, 943-943.	0.7	11
1468	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021, 13, 3750.	1.7	16
1469	Glioblastoma Multiforme—A Look at the Past and a Glance at the Future. <i>Pharmaceutics</i> , 2021, 13, 1053.	2.0	20
1470	Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1983-1994.	0.9	2
1471	Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease. <i>Seminars in Radiation Oncology</i> , 2021, 31, 200-204.	1.0	2
1472	Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth. <i>Cancers</i> , 2021, 13, 3773.	1.7	7
1473	The drug development pipeline for glioblastoma—A cross sectional assessment of the FDA Orphan Drug Product designation database. <i>PLoS ONE</i> , 2021, 16, e0252924.	1.1	6
1474	Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2022, 34, 221-234.	0.7	3
1475	Optical tissue clearing and machine learning can precisely characterize extravasation and blood vessel architecture in brain tumors. <i>Communications Biology</i> , 2021, 4, 815.	2.0	9

#	ARTICLE	IF	CITATIONS
1476	A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 792-803.	0.4	23
1477	Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device. <i>Frontiers in Oncology</i> , 2021, 11, 708017.	1.3	13
1478	The blood-tumour barrier in cancer biology and therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 696-714.	12.5	112
1479	Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 228.	3.5	45
1480	Assessment of neurological function using the National Institute of Health Stroke Scale in patients with gliomas. <i>Neuro-Oncology Practice</i> , 2021, 8, 699-705.	1.0	1
1481	Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab. <i>Diagnostics</i> , 2021, 11, 1263.	1.3	5
1482	Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 154, 187-196.	1.4	8
1483	Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103372.	2.0	19
1484	Radiotherapy of High-Grade Gliomas: First Half of 2021 Update with Special Reference to Radiosensitization Studies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8942.	1.8	11
1485	Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 273.	3.5	7
1486	Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. <i>Cancers</i> , 2021, 13, 4123.	1.7	9
1487	Machine Learning-Based Prediction of Early Recurrence in Glioblastoma Patients: A Glance Towards Precision Medicine. <i>Neurosurgery</i> , 2021, 89, 873-883.	0.6	5
1488	Emerging Therapeutic Strategies for Brain Tumors. <i>NeuroMolecular Medicine</i> , 2022, 24, 23-34.	1.8	3
1489	Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. <i>Journal of Clinical Neuroscience</i> , 2021, 90, 82-88.	0.8	6
1491	Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8289.	1.8	10
1492	The Hippo-TAZ axis mediates vascular endothelial growth factor C in glioblastoma-derived exosomes to promote angiogenesis. <i>Cancer Letters</i> , 2021, 513, 1-13.	3.2	18
1493	Oral drug delivery for immunoengineering. <i>Bioengineering and Translational Medicine</i> , 2022, 7, e10243.	3.9	5
1494	APLN/APLNR Signaling Controls Key Pathological Parameters of Glioblastoma. <i>Cancers</i> , 2021, 13, 3899.	1.7	7

#	ARTICLE	IF	CITATIONS
1495	Tumor-Associated Microglia and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy. <i>Cancers</i> , 2021, 13, 4255.	1.7	53
1496	Expression Analysis of $\alpha 5$ Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma. <i>Pharmaceutics</i> , 2021, 14, 882.	1.7	3
1497	Impairment of Autophagic Flux Participates in the Antitumor Effects of TAT-Cx43266-283 in Glioblastoma Stem Cells. <i>Cancers</i> , 2021, 13, 4262.	1.7	6
1498	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 703764.	1.3	27
1499	Genome-wide profiling of alternative splicing in glioblastoma and their clinical value. <i>BMC Cancer</i> , 2021, 21, 958.	1.1	4
1500	Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1246.	0.8	7
1501	Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients. <i>Frontiers in Immunology</i> , 2021, 12, 722479.	2.2	1
1502	Bioactive Heterocyclic Compounds as Potential Therapeutics in the Treatment of Gliomas: A Review. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 551-565.	0.9	5
1503	Re-irradiation for high-grade gliomas: Has anything changed?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 767-786.	0.9	8
1504	Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab133.	0.4	24
1505	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). <i>European Journal of Cancer</i> , 2021, 155, 179-190.	1.3	13
1506	Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 747690.	1.3	10
1507	Intratumoral VEGF nanotrappor reduces glioblastoma vascularization and tumor cell mass. <i>Journal of Controlled Release</i> , 2021, 339, 381-390.	4.8	12
1508	Neurosurgical Advances for Malignant Gliomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 364-370.	1.0	2
1510	Medical and Neurological Management of Brain Tumor Complications. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 53.	2.0	5
1511	Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9975.	1.8	10
1512	Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells. <i>Pharmaceutics</i> , 2021, 13, 1410.	2.0	4
1513	Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress. <i>Frontiers in Oncology</i> , 2021, 11, 719623.	1.3	5

#	ARTICLE	IF	CITATIONS
1514	Biomimetic and cell-based nanocarriers – New strategies for brain tumor targeting. <i>Journal of Controlled Release</i> , 2021, 337, 482-493.	4.8	27
1515	Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. <i>Pathology</i> , 2022, 54, 55-62.	0.3	6
1516	A Calcium-Related Immune Signature in Prognosis Prediction of Patients With Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723103.	1.8	1
1517	Efficacy of Whole-Ventricular Radiotherapy in Patients Undergoing Maximal Tumor Resection for Glioblastomas Involving the Ventricle. <i>Frontiers in Oncology</i> , 2021, 11, 736482.	1.3	2
1518	Follow-up of intra-arterial delivery of bevacizumab for treatment of butterfly glioblastoma in patient with first-in-human, real-time MRI-guided intra-arterial neurointervention. <i>Journal of NeuroInterventional Surgery</i> , 2021, 13, 1037-1039.	2.0	4
1519	Progress and prospect in tumor treating fields treatment of glioblastoma. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111810.	2.5	21
1520	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. <i>Lancet Oncology</i> , The, 2021, 22, e456-e465.	5.1	53
1521	Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 371-384.	0.4	18
1522	Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 51, 128371.	1.0	4
1523	Quality of Life Is Independently Associated With Neurocognitive Function in Patients With Brain Tumors: Analysis of a Prospective Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 754-763.	0.4	6
1524	The relationship between the degree of brain edema regression and changes in cognitive function in patients with recurrent glioma treated with bevacizumab and temozolomide. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 4556-4568.	1.1	5
1525	Intraoperative radiotherapy for glioblastoma: A systematic review of techniques and outcomes. <i>Journal of Clinical Neuroscience</i> , 2021, 93, 36-41.	0.8	7
1526	Local and systemic delivery strategies for glioma immunotherapy. , 2022, , 295-332.		0
1527	Heat shock protein vaccines in glioblastoma. , 2022, , 39-53.		0
1528	Immune checkpoint blockade therapy in high-grade glioma. , 2022, , 91-108.		0
1529	Genetic Architectures and Cell-of-Origin in Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 615400.	1.3	26
1530	Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells. <i>Anticancer Research</i> , 2021, 41, 757-764.	0.5	0
1531	Glioma stem cells, plasticity, and potential therapeutic vulnerabilities. , 2021, , 83-102.		0

#	ARTICLE	IF	CITATIONS
1532	Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing. <i>Cancers</i> , 2021, 13, 484.	1.7	27
1533	Endoglin and TGF- β 2 signaling in glioblastoma. <i>Cell and Tissue Research</i> , 2021, 384, 613-624.	1.5	7
1534	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1811-1820.	2.0	11
1535	The role of <i>RB1</i> alteration and 4q12 amplification in IDH-WT glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, v03050.	0.4	5
1536	Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , 2021, 127, 1620-1629.	2.0	56
1537	New Glioma Molecular Classification for Precise Therapeutic Decision Based on Spatially-Resolved Proteogenomics Guided by MALDI-MSI and Clinical Data Integration. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1538	Simultaneous high PD-L1 and low VEGFR2 expression is associated with better overall survival in rectal cancer. <i>Translational Cancer Research</i> , 2021, 10, 499-508.	0.4	0
1540	Nanopolymeric systems to improve brain cancer treatment outcomes. , 2021, , 355-394.		0
1541	In search of predictive and response markers in antiangiogenic therapy of glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 184-185.	0.6	0
1542	Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma. <i>Cancers</i> , 2021, 13, 229.	1.7	13
1543	The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. <i>Journal of Neurosurgical Sciences</i> , 2021, 64, 502-508.	0.3	4
1544	Anti-angiogenic therapy for high-grade glioma. <i>The Cochrane Library</i> , 2018, 2018, CD008218.	1.5	81
1545	Adult High-Grade (Diffuse) Glioma. <i>Molecular Pathology Library</i> , 2015, , 77-93.	0.1	2
1546	Advanced Physiologic Imaging: Perfusion Theory and Applications. , 2020, , 61-91.		3
1547	Primary Central Nervous System Tumors. , 2020, , 295-325.		1
1548	Glioblastoma in the Elderly. <i>Cancer Treatment and Research</i> , 2015, 163, 159-170.	0.2	2
1549	Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas. <i>Cancer Treatment and Research</i> , 2015, 163, 117-142.	0.2	5
1550	Emerging Strategies for the Treatment of Tumor Stem Cells in Central Nervous System Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2015, 853, 167-187.	0.8	2

#	ARTICLE	IF	CITATIONS
1551	Anti-angiogenics and Radiation Therapy. , 2017, , 1-10.		2
1553	Imaging Biomarkers in Preclinical Studies on Brain Tumors. Biomarkers in Disease, 2015, , 391-413.	0.0	1
1554	Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy. Journal of Neuro-Oncology, 2017, 134, 169-175.	1.4	20
1555	Novel Therapies for Glioblastoma. Current Neurology and Neuroscience Reports, 2020, 20, 19.	2.0	50
1557	Arsenic-based Anticancer Agents. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 196-214.	0.8	2
1558	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. Japanese Journal of Clinical Oncology, 2020, 50, 787-793.	0.6	6
1559	An Update on Medications for Brain Arteriovenous Malformations. Neurosurgery, 2020, 87, 871-878.	0.6	13
1560	â€œZooming inâ€ on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing. Neurosurgery, 2021, 88, 477-486.	0.6	15
1567	Radiogenomic characterization of response to chemo-radiation therapy in glioblastoma is associated with PI3K/AKT/mTOR and apoptosis signaling pathways. , 2019, , .		2
1568	Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance. Cancer Research, 2020, 80, 1498-1511.	0.4	35
1569	Antiangiogenic Therapy of High-Grade Gliomas. Progress in Neurological Surgery, 2018, 31, 180-199.	1.3	13
1570	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight, 2019, 4, .	2.3	82
1571	Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. Journal of Clinical Investigation, 2020, 130, 6041-6053.	3.9	37
1572	Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme. BMC Cancer, 2019, 19, 117.	1.1	37
1573	Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. Journal of Patient-Reported Outcomes, 2019, 3, 58.	0.9	2
1574	18 Brain tumor imaging with ALA. Series in Cellular and Clinical Imaging, 2017, , 347-384.	0.2	2
1575	High-grade Gliomas. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1548-1563.	0.4	49
1576	Adult Gliomas. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1452-1475.	0.4	8

#	ARTICLE	IF	CITATIONS
1577	Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials. <i>Medical Science Monitor</i> , 2016, 22, 3486-3492.	0.5	7
1578	Advances in treating glioblastoma. <i>F1000prime Reports</i> , 2014, 6, 46.	5.9	42
1579	Comprehensive Analysis of Glycolytic Enzymes as Therapeutic Targets in the Treatment of Glioblastoma. <i>PLoS ONE</i> , 2015, 10, e0123544.	1.1	101
1580	The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells. <i>PLoS ONE</i> , 2015, 10, e0131441.	1.1	29
1581	Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme. <i>PLoS ONE</i> , 2015, 10, e0137678.	1.1	6
1582	Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders. <i>PLoS ONE</i> , 2016, 11, e0145375.	1.1	20
1583	Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors. <i>PLoS ONE</i> , 2016, 11, e0155315.	1.1	18
1584	Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. <i>PLoS ONE</i> , 2016, 11, e0161484.	1.1	12
1585	Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. <i>PLoS ONE</i> , 2016, 11, e0167917.	1.1	28
1586	The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2016, 11, e0168264.	1.1	9
1587	Reirradiation of Recurrent Pediatric Brain Tumors after Initial Proton Therapy. <i>International Journal of Particle Therapy</i> , 2016, 3, 1-12.	0.9	5
1588	Current Standards of Care in Glioblastoma Therapy. , 0, , 197-241.		114
1589	Recurring Glioblastoma: A Case for Reoperation?. , 0, , 281-296.		5
1590	Glioblastoma: To Target the Tumor Cell or the Microenvironment?. , 0, , 315-340.		31
1591	Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy. , 0, , 341-358.		8
1592	The History of Neuroscience and Neurosurgery in Japan. <i>International Neuroscience Journal</i> , 2015, 1, 31-40.	0.4	5
1593	Glioblastoma: análisis molecular y sus implicancias clínicas. <i>Revista Peruana De Medicina De Experimental Y Salud Publica</i> , 2015, 32, 316.	0.1	5
1594	Hypoxia and glioblastoma therapy. <i>Aging</i> , 2015, 7, 523-524.	1.4	4

#	ARTICLE	IF	CITATIONS
1595	SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma. <i>Oncoscience</i> , 2015, 2, 102-110.	0.9	13
1596	Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma. <i>Oncotarget</i> , 2016, 7, 47808-47820.	0.8	28
1597	Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. <i>Oncotarget</i> , 2016, 7, 70948-70958.	0.8	43
1598	Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes. <i>Oncotarget</i> , 2016, 7, 59902-59916.	0.8	26
1599	Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging. <i>Oncotarget</i> , 2016, 7, 69606-69615.	0.8	11
1600	<i>In vivo</i> phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued. <i>Oncotarget</i> , 2016, 7, 71594-71607.	0.8	11
1601	Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. <i>Oncotarget</i> , 2017, 8, 7003-7013.	0.8	72
1602	Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 42214-42225.	0.8	81
1603	Biological basis and clinical study of glycogen synthase kinase-3 β -targeted therapy by drug repositioning for glioblastoma. <i>Oncotarget</i> , 2017, 8, 22811-22824.	0.8	38
1604	Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 57337-57344.	0.8	29
1605	Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates. <i>Oncotarget</i> , 2017, 8, 44141-44158.	0.8	44
1606	Evaluation of cumulative prognostic score based on pretreatment plasma fibrinogen and serum albumin levels in patients with newly diagnosed high-grade gliomas. <i>Oncotarget</i> , 2017, 8, 49605-49614.	0.8	25
1607	Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. <i>Oncotarget</i> , 2017, 8, 64932-64953.	0.8	58
1608	Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 74170-74177.	0.8	21
1609	Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. <i>Oncotarget</i> , 2014, 5, 2208-2220.	0.8	108
1610	Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas. <i>Oncotarget</i> , 2017, 8, 89607-89619.	0.8	19
1611	Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. <i>Oncotarget</i> , 2017, 8, 87124-87135.	0.8	8
1612	Glioblastoma research: US and international networking achievements. <i>Oncotarget</i> , 2017, 8, 115730-115735.	0.8	4

#	ARTICLE	IF	CITATIONS
1613	Paradoxical findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. <i>Oncotarget</i> , 2017, 8, 103890-103899.	0.8	14
1614	Acid ceramidase and its inhibitors: a <i>de novo</i> drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. <i>Oncotarget</i> , 2017, 8, 112662-112674.	0.8	51
1615	MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. <i>Oncotarget</i> , 2014, 5, 7651-7662.	0.8	79
1616	Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial. <i>Oncotarget</i> , 2018, 9, 6752-6762.	0.8	21
1617	Combination therapy of 7-O-succinyl macrolactin A tromethamine salt and temozolomide against experimental glioblastoma. <i>Oncotarget</i> , 2018, 9, 2140-2147.	0.8	4
1618	Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility. <i>Oncotarget</i> , 2014, 5, 8690-8702.	0.8	28
1619	Evaluating vacquinol-1 in rats carrying glioblastoma models RG2 and NS1. <i>Oncotarget</i> , 2018, 9, 8391-8399.	0.8	9
1620	A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. <i>Oncotarget</i> , 2018, 9, 21569-21579.	0.8	20
1621	The immune-related microRNA miR-146b is upregulated in glioblastoma recurrence. <i>Oncotarget</i> , 2018, 9, 29036-29046.	0.8	12
1622	Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. <i>Oncotarget</i> , 2018, 9, 28155-28164.	0.8	4
1623	Tumour treating fields in a combinational therapeutic approach. <i>Oncotarget</i> , 2018, 9, 36631-36644.	0.8	26
1624	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. <i>Oncotarget</i> , 2015, 6, 31050-31068.	0.8	52
1625	Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe. <i>Oncotarget</i> , 2015, 6, 2101-2119.	0.8	30
1626	High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma. <i>Oncotarget</i> , 2015, 6, 4901-4919.	0.8	29
1627	Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. <i>Oncotarget</i> , 2015, 6, 11664-11675.	0.8	45
1628	Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 14507-14521.	0.8	45
1629	Modulation of cerebral endothelial cell function by TGF- β 2 in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. <i>Oncotarget</i> , 2015, 6, 22480-22495.	0.8	56
1630	Endothelial-like malignant glioma cells in dynamic three dimensional culture identifies a role for VEGF and FGFR in a tumor-derived angiogenic response. <i>Oncotarget</i> , 2015, 6, 22191-22205.	0.8	17

#	ARTICLE	IF	CITATIONS
1631	Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. <i>Oncotarget</i> , 2015, 6, 34030-34037.	0.8	17
1632	The radiosensitivity index predicts for overall survival in glioblastoma. <i>Oncotarget</i> , 2015, 6, 34414-34422.	0.8	100
1633	Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?. <i>Oncotarget</i> , 2016, 7, 2313-2328.	0.8	29
1634	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. <i>Oncotarget</i> , 2016, 7, 21247-21258.	0.8	86
1635	Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation. <i>Oncotarget</i> , 2016, 7, 83976-83986.	0.8	53
1636	Drug resistance in cancer: molecular evolution and compensatory proliferation. <i>Oncotarget</i> , 2016, 7, 11746-11755.	0.8	60
1637	VEGF promotes gastric cancer development by upregulating CRMP4. <i>Oncotarget</i> , 2016, 7, 17074-17086.	0.8	21
1638	Histopathological investigation of glioblastomas resected under bevacizumab treatment. <i>Oncotarget</i> , 2016, 7, 52423-52435.	0.8	42
1639	Targeting BET bromodomain proteins in solid tumors. <i>Oncotarget</i> , 2016, 7, 53997-54009.	0.8	86
1640	A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. <i>Oncotarget</i> , 2016, 7, 45764-45775.	0.8	35
1641	Dynamic Reorganization of Microtubule and Glioma Invasion. <i>Acta Medica Okayama</i> , 2019, 73, 285-297.	0.1	5
1642	ONC201: a new treatment option being tested clinically for recurrent glioblastoma. <i>Translational Cancer Research</i> , 2017, 6, S1239-S1243.	0.4	31
1643	Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts. <i>Translational Cancer Research</i> , 2018, 7, S802-S805.	0.4	9
1644	On the subventricular zone origin of human glioblastoma. <i>Translational Cancer Research</i> , 2019, 8, 11-13.	0.4	1
1645	Bevacizumab in recurrent glioblastoma. <i>Translational Cancer Research</i> , 2019, 8, S162-S163.	0.4	1
1646	Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 147-156.	0.7	15
1648	MORPHOLOGIC AND MOLECULAR FEATURES OF PRIMARY GLIOBLASTOMA IN PATIENTS SURVIVING MORE THAN 3 YEARS. <i>Siberian Journal of Oncology</i> , 2019, 18, 34-44.	0.1	3
1649	Cold Atmospheric Plasma as a Novel Therapeutic Tool for the Treatment of Brain Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 2195-2206.	0.9	13

#	ARTICLE	IF	CITATIONS
1650	Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival?. <i>Current Molecular Medicine</i> , 2016, 16, 447-464.	0.6	7
1651	2-(l%-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 813-820.	0.9	5
1652	Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. <i>Anticancer Research</i> , 2017, 37, 21-33.	0.5	105
1653	A Retrospective Evaluation of Bevacizumab Treatment in Patients with Progressive Malignant Glioma in Northern Sweden. <i>Anticancer Research</i> , 2017, 37, 1869-1874.	0.5	4
1654	Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma. <i>Anticancer Research</i> , 2017, 37, 3871-3876.	0.5	10
1655	Inhibition of Bevacizumab-induced Epithelialâ€Mesenchymal Transition by BATF2 Overexpression Involves the Suppression of Wnt/l ² -Catenin Signaling in Glioblastoma Cells. <i>Anticancer Research</i> , 2017, 37, 4285-4294.	0.5	17
1656	Distribution of tumor-infiltrating immune cells in glioblastoma. <i>CNS Oncology</i> , 2018, 7, CNS21.	1.2	42
1657	The algorithms of adjuvant therapy in gliomas and their effect on survival. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 179-186.	0.3	5
1658	Overview on current treatment standards in high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 225-238.	0.4	18
1659	Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas. <i>Acta Biomedica</i> , 2020, 91, 61-78.	0.2	12
1660	An autopsy case of widespread brain dissemination of glioblastoma unnoticed by magnetic resonance imaging after treatment with bevacizumab. , 2019, 10, 137.		6
1661	Epithelioid glioblastoma presenting as multicentric glioma: A case report and review of the literature. , 2020, 11, 8.		4
1662	Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma. <i>Journal of Rare Diseases Research & Treatment</i> , 2016, 1, 51-55.	1.1	5
1663	Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients. <i>Neurosurgical Focus</i> , 2020, 49, E11.	1.0	4
1664	Glioblastoma Cellular Origin and the Firework Pattern of Cancer Genesis from the Subventricular Zone. <i>Journal of Korean Neurosurgical Society</i> , 2020, 63, 26-33.	0.5	18
1665	Molecular Mechanisms of Treatment Resistance in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 351.	1.8	106
1666	Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. <i>Oncology Letters</i> , 2017, 13, 3767-3773.	0.8	6
1667	Patientâ€derived orthotopic xenograft glioma models fail to replicate the magnetic resonance imaging features of the original patient tumor. <i>Oncology Reports</i> , 2020, 43, 1619-1629.	1.2	7

#	ARTICLE	IF	CITATIONS
1668	Contributions of immune cell populations in the maintenance, progression, and therapeutic modalities of glioma. <i>AIMS Allergy and Immunology</i> , 2018, 2, 24-44.	0.3	2
1669	Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?. <i>Annals of Translational Medicine</i> , 2015, 3, 7.	0.7	31
1670	Current trends in the surgical management and treatment of adult glioblastoma. <i>Annals of Translational Medicine</i> , 2015, 3, 121.	0.7	163
1671	Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?. <i>Annals of Translational Medicine</i> , 2016, 4, 36.	0.7	8
1672	Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. <i>Annals of Translational Medicine</i> , 2016, 4, 54.	0.7	46
1673	Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 229-237.	0.1	16
1674	Traumatic brain injury and subsequent glioblastoma development: Review of the literature and case reports. , 2016, 7, 78.		31
1675	Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report. <i>Glioma (Mumbai, India)</i> , 2019, 2, 167.	0.0	5
1676	Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro. <i>Cancer Research and Treatment</i> , 2019, 51, 696-705.	1.3	16
1677	Human Cytomegalovirus (HCMV) infection was not correlated with overall survival in glioblastomas. <i>Neoplasma</i> , 2018, 65, 431-435.	0.7	7
1678	Maximizing Function and Quality of Life of Patients with Glioblastoma after Surgical Resection: A Review of Current Literature. <i>Journal of Cancer Therapy</i> , 2016, 07, 857-888.	0.1	6
1679	Chemotherapy for adults with malignant glioma: a systematic review and network meta-analysis. <i>Turkish Neurosurgery</i> , 2015, 27, 174-181.	0.1	9
1680	Cytotoxic effect of boron application on glioblastoma cells. <i>Turkish Neurosurgery</i> , 2020, 31, 206-210.	0.1	6
1681	Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. <i>World Journal of Experimental Medicine</i> , 2014, 4, 58.	0.9	12
1682	Receptor Tyrosine Kinase Interaction with the Tumor Microenvironment in Malignant Progression of Human Glioblastoma. , 0, , .		2
1683	Development of targeted therapies in treatment of glioblastoma. <i>Cancer Biology and Medicine</i> , 2015, 12, 223-37.	1.4	54
1684	Stereotactic Radiosurgery for Glioblastoma. <i>Cureus</i> , 2015, 7, e413.	0.2	32
1685	Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard-versus Abbreviated-Course Radiotherapy. , 2015, 19, 15-20.		21

#	ARTICLE	IF	CITATIONS
1686	Response Assessment of Bevacizumab for Treatment of Malignant Glioma by Neuroimaging. Japanese Journal of Neurosurgery, 2016, 25, 912-921.	0.0	1
1687	Preoperative Apparent Diffusion Coefficient of Peritumoral Lesion Associate with Recurrence in Patients with Glioblastoma. Neurologia Medico-Chirurgica, 2022, 62, 28-34.	1.0	3
1688	Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 269-282.	0.9	8
1689	Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Frontiers in Oncology, 2021, 11, 749496.	1.3	13
1690	A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab156.	0.4	4
1691	A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. Journal of Neuro-Oncology, 2021, 155, 297-306.	1.4	5
1692	Hijacking Sexual Immuno-Privilege in GBM—An Immuno-Evasion Strategy. International Journal of Molecular Sciences, 2021, 22, 10983.	1.8	6
1693	Eudragit, a Nifty Polymer for Anticancer Preparations: A Patent Review. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 92-101.	0.8	4
1694	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. Neuro-Oncology Advances, 2021, 3, vdab142.	0.4	15
1695	Epigenetic approaches for cervical neoplasia screening (Review). Experimental and Therapeutic Medicine, 2021, 22, 1481.	0.8	10
1696	Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial. Journal of Neuro-Oncology, 2021, 155, 117-124.	1.4	8
1697	Hypoxia signaling: Challenges and opportunities for cancer therapy. Seminars in Cancer Biology, 2022, 85, 185-195.	4.3	17
1698	Glioblastoma cytotoxicity conferred through dual disruption of endolysosomal homeostasis by Vacquinol-1. Neuro-Oncology Advances, 2021, 3, vdab152.	0.4	1
1699	Three-dimensional culture models to study glioblastoma—current trends and future perspectives. Current Opinion in Pharmacology, 2021, 61, 91-97.	1.7	11
1700	Constructing nanocomplexes by multicomponent self-assembly for curing orthotopic glioblastoma with synergistic chemo-photothermal therapy. Biomaterials, 2021, 279, 121193.	5.7	16
1701	Recent Advance and Updates in Chemotherapy for Glioma. Japanese Journal of Neurosurgery, 2014, 23, 547-558.	0.0	0
1702	Imaging Biomarkers in Preclinical Studies on Brain Tumors. , 2014, , 1-19.		0
1703	Novel Strategies in Chemotherapy for Gliomas. Japanese Journal of Neurosurgery, 2015, 24, 386-398.	0.0	0

#	ARTICLE	IF	CITATIONS
1704	Connexins: Bridging the Gap Between Cancer Cell Communication in Glioblastoma. , 2015, , 29-41.		1
1705	Are Viral Epitopes Potential Targets for Effective Glioblastoma Immunotherapy. Journal of Carcinogenesis & Mutagenesis, 2015, 06, .	0.3	0
1706	Glioblastoma, bone sarcoma, and liver cancer: tough battles rage on for some tumors. Journal of Community and Supportive Oncology, 2015, 13, 162-166.	0.1	0
1708	Targeted Therapies in Brain Tumours: An Overview. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 1-23.	0.1	0
1709	Radiobiological Hints from Clinical Studies. Current Clinical Pathology, 2016, , 29-40.	0.0	0
1710	Antiangiogenic Therapy for Glioblastoma. , 2016, , 143-149.		1
1711	Hirntumoren. Springer-Lehrbuch, 2016, , 311-365.	0.1	1
1712	Chemotherapeutics and Their Efficacy. , 2016, , 133-141.		0
1713	Updates in Genetic Molecular Targeted Therapy for Glioblastoma. Cancer and Oncology Research, 2016, 4, 1-15.	0.2	0
1714	Sense and sensibility to early combine bevacizumab to radiation treatment of brain metastasis: reply to Lou and Sperduto. Annals of Translational Medicine, 2016, 4, 148-148.	0.7	0
1715	Lysophosphatidic Acid Signalling Enhances Glioma Stem Cell Properties. Pancreatic Islet Biology, 2017, , 171-189.	0.1	0
1716	Prognosis in glioblastoma: insight gained from recent prospective trials. Translational Cancer Research, 2017, 6, S158-S159.	0.4	0
1717	Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations. Journal of Neuro-Oncology, 2017, 134, 551-557.	1.4	1
1718	INFLUENCE OF CLINICAL CHARACTERISTICS AND VOLUME OF CYTOREDUCTION IN PATIENTS WITH PRIMARY GLIOBLASTOMA ON OVERALL SURVIVAL. Voprosy Onkologii, 2017, 63, 907-914.	0.1	0
1720	Pediatric Chemotherapy. , 2018, , 1-15.		0
1721	The Value of Anti-angiogenics in Brain Tumor Therapy. , 2018, , 1-18.		0
1722	Medical Complications of Brain Tumors. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1635-1652.	0.4	4
1723	Benefits and Pitfalls of Tumor Vessel Normalization. , 2018, , 1-21.		0

#	ARTICLE	IF	CITATIONS
1724	Problem and Handling of Anti-angiogenic Therapy for Glioblastoma : Vessel Co-option and Vascular Mimicry. Japanese Journal of Neurosurgery, 2018, 27, 723-735.	0.0	0
1725	High-Grade Gliomas. , 2018, , 580-585.e2.		0
1726	The Value of Anti-angiogenics in Primary Brain Tumor Therapy. , 2018, , 1-18.		0
1728	Malignant Brain Tumors. , 2019, , 117-133.		2
1729	THE VALUE OF PROGNOSTIC FACTORS FOR GLIOBLASTOMA TREATED WITH CONCURRENT THERMOCHEMORADIOTHERAPY. Siberian Journal of Oncology, 2018, 17, 27-36.	0.1	0
1730	The 2017 Incentive Award of the Okayama Medical Association in Cancer Research (2017 Hayashibara) Tj ETQq1 1 0.784314,rgBT /Over	0.0	0
1732	Central Nervous System Cancers. , 2019, , 83-131.		1
1733	The Value of Anti-angiogenics in Primary Brain Tumor Therapy. , 2019, , 609-625.		0
1735	Glioma Treatment focusing on Brain Function. Japanese Journal of Neurosurgery, 2019, 28, 686-698.	0.0	0
1736	Gliome. Springer Reference Medizin, 2019, , 1-14.	0.0	0
1737	Benefits and Pitfalls of Tumor Vessel Normalization. , 2019, , 51-71.		1
1738	Anti-angiogenics and Radiation Therapy. , 2019, , 349-358.		0
1739	EFFECTIVENESS OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF GLIOBLASTOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Voprosy Onkologii, 2019, 65, 546-555.	0.1	1
1741	Physical Exercise during Radiation and Chemotherapy. The Japanese Journal of Rehabilitation Medicine, 2019, 56, 618-622.	0.0	0
1743	Indications and Limitations of Conventional Imaging“ Current Clinical Practice in theContext of Standard Therapy. , 2020, , 1-15.		1
1744	Ausgangslage f¼r Rehabilitationsmaßnahmen bei HirntumorpatientInnen. , 2020, , 227-236.		0
1745	Chemotherapy and Future Developments. , 2020, , 29-37.		0
1748	Revisiting anti-angiogenic therapy for recurrent glioblastoma. Translational Cancer Research, 2019, 8, S569-S572.	0.4	2

#	ARTICLE	IF	CITATIONS
1749	Content of cells of innate and acquired immunity in peripheral blood in brain tumors. Journal of the National Academy of Medical Sciences of Ukraine, 2019, , 397-408.	0.1	0
1750	Gliome. Springer Reference Medizin, 2020, , 1-14.	0.0	0
1751	Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. Korean Journal of Radiology, 2020, 21, 471.	1.5	5
1752	Model for and analysis of intraoperative brain tumor boundary detection based on known spectral signatures of glioblastoma. , 2020, , .		0
1753	Integrative transcriptome analysis identified a BMP signaling pathwayâ€regulated lncRNA AC068643.1 in IDH mutant and wildâ€type glioblastomas. Oncology Letters, 2020, 20, 75-84.	0.8	3
1754	Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways. Novel Approaches in Cancer Study, 2020, 4, .	0.2	4
1755	Risk of Hypertension Associated with Antivascular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. Iranian Red Crescent Medical Journal, 2020, 22, .	0.5	2
1756	Modern Treatments for Gliomas Improve Outcome. Current Cancer Therapy Reviews, 2020, 16, 221-245.	0.2	0
1757	Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma. Frontiers in Oncology, 2021, 11, 759873.	1.3	7
1758	Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT. Cancers, 2021, 13, 5420.	1.7	6
1759	Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies. Advanced Drug Delivery Reviews, 2021, 179, 113999.	6.6	32
1760	Potential Risk Factors of Glioblastoma Multiforme in Greek Adults: A Case- Control Study. Journal of Clinical Medical Research, 2020, 01, .	0.1	1
1761	Current Status of Adjuvant Therapy for Glioblastoma and Potential Novel Therapies. Japanese Journal of Neurosurgery, 2020, 29, 188-197.	0.0	0
1762	Neuroonkologie. , 2020, , 257-271.		0
1763	Chemotherapy for Brain Tumors. , 2021, , 357-383.		0
1764	Drug Repositioning for the Treatment of Glioma: Current State and Future Perspective. , 0, , .		0
1765	Neuropsychological Assessment in Brain Tumor Patients. , 2021, , 283-298.		0
1766	Gliome des Erwachsenenalters. Springer Reference Medizin, 2021, , 1-12.	0.0	0

#	ARTICLE	IF	CITATIONS
1767	Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa171.	0.4	4
1768	ONCOLYTIC VIROTHERAPY IN GLIOBLASTOMA TREATMENT: PROGRESS AND CHALLENGES IN CLINICAL RESEARCH (LITERATURE REVIEW). <i>Siberian Journal of Oncology</i> , 2020, 19, 133-140.	0.1	0
1769	Survival Analysis II. , 2020, , 1-28.		1
1770	https://researchopenworld.com/the-addition-of-valproic-acid-to-concurrent-radiation-therapy-and-temozolomide-improves-patient-outcome/ , 2020, 5, .		7
1771	Gliome. <i>Springer Reference Medizin</i> , 2020, , 997-1010.	0.0	0
1772	Current Applications and Future Perspectives of Brain Tumor Imaging. <i>Journal of the Korean Society of Radiology</i> , 2020, 81, 467.	0.1	1
1773	Molecular Targets in Craniopharyngioma. , 2020, , 209-221.		1
1774	Tumeurs cérébrales, gliomes malins. , 2020, , 227-237.e2.		0
1775	Immunopathology and Immunotherapy of Central Nervous System Cancer. , 2020, , 379-425.		0
1776	Glioblastoma. , 2020, , 173-182.		0
1777	Malignome des zentralen Nervensystems (ZNS). , 2020, , 1021-1055.		0
1778	Translating Targeted Radiosensitizers into the Clinic. <i>Cancer Drug Discovery and Development</i> , 2020, , 17-33.	0.2	0
1779	Angiogenesis in glioblastoma: Molecular and cellular mechanisms and clinical applications. <i>Acta Facultatis Medicae Naissensis</i> , 2020, 37, 211-230.	0.1	1
1781	Proteomic Distributions in CD34+ Microvascular Niche Patterns of Glioblastoma. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 99-110.	1.3	1
1782	Ventricle wall resection contributes to supramaximal resection and prognosis in SVZ-involved frontal gliomas: A single center retrospective study. <i>Clinical Neurology and Neurosurgery</i> , 2021, 211, 107015.	0.6	2
1783	Non-Coding RNAs in Glioma Microenvironment and Angiogenesis. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 763610.	1.4	12
1784	Large Animal Models of Glioma: Current Status and Future Prospects. <i>Anticancer Research</i> , 2021, 41, 5343-5353.	0.5	18
1785	Neues zur Diagnostik und Therapie von Gliomen. <i>Neuroradiologie Scan</i> , 2020, 10, 199-214.	0.0	0

#	ARTICLE	IF	CITATIONS
1787	Lysophospholipid Signalling and the Tumour Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1270, 123-144.	0.8	1
1788	HEMATOTOXIC ADVERSE DRUG REACTIONS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS AND CYTOTOXIC DRUGS IN THE TREATMENT OF GLIOBLASTOMA: A SYSTEMATIC REVIEW. <i>Siberian Journal of Oncology</i> , 2020, 19, 121-130.	0.1	1
1789	A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa146.	0.4	10
1790	Does the dural resection bed need to be irradiated? Patterns of recurrence and implications for postoperative radiotherapy for temporal lobe gliomas. <i>Neuro-Oncology Practice</i> , 2021, 8, 190-198.	1.0	1
1791	Quantitative Features From CHO PET Distinguish the WHO Grades of Primary Diffuse Glioma. <i>Clinical Nuclear Medicine</i> , 2021, 46, 103-110.	0.7	8
1792	The role of extracellular vesicles in the diagnosis of glioblastoma progression. <i>Uspehi Molekularnoj Onkologii</i> , 2020, 7, 8-18.	0.1	0
1793	Deep learning to classify single-cell RNA sequencing in primary glioblastoma. , 2020, , .		1
1794	Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 385-405.	1.0	26
1795	Mechanism and Function of Angiogenin in Hematopoietic Malignancy. <i>Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao = Chinese Journal of Biochemistry and Molecular Biology</i> , 2015, 31, 1267-1275.	0.0	2
1797	Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma. , 2016, 1, 51-55.		2
1798	Icariside II induces cell cycle arrest and apoptosis in human glioblastoma cells through suppressing Akt activation and potentiating FOXO3a activity. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 2508-2519.	0.0	4
1799	Management and treatment recommendations for World Health Organization Grade III and IV gliomas. <i>International Journal of Health Sciences</i> , 2017, 11, 54-62.	0.4	4
1800	Long noncoding RNA ZEB1-AS1 promotes the tumorigenesis of glioma cancer cells by modulating the miR-200c/141-ZEB1 axis. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 3395-3412.	0.0	31
1801	Biomarkers for glioblastoma multiforme: status quo. <i>Journal of Clinical and Translational Research</i> , 2016, 2, 3-10.	0.3	10
1802	Wild-type defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. <i>American Journal of Cancer Research</i> , 2019, 9, 1734-1745.	1.4	3
1803	Newly Diagnosed Glioblastoma: A Review on Clinical Management. <i>Oncology</i> , 2019, 33, 91-100.	0.4	42
1804	Organoid models of glioblastoma: advances, applications and challenges. <i>American Journal of Cancer Research</i> , 2020, 10, 2242-2257.	1.4	8
1805	Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways. <i>Novel Approaches in Cancer Study</i> , 2020, 4, 398-401.	0.2	1

#	ARTICLE	IF	CITATIONS
1806	CircularRNA circPARP4 promotes glioblastoma progression through sponging miR-125a-5p and regulating FUT4. American Journal of Cancer Research, 2021, 11, 138-156.	1.4	5
1807	circRNA-0002109 promotes glioma malignant progression via modulating the miR-129-5P/EMP2 axis. Molecular Therapy - Nucleic Acids, 2022, 27, 1-15.	2.3	7
1808	Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma. Scientific Reports, 2021, 11, 22057.	1.6	1
1809	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Journal of Neuro-Oncology, 2021, 155, 363-372.	1.4	11
1810	Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. Journal of Neuro-Oncology, 2022, 156, 185-193.	1.4	2
1811	Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. Neuro-Oncology Advances, 2021, 3, v133-v143.	0.4	11
1812	GRPEL2 Knockdown Exerts Redox Regulation in Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 12705.	1.8	3
1813	Surviving Over a Decade With Glioblastoma: A Clinical Course Characterized by Multiple Recurrences, Numerous Salvage Treatments, and Novel Use of Cesium-131 Tiles. Cureus, 2021, 13, e19573.	0.2	1
1814	Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. Journal of Neuro-Oncology, 2021, 155, 307-317.	1.4	9
1815	Hypoxia: The Cornerstone of Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 12608.	1.8	62
1816	Endothelial cell-specific reduction of heparan sulfate suppresses glioma growth in mice. Discover Oncology, 2021, 12, 50.	0.8	3
1817	Emerging therapeutic targets for cerebral edema. Expert Opinion on Therapeutic Targets, 2021, 25, 917-938.	1.5	15
1818	Treatment Response. , 2022, , 589-596.		0
1819	Chronic pathophysiological changes in the normal brain parenchyma caused by radiotherapy accelerate glioma progression. Scientific Reports, 2021, 11, 22110.	1.6	4
1820	Hematological adverse events in the management of glioblastoma. Journal of Neuro-Oncology, 2022, 156, 153-161.	1.4	4
1821	Macrophage-Mediated Porous Magnetic Nanoparticles for Multimodal Imaging and Postoperative Photothermal Therapy of Gliomas. ACS Applied Materials & Interfaces, 2021, 13, 56825-56837.	4.0	23
1822	Temporal Trends in Glioblastoma Survival. Neurologist, 2022, 27, 119-124.	0.4	7
1823	Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis. BMJ Open, 2021, 11, e048975.	0.8	5

#	ARTICLE	IF	CITATIONS
1824	A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 689-696.	3.2	38
1825	A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab164.	0.4	11
1826	PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. <i>BMC Cancer</i> , 2022, 22, 14.	1.1	5
1827	Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach. <i>Journal of Neurosurgical Sciences</i> , 2023, 67, .	0.3	5
1828	Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 812916.	1.3	13
1829	A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac006.	0.4	14
1830	miR-138-5p Inhibits the Growth and Invasion of Glioma Cells by Regulating WEE1. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-12.	0.7	2
1831	Preoperative Stereotactic Radiosurgery for Glioblastoma. <i>Biology</i> , 2022, 11, 194.	1.3	7
1832	Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1353.	1.8	67
1833	Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation. <i>Journal of Cancer</i> , 2022, 13, 354-363.	1.2	13
1834	Ceramide Composition in Exosomes for Characterization of Glioblastoma Stem-Like Cell Phenotypes. <i>Frontiers in Oncology</i> , 2021, 11, 788100.	1.3	7
1835	A novel hypocrellin-based assembly for sonodynamic therapy against glioblastoma. <i>Journal of Materials Chemistry B</i> , 2021, 10, 57-63.	2.9	9
1836	Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. <i>Acta Neuropathologica Communications</i> , 2022, 10, 1.	2.4	28
1837	High grade gliomas. <i>Progress in Brain Research</i> , 2022, 268, 259-270.	0.9	2
1838	Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis. <i>American Journal of Neuroradiology</i> , 2022, 43, 202-206.	1.2	11
1839	Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 541.	1.4	1
1840	Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 522-534.	2.0	17
1841	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426.	0.8	67

#	ARTICLE	IF	CITATIONS
1842	Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma. <i>Journal of Neuro-Oncology</i> , 2022, 157, 137-146.	1.4	8
1843	Metabolic characteristics of [18F]fluoroboronotyrosine (FBY) PET in malignant brain tumors. <i>Nuclear Medicine and Biology</i> , 2022, 106-107, 80-87.	0.3	11
1844	Global management of brain metastasis from renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103600.	2.0	2
1845	Glioma targeted therapy: insight into future of molecular approaches. <i>Molecular Cancer</i> , 2022, 21, 39.	7.9	274
1846	Global Research Trends in Radiotherapy for Gliomas: A Systematic Bibliometric Analysis. <i>World Neurosurgery</i> , 2022, 161, e355-e362.	0.7	9
1847	A Multielement Prognostic Nomogram Based on a Peripheral Blood Test, Conventional MRI and Clinical Factors for Glioblastoma. <i>Frontiers in Neurology</i> , 2022, 13, 822735.	1.1	2
1848	Pretreatment patient-reported cognitive function in patients with diffuse glioma. <i>Acta Neurochirurgica</i> , 2022, 164, 703-711.	0.9	4
1849	Newly Diagnosed Glioblastoma in Elderly Patients. <i>Current Oncology Reports</i> , 2022, 24, 325-334.	1.8	3
1850	Brain Tumor Imaging: Applications of Artificial Intelligence. <i>Seminars in Ultrasound, CT and MRI</i> , 2022, 43, 153-169.	0.7	10
1851	Selective Single-Cell Expansion on a Microfluidic Chip for Studying Heterogeneity of Glioma Stem Cells. <i>Analytical Chemistry</i> , 2022, 94, 3245-3253.	3.2	5
1852	Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival?. <i>Current Molecular Medicine</i> , 2016, , .	0.6	2
1854	Nuclear medicine therapy of CNS tumors. , 2022, , .		0
1855	Psychosocial issues in cancer patients with neurological complications. , 2022, , 611-634.		0
1856	Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3510-3519.	0.8	7
1857	Identification of Four Metabolic Subtypes of Glioma Based on Glycolysis-Cholesterol Synthesis Genes. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-16.	0.7	2
1858	Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients. <i>Current Oncology Reports</i> , 2022, 24, 493-500.	1.8	3
1859	Complete and Incomplete Resection for Progressive Glioblastoma Prolongs Post-Progression Survival. <i>Frontiers in Oncology</i> , 2022, 12, 755430.	1.3	8
1860	Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes. <i>Frontiers in Radiology</i> , 2022, 1, .	1.2	3

#	ARTICLE	IF	CITATIONS
1861	Glioblastoma Vasculature: From its Critical Role in Tumor Survival to Relevant in Vitro Modelling. <i>Frontiers in Drug Delivery</i> , 2022, 2, .	0.4	2
1862	CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma. <i>Frontiers in Immunology</i> , 2022, 13, 810832.	2.2	7
1863	Molecular Mechanisms and Clinical Challenges of Glioma Invasion. <i>Brain Sciences</i> , 2022, 12, 291.	1.1	6
1864	Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy. <i>Cancers</i> , 2022, 14, 1176.	1.7	28
1865	Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment. <i>Journal of Neuro-Oncology</i> , 2022, 157, 405-415.	1.4	0
1866	Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study. <i>World Neurosurgery</i> , 2022, 159, e479-e487.	0.7	2
1867	Limited field adaptive radiotherapy for glioblastoma: changes in target volume and organ at risk doses. <i>Radiation Oncology Journal</i> , 2022, 40, 9-19.	0.7	6
1868	Glioblastoma with concomitant moyamoya vasculopathy in neurofibromatosis type 1: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 3, .	0.1	1
1869	Angiogenesis-Related Gene Signature-Derived Risk Score for Glioblastoma: Prospects for Predicting Prognosis and Immune Heterogeneity in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 778286.	1.8	6
1870	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance. <i>Frontiers in Oncology</i> , 2022, 12, 852950.	1.3	9
1871	Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells. <i>Cancers</i> , 2022, 14, 1551.	1.7	4
1872	Tumor-Mediated Neutrophil Polarization and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3218.	1.8	20
1873	Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 874554.	1.3	10
1874	β ² -Catenin marks proliferating endothelial cells in glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2022, 98, 203-206.	0.8	3
1875	Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme. <i>Neuroscience</i> , 2022, 491, 240-270.	1.1	22
1876	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
1877	Pyridine-NBD: A homocysteine-selective fluorescent probe for glioblastoma (GBM) diagnosis based on a blood test. <i>Analytica Chimica Acta</i> , 2022, 1202, 339678.	2.6	11
1878	Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma. <i>Biochemical and Biophysical Research Communications</i> , 2022, 604, 158-164.	1.0	7

#	ARTICLE	IF	CITATIONS
1879	Magnetic covalent organic framework nanospheres-based miRNA biosensor for sensitive glioma detection. <i>Bioactive Materials</i> , 2022, 14, 145-151.	8.6	22
1880	Tumor treating fields: a comprehensive overview of the underlying molecular mechanism. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 19-28.	1.5	12
1881	Immunotherapy against Gliomas. , 0, , .		0
1882	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 358-383.	0.6	1
1883	Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 893-912.	1.6	13
1884	Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1781-1804.	5.7	27
1885	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?. <i>Frontiers in Oncology</i> , 2021, 11, 718590.	1.3	14
1886	Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101956.	3.9	7
1887	Impact of systemic therapies on cognition in patients with primary brain tumors. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 569.	0.1	1
1888	Interaction of curcumin with glioblastoma cells via high and low linear energy transfer radiation therapy inducing radiosensitization effects. <i>Journal of Radiation Research</i> , 2022, 63, 342-353.	0.8	5
1889	Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma. <i>Cancers</i> , 2022, 14, 1958.	1.7	7
1890	Galvanotactic Migration of Glioblastoma and Brain Metastases Cells. <i>Life</i> , 2022, 12, 580.	1.1	6
1891	Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists. <i>Journal of Neuro-Oncology</i> , 2022, 158, 69-79.	1.4	7
1892	Tumor Microenvironment in Glioma Invasion. <i>Brain Sciences</i> , 2022, 12, 505.	1.1	28
1893	Emerging therapies for glioblastoma: current state and future directions. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 142.	3.5	103
1894	Antibody-Based Formats to Target Glioblastoma: Overcoming Barriers to Protein Drug Delivery. <i>Molecular Pharmaceutics</i> , 2022, 19, 1233-1247.	2.3	2
1895	MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. <i>Journal of Neuro-Oncology</i> , 2022, 157, 561-571.	1.4	5
1896	Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 879-892.	1.7	8

#	ARTICLE	IF	CITATIONS
1914	Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21â€“05). Japanese Journal of Clinical Oncology, 2022, 52, 843-849.	0.6	1
1915	Quality of life in patients with glioblastoma and their relatives. Acta Neurologica Scandinavica, 2022, 146, 82-91.	1.0	10
1916	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. Science Advances, 2022, 8, eabl9171.	4.7	30
1917	Efficacy and safety of bevacizumab combined with temozolomide in the treatment of recurrent malignant gliomas and its influence on serum tumor markers.. American Journal of Translational Research (discontinued), 2021, 13, 13886-13893.	0.0	0
1918	The efficacy and safety of extended adjuvant temozolomide following concurrent radio-chemotherapy among Egyptian patients with newly diagnosed glioblastoma multiforme.. American Journal of Cancer Research, 2022, 12, 355-370.	1.4	0
1919	Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis. Technology in Cancer Research and Treatment, 2022, 21, 153303382110352.	0.8	3
1920	Molecular Analysis in a Glioblastoma Cohortâ€”Results of a Prospective Analysis. Journal of Personalized Medicine, 2022, 12, 685.	1.1	5
1921	Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Frontiers in Oncology, 2022, 12, 896246.	1.3	14
1922	Skull modulated strategies to intensify tumor treating fields on brain tumor: a finite element study. Biomechanics and Modeling in Mechanobiology, 2022, 21, 1133-1144.	1.4	4
1923	Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells. International Journal of Molecular Sciences, 2022, 23, 5238.	1.8	4
1924	Long Term Survivals in Aggressive Primary Brain Malignancies Treated With an Adjuvant Ketogenic Diet. Frontiers in Nutrition, 2022, 9, 770796.	1.6	4
1926	The use of radiosensitizing agents in the therapy of glioblastoma multiformeâ€”a comprehensive review. Strahlentherapie Und Onkologie, 2022, 198, 507-526.	1.0	8
1927	Multi-omics analysis predicts fibronectin 1 as a prognostic biomarker in glioblastoma multiforme. Genomics, 2022, 114, 110378.	1.3	7
1928	Venous thromboembolic events in glioblastoma patients: An epidemiological study. European Journal of Neurology, 2022, 29, 2386-2397.	1.7	7
1929	Optimal managements of elderly patients with glioblastoma. Japanese Journal of Clinical Oncology, 2022, 52, 833-842.	0.6	2
1930	XIST in Brain Cancer. Clinica Chimica Acta, 2022, 531, 283-290.	0.5	5
1931	Molecular mechanisms of drug resistance of glioblastoma. Part 1: ABC family proteins and inhibitors. Meditsinskii Akademicheskii Zhurnal, 2021, 21, 85-106.	0.2	0
1932	Chromatin structure predicts survival in glioma patients. Scientific Reports, 2022, 12, 8221.	1.6	1

#	ARTICLE	IF	CITATIONS
1933	Non-metabolic functions of phosphofructokinase-1 orchestrate tumor cellular invasion and genome maintenance under bevacizumab therapy. <i>Neuro-Oncology</i> , 2023, 25, 248-260.	0.6	4
1934	Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. <i>CNS Oncology</i> , 2022, 11, .	1.2	5
1935	Updates in IDH-Wildtype Glioblastoma. <i>Neurotherapeutics</i> , 2022, 19, 1705-1723.	2.1	26
1936	The Vascular Microenvironment in Glioblastoma: A Comprehensive Review. <i>Biomedicines</i> , 2022, 10, 1285.	1.4	11
1937	Role of magnetic resonance imaging following postoperative radiotherapy in clinical decision-making of patients with high-grade glioma. <i>Radiologia Medica</i> , 0, , .	4.7	5
1938	Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction. <i>Cardiovascular Research</i> , 2023, 119, 710-728.	1.8	4
1939	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. <i>British Journal of Cancer</i> , 2022, 127, 976-987.	2.9	26
1940	The brilliance of nanoscience over cancer therapy: Novel promising nanotechnology-based methods for eradicating glioblastoma. <i>Journal of the Neurological Sciences</i> , 2022, 440, 120316.	0.3	10
1941	Glioblastoma. , 2023, , 388-392.		0
1942	The Cost-Effectiveness Evaluation of the Intraoperative Additional Photodynamic Therapy for the Treatment of Newly Diagnosed Glioblastoma. <i>Nippon Laser Igakkaishi</i> , 2022, , .	0.0	0
1943	Novel Pharmacological Treatment Options in Pediatric Glioblastoma—A Systematic Review. <i>Cancers</i> , 2022, 14, 2814.	1.7	4
1944	Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1945	Patient-reported cognitive function before and after glioma surgery. <i>Acta Neurochirurgica</i> , 2022, 164, 2009-2019.	0.9	4
1946	Silicon-based nanoprobe cross the blood-brain barrier for photothermal therapy of glioblastoma. <i>Nano Research</i> , 2022, 15, 7392-7401.	5.8	8
1947	Introducing FCR6—Brain: Measuring fear of cancer recurrence in brain tumor patients and their caregivers. <i>Neuro-Oncology Practice</i> , 2022, 9, 509-519.	1.0	4
1948	STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response. <i>Pharmacological Research</i> , 2022, 182, 106311.	3.1	51
1949	Diagnosis and Drug Prediction of Parkinson's Disease Based on Immune-Related Genes. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 1809-1819.	1.1	3
1950	Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches. , 2022, 39, .		8

#	ARTICLE	IF	CITATIONS
1951	Prognostic Value and Biological Function of Galectins in Malignant Glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1952	Decision-making around end-of-life care in brain cancer patients: A scoping review. <i>Ethics, Medicine and Public Health</i> , 2022, 23, 100778.	0.5	0
1954	Analysis of the potential role of photocurable hydrogel in patient-derived glioblastoma organoid culture through RNA sequencing. <i>Biomaterials Science</i> , 2022, 10, 4902-4914.	2.6	3
1955	A Comprehensive Clinical Review of Adult-Type Diffuse Glioma Incorporating the 2021 World Health Organization Classification. <i>Neurographics</i> , 2022, 12, 43-70.	0.0	3
1956	Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice. <i>Neurotherapeutics</i> , 2022, 19, 1818-1831.	2.1	11
1957	Survival Outcomes and Prognostic Factors in Glioblastoma. <i>Cancers</i> , 2022, 14, 3161.	1.7	33
1958	Glioblastoma Treatment: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7207.	1.8	38
1959	Magnetic Resonance Spectroscopic Imaging for Detecting Metabolic Changes in Glioblastoma After Anti-angiogenic Therapy-A Systematic Literature Review. <i>Neuro-Oncology Advances</i> , 0, .	0.4	0
1960	The role of liquid biopsy in the diagnosis of glioblastoma progression. <i>Siberian Journal of Oncology</i> , 2022, 21, 104-116.	0.1	1
1961	Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	23
1962	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	0.6	35
1963	Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib. <i>Genes</i> , 2022, 13, 1198.	1.0	1
1964	Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta-analysis. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 1476-1491.	1.9	5
1965	Vascular complications in patients with brain tumors. <i>Current Opinion in Oncology</i> , 2022, 34, 698-704.	1.1	0
1966	Mid-term treatment-related cognitive sequelae in glioma patients. <i>Journal of Neuro-Oncology</i> , 2022, 159, 65-79.	1.4	2
1968	Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1763.	1.4	4
1970	Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
1971	Survival Analysis II. , 2022, , 1743-1770.		0

#	ARTICLE	IF	CITATIONS
1972	Computational Intelligence Approach to improve the Classification Accuracy of Brain Tumour Detection. , 2022, , .		7
1973	Continuing maintenance temozolomide therapy beyond 12Âcycles confers no clinical benefit over discontinuation at 12Âcycles in patients with <i>IDH1/2</i>-wildtype glioblastoma. Japanese Journal of Clinical Oncology, 0, , .	0.6	0
1974	Non-occlusive mesenteric ischemia during bevacizumab treatment for glioblastoma: a case report. Acta Neurochirurgica, 0, , .	0.9	1
1975	Molecular matched targeted therapies for primary brain tumorsâ”a single center retrospective analysis. Journal of Neuro-Oncology, 2022, 159, 243-259.	1.4	7
1976	Lipid Metabolism in Glioblastoma: From De Novo Synthesis to Storage. Biomedicines, 2022, 10, 1943.	1.4	19
1977	Multimodal targeting of glioma with functionalized nanoparticles. Cancer Cell International, 2022, 22, .	1.8	13
1978	Potential 18F-RGD PET/CT and DCE-MRI Imaging-Based Biomarkers for Postoperative Survival Prediction Among Patients With Newly Diagnosed Glioblastoma Treated With Bevacizumab and Chemoradiotherapy. Frontiers in Oncology, 0, 12, .	1.3	0
1979	In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific Reports, 2022, 12, .	1.6	0
1980	Exploring the origin of the cancer stem cell niche and its role in anti-angiogenic treatment for glioblastoma. Frontiers in Oncology, 0, 12, .	1.3	7
1981	Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. International Reviews of Immunology, 2022, 41, 582-605.	1.5	12
1982	Downregulated ferroptosisâ”related gene <scp>SQLE</scp> facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma. CNS Neuroscience and Therapeutics, 2022, 28, 2104-2115.	1.9	8
1983	Matricellular protein tenascin C: Implications in glioma progression, gliomagenesis, and treatment. Frontiers in Oncology, 0, 12, .	1.3	3
1985	Emerging immune-based technologies for high-grade gliomas. Expert Review of Anticancer Therapy, 2022, 22, 957-980.	1.1	1
1986	Application of intraoperative photodynamic therapy in patients suspected of recurrence post radical surgery: A single center experience. Photodiagnosis and Photodynamic Therapy, 2022, 40, 103047.	1.3	1
1987	Novel Clinical Trial Designs in Neuro-Oncology. Neurotherapeutics, 2022, 19, 1844-1854.	2.1	3
1988	Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, .	3.3	18
1989	Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis. PLoS ONE, 2022, 17, e0273242.	1.1	4
1990	PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells. Frontiers in Oncology, 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
1991	Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 275-288.	2.0	5
1992	Identification of Prognostic Signature of Necroptosis-Related lncRNAs and Molecular Subtypes in Glioma. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-21.	0.7	1
1993	Exosomal B7â€“H4 from irradiated glioblastoma cells contributes to increase FoxP3 expression of differentiating Th1 cells and promotes tumor growth. <i>Redox Biology</i> , 2022, 56, 102454.	3.9	12
1994	Overview of pathology and treatment of primary brain tumours. , 2022, , 9-24.		0
1995	A â€“Globalâ€™ Approach to Developing Treatments for Malignant Brain Tumors. <i>Japanese Journal of Neurosurgery</i> , 2022, 31, 564-572.	0.0	0
1996	Neuroimaging issues in assessing glioma response to brain tumour therapy. , 2022, , 809-819.		0
1997	Identification and validation of roles of lysyl oxidases in the predictions of prognosis, chemotherapy and immunotherapy in glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1998	An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid. <i>Cancers</i> , 2022, 14, 4244.	1.7	4
1999	HECTD3 regulates the tumorigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway. <i>British Journal of Cancer</i> , 2022, 127, 1925-1938.	2.9	7
2000	Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. <i>Cancer Cell</i> , 2022, 40, 1111-1127.e9.	7.7	30
2001	The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma. <i>Biomedicines</i> , 2022, 10, 2292.	1.4	6
2002	Current and promising treatment strategies in glioma. <i>Reviews in the Neurosciences</i> , 2022, , .	1.4	3
2003	A lipid metabolism-related risk signature for patients with gliomas constructed with TCGA and CGGA data. <i>Medicine (United States)</i> , 2022, 101, e30501.	0.4	0
2004	Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth. <i>Cancer Gene Therapy</i> , 0, , .	2.2	0
2005	Potassium Ion Channels in Malignant Central Nervous System Cancers. <i>Cancers</i> , 2022, 14, 4767.	1.7	5
2006	Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	3
2007	Clinical, Therapeutic, and Prognostic Experience in Patients With Glioblastoma. <i>Cureus</i> , 2022, , .	0.2	0
2008	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2

#	ARTICLE	IF	CITATIONS
2009	Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	1
2010	Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19). <i>Discover Oncology</i> , 2022, 13, .	0.8	3
2011	Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. <i>Brain Sciences</i> , 2022, 12, 1426.	1.1	1
2012	Music improves the therapeutic effects of bevacizumab in rats with glioblastoma: Modulation of drug distribution to the brain. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2014	Reirradiation for Recurrent Glioblastoma: What We Know and What We Do Not. <i>Journal of Clinical Oncology</i> , 2023, 41, 1183-1188.	0.8	7
2015	Potential of Lipid Based Nanodrug Carriers for Targeted Treatment of Glioblastoma: Recent Progress and Challenges Ahead. , 0, , .		0
2017	Identifying overall survival in 98 glioblastomas using VASARI features at 3T. <i>Clinical Imaging</i> , 2022, , .	0.8	3
2020	Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. <i>European Journal of Cancer</i> , 2023, 178, 162-170.	1.3	1
2021	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
2022	Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions. <i>Journal of Controlled Release</i> , 2022, 352, 338-370.	4.8	25
2023	Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma. , 2022, 1, 100014.		10
2024	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. <i>Current Opinion in Neurology</i> , 2022, 35, 803-813.	1.8	7
2025	Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. <i>Cancers</i> , 2022, 14, 5522.	1.7	3
2026	Surgical cytoreduction of deep-seated high-grade glioma through tubular retractor. <i>Journal of Neurosurgery</i> , 2022, , 1-12.	0.9	0
2027	Alterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2028	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2029	Initiatives Toward Clinical Boron Neutron Capture Therapy in Japan. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2023, 38, 201-207.	0.7	3
2030	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
2031	Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies. <i>Cancer Biology and Medicine</i> , 2022, 19, 1423-1427.	1.4	2
2032	Bioinformatics analysis identified RGS4 as a potential tumor promoter in glioma. <i>Pathology Research and Practice</i> , 2022, 240, 154225.	1.0	1
2033	Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2022, 160, 433-443.	1.4	6
2034	Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival. <i>Nature Communications</i> , 2022, 13, .	5.8	14
2035	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2036	Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells. <i>Molecules</i> , 2022, 27, 7968.	1.7	2
2037	Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2023, 9, 112.	3.4	133
2038	Central nervous system tumors. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 211-235.	0.0	0
2039	Treatment of Adult Gliomas: A Current Update. <i>Brain & Neurorehabilitation</i> , 2022, 15, .	0.4	7
2040	Glioblastoma Antigen Expression for Tumor Targeting. , 2022, , .		0
2041	Impact of Bloodâ€“Brain Barrier to Delivering a Vascular-Disrupting Agent: Predictive Role of Multiparametric MRI in Rodent Craniofacial Metastasis Models. <i>Cancers</i> , 2022, 14, 5826.	1.7	0
2042	Mutual regulation between phosphofructokinase 1 platelet isoform and VEGF promotes glioblastoma tumor growth. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
2043	Clinical characteristics and prognosis of patients with glioblastoma: A review of survival analysis of 1674 patients based on SEER database. <i>Medicine (United States)</i> , 2022, 101, e32042.	0.4	6
2044	Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	17
2045	Digging deeper for new targets in bevacizumab resistance. <i>Neuro-Oncology</i> , 0, , .	0.6	0
2046	Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma. , 0, 13, 583.		1
2047	The prospect of tumor microenvironment-modulating therapeutical strategies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2048	A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1

#	ARTICLE	IF	CITATIONS
2049	Federated learning enables big data for rare cancer boundary detection. <i>Nature Communications</i> , 2022, 13, .	5.8	71
2050	Central Nervous System Ischemia Associated with Bevacizumab: An Analysis of the Japanese Adverse Drug Event Report Database. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 1805-1811.	0.6	0
2051	Stelletin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair. <i>Advanced Science</i> , 2023, 10, .	5.6	6
2052	Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?. <i>Neuro-Oncology</i> , 2023, 25, 631-634.	0.6	14
2053	Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. <i>Radiotherapy and Oncology</i> , 2023, 181, 109435.	0.3	9
2054	Signaling pathways in brain tumors and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	13
2055	Single-cell RNA sequencing reveals changes in glioma-associated macrophage polarization and cellular states of malignant gliomas with high AQP4 expression. <i>Cancer Gene Therapy</i> , 2023, 30, 716-726.	2.2	3
2056	Key Clinical Principles in the Management of Glioblastoma. <i>JCO Oncology Practice</i> , 2023, 19, 180-189.	1.4	12
2057	Targeted therapies in patients with newly diagnosed glioblastoma—A systematic meta-analysis of randomized clinical trials. <i>International Journal of Cancer</i> , 2023, 152, 2373-2382.	2.3	7
2059	Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2060	Intranasal delivery of full-length anti-Nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	11
2061	Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. <i>Neuro-Oncology</i> , 2023, 25, 1085-1097.	0.6	11
2062	Projecting overall survival in health-economic models: uncertainty and maturity of data. <i>Current Medical Research and Opinion</i> , 2023, 39, 367-374.	0.9	1
2063	Systemic Treatment in Glioblastoma. , 0, , .		0
2064	A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Adults. <i>Practical Radiation Oncology</i> , 2023, 13, 231-238.	1.1	1
2065	New therapeutic strategies based on molecularly targeted therapy in glioblastoma — a case report and review of the literature. <i>Current Issues in Pharmacy and Medical Sciences</i> , 2022, .	0.1	0
2066	Neurovascular Interactions in the Development of the Vasculature. <i>Life</i> , 2023, 13, 42.	1.1	2
2067	Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. <i>OncoTargets and Therapy</i> , 0, Volume 16, 71-86.	1.0	6

#	ARTICLE	IF	CITATIONS
2068	Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma. <i>Cancers</i> , 2023, 15, 830.	1.7	8
2069	The efficacy of targeted therapy combined with radiotherapy and temozolomide-based chemotherapy in the treatment of glioma: A systemic review and meta-analysis of phase II/III randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2070	The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics. <i>Annual Review of Cancer Biology</i> , 2023, 7, .	2.3	0
2071	MR Imaging, MGMT Promoter Methylation Features and Prognostic Analysis of Subventricular Zone Contacting IDH Wild-type Glioblastoma. <i>Current Medical Imaging</i> , 2023, 19, .	0.4	0
2072	Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	17
2073	Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 269-286.	2.5	0
2076	Computational Intelligence approach to improve the Classification accuracy of Brain Tumor Detection. , 2022, , .		0
2077	Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism. <i>Nature Communications</i> , 2023, 14, .	5.8	20
2078	Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?. <i>Journal of Neurology</i> , 2023, 270, 2702-2714.	1.8	6
2079	Differential Transcriptome Responses in Human THP-1 Macrophages Following Exposure to T98G and LN-18 Human Glioblastoma Secretions: A Simplified Bioinformatics Approach to Understanding Patient-Glioma-Specific Effects on Tumor-Associated Macrophages. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5115.	1.8	1
2080	KDELC2 Upregulates Glioblastoma Angiogenesis via Reactive Oxygen Species Activation and Tumor-Associated Macrophage Proliferation. <i>Antioxidants</i> , 2023, 12, 923.	2.2	2
2081	Long non-coding RNA in glioblastoma invasion: Angiogenesis and mesenchymal transition via PI3K and Wnt signalling. <i>Asia-Pacific Journal of Molecular Biology and Biotechnology</i> , 0, , 36-52.	0.2	1
2082	Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells. <i>Pathology Research and Practice</i> , 2023, 245, 154427.	1.0	6
2083	Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma. <i>Radiotherapy and Oncology</i> , 2023, 183, 109633.	0.3	3
2084	Prognosis prediction for glioblastoma multiforme patients using machine learning approaches: Development of the clinically applicable model. <i>Radiotherapy and Oncology</i> , 2023, 183, 109617.	0.3	3
2085	Diabetes Mellitus Management in the Context of Cranial Tumors. , 2023, 1, 29-39.		1
2086	Management of Patients with High-Grade Glioma. <i>European Medical Journal Oncology</i> , 0, , 91-99.	0.0	1
2087	Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials. <i>Cancer Investigation</i> , 2023, 41, 305-317.	0.6	1

#	ARTICLE	IF	CITATIONS
2088	Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
2089	MGMT methylation: Is it time to embrace the shades of grey?. <i>Neuro-Oncology Practice</i> , 2023, 10, 111-112.	1.0	0
2090	A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma. <i>Tomography</i> , 2023, 9, 362-374.	0.8	1
2091	Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	40
2092	The impact of brain lesions on health-related quality of life in patients with WHO CNS grade 3 or 4 glioma: a lesion-function and resting-state fMRI analysis. <i>Journal of Neuro-Oncology</i> , 2023, 161, 643-654.	1.4	1
2093	The Immunology of Brain Tumors. , 2023, , .		0
2094	Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas. <i>Acta Neurochirurgica</i> , 2023, 165, 693-699.	0.9	0
2095	Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. <i>Cancers</i> , 2023, 15, 1194.	1.7	2
2096	Modeling glioblastoma complexity with organoids for personalized treatments. <i>Trends in Molecular Medicine</i> , 2023, 29, 282-296.	3.5	7
2097	Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	1
2099	PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. <i>Cell Metabolism</i> , 2023, 35, 517-534.e8.	7.2	20
2100	Nanotechnological advancements in the brain tumor therapy: a novel approach. <i>Therapeutic Delivery</i> , 2022, 13, 531-557.	1.2	2
2101	Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging. <i>Radiation Oncology</i> , 2023, 18, .	1.2	1
2102	Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review. <i>BMC Cancer</i> , 2023, 23, .	1.1	5
2103	Update for astrocytomas: medical and surgical management considerations. , 0, , 1-26.		2
2104	An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone. <i>Experimental and Molecular Medicine</i> , 2023, 55, 470-484.	3.2	5
2105	Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
2106	Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma. , 2023, 2, 114-130.		0

#	ARTICLE	IF	CITATIONS
2107	The Role of Long Noncoding RNAs in Glioblastoma: What the Neurosurgeon Should Know. <i>Neurosurgery</i> , 2023, Publish Ahead of Print, .	0.6	0
2108	High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
2109	The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. <i>European Journal of Pharmacology</i> , 2023, 949, 175586.	1.7	27
2110	Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	3
2111	Refining the Intraoperative Identification of Suspected High-Grade Glioma Using a Surgical Fluorescence Biomarker: GALA BIDD Study Report. <i>Journal of Personalized Medicine</i> , 2023, 13, 514.	1.1	1
2112	Nucleolin promotes angiogenesis and endothelial metabolism along the oncofetal axis in the human brain vasculature. <i>JCI Insight</i> , 2023, 8, .	2.3	0
2113	The strange Microenvironment of Glioblastoma. <i>Revue Neurologique</i> , 2023, , .	0.6	1
2114	IDENTIFICATION OF ANTI-CANCEROUS DRUGS FOR THE MUTATED SNAP25 PROTEIN RELATED TO BRAIN TUMOR THROUGH STRUCTURE-BASED VIRTUAL SCREENING APPROACH. <i>Innovare Journal of Medical Sciences</i> , 0, , 40-45.	0.2	0
2115	Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future. <i>Current Oncology Reports</i> , 2023, 25, 589-598.	1.8	2
2116	High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. <i>Cancers</i> , 2023, 15, 2196.	1.7	2
2117	TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report. <i>Brain Sciences</i> , 2023, 13, 633.	1.1	0
2118	Targeting angiogenesis in oncology, ophthalmology and beyond. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 476-495.	21.5	43
2119	Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
2121	Role of Molecular Targeted Therapeutic Drugs in Treatment of Glioblastoma: A Review Article. <i>Global Medical Genetics</i> , 2023, 10, 042-047.	0.4	1
2122	Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?. <i>Current Oncology Reports</i> , 2023, 25, 777-785.	1.8	4
2123	Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 710-726.	2.5	2
2124	Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522311711.	0.5	0
2132	Clinical Applications of Dynamic Contrast-Enhanced (DCE) Permeability Imaging. , 2023, , 175-200.		1

#	ARTICLE	IF	CITATIONS
2134	Newly diagnosed glioblastoma: A review on clinical management. , 2023, , 101-123.		0
2144	Editorial: Untangling post-treatment follow up of brain tumors: the role of neuroimaging. <i>Frontiers in Radiology</i> , 0, 3, .	1.2	0
2154	Potential functions and therapeutic implications of glioma-resident mesenchymal stem cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 853-866.	2.4	2
2173	Enhancing Brain Tumor Detection Classification Accuracy with Computational Intelligence. , 2023, , .		0
2188	Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity. <i>Journal of Neuro-Oncology</i> , 2023, 164, 505-524.	1.4	5
2196	From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
2202	Editorial: Epigenetic and metabolic regulation of primary and metastatic brain cancers. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2212	Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients. <i>Methods in Cell Biology</i> , 2023, , .	0.5	0
2225	Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy. <i>Journal of Neuro-Oncology</i> , 0, , .	1.4	0
2229	Management of Older Patients with Brain Tumors. , 2023, , 249-266.		0
2241	Re-examining What the Results of α Measurement of Oxygen Level in Tissues Really Mean. <i>Molecular Imaging and Biology</i> , 0, , .	1.3	0
2260	Cellular signaling in glioblastoma: A molecular and clinical perspective. <i>International Review of Cell and Molecular Biology</i> , 2024, , .	1.6	0
2261	Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2024, 167, 231-232.	1.4	0
2263	Brain Gliomas of Adulthood. , 2023, , 1-20.		0
2279	Primäre und sekundäre Neoplasien des ZNS. , 2024, , 493-516.		0